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Abstract
Background: Health-related Quality of Life (HRQoL) values determined using direct
elicitation methods and generic preference-based measures are important for economic
evaluations of healthcare interventions. The ophthalmology clientele is vulnerable to
psychological stressors in the context of the coronavirus disease 2019 (COVID-19)
pandemic.
Objectives: To systematically identify and summarize the quality of life (QoL) of eye
disease patients in general in North America and seniors with eye diseases during the
COVID-19 pandemic.
Methods: A systematic review identified North American studies that quantified HRQoL of
eye disease patients. A cross-sectional study was conducted among seniors with eye diseases
and backwards stepwise regression models were built.
Results: The systematic review revealed that HRQoL across patients with glaucoma, agerelated macular degeneration (ARMD), diabetic retinopathy (DR), cataracts, uveitis, and dry
eye disease (DED) was similar using the SF-12 and SF-36. Utility values across patients with
ARMD, DR, cataracts, uveitis, and DED appear to be similar while values in patients with
glaucoma appear to be higher. The cross-sectional survey revealed that HRQoL, visionrelated QoL (VRQoL), and sleep quality appeared to be good. Depression and anxiety
symptoms appeared to be low, while community integration and social support were
moderate. The presence of retinal disease and the number of non-ocular comorbidities
negatively impacted VRQoL and social support and community integration. Education
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impacted social support and community integration negatively. of mobility aids appeared to
negatively affect depressive symptoms and sleep quality.
Conclusion: Overall QoL among North American patients and seniors with eye diseases
appeared to be generally good.
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Summary for Lay Audience
Eye diseases have been associated with numerous negative impacts on a patient’s quality of
life (QoL) and overall wellbeing. This thesis investigates the QoL of patients with eye
diseases from two different angles. The first angle is through a systematic review of literature
that looks at QoL from a health economics point of view. In particular, the review focuses on
the values produced by standardized questionnaires and techniques from previous studies to
quantify the overall QoL of North American patients with eye diseases. This review revealed
that the QoL across patients with glaucoma, age-related macular degeneration, diabetic
retinopathy, cataracts, uveitis, and dry eye disease appeared to be similar. However, there
may be evidence that the QoL of patients with glaucoma is higher than in patients with other
diseases.
The second angle in which QoL of eye disease patients is investigated is through conducting
a survey that specifically focuses on seniors with eye diseases to see how their QoL has been
during the recent coronavirus disease 2019 (COVID-19) pandemic. This survey looked at
QoL using many different measures. The results of this survey revealed that the QoL and
sleep quality of seniors with eye diseases appeared to be good. Depression and anxiety
appeared to be low, while community integration and social support were moderate. More
specifically, having retinal disease and more non-eye diseases negatively affected visual
aspects of QoL and community integration and social support. Having a greater education
also appeared to negatively affect community integration and social support. Finally, the use
of a mobility aid appeared to negatively affect sleep quality and depression. The findings
revealed by these studies are important because they could provide necessary information for
iii

making economic assessments and evaluations for many different eye diseases. Furthermore,
the findings help potentially quantify the effects of COVID-19 beyond the direct impact of
the virus. This, in turn, may help to improve the future quality of care during non-COVID-19
conditions and during potential future pandemic situations. Overall, the findings from this
thesis may be used to improve patients' overall care for eye diseases in the future.
.
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Chapter 1
1 Introduction
Eye diseases have been associated with numerous negative impacts on a patient’s
quality of life (QoL). Assessing the QoL of a patient with eye disease is important in
identifying the severity of visual impairment to the patient's well-being. QoL is the
individual perception of a patient about their position in life including the psychological,
social, and physical domains. Therefore, health-related QoL (HRQoL) focuses on their
beliefs, expectations, and experiences with their disease and treatment in the context of
one’s health. This chapter introduces an evaluation of the QoL of patients with eye
disease and visual impairment to identify the major threats of the eye diseases to their
lives. Vision-related QoL (VRQoL) reflects a patient's perception of their visual abilities
and the associated impacts on their general life experience. Hence, the assessment of their
QoL will reveal the progression of eye disease and its impacts on their visual capabilities
as well as the quality of their life. In general, this research project evaluates different
states of visual impairment that have significant impacts on a person’s QoL.
Vision forms an integral part of a person’s life. From a functional point of view,
vision and eyesight account for a large percentage of a person’s performance in their
social and functional life 1. Thus, vision provides them with access to almost all areas of
life including their social, physical, and emotional experiences. Based on this concept,
visual health forms an integral part of a person’s life and can cause various impacts if
vision impairment occurs. Therefore, VRQoL also reflects the role of visual perceptions
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on a person’s participation in daily life activities including mobility, religion, and
recreation among others 2,3.
Changes in the visual capabilities of a person may affect their QoL in many ways.
At first glance, eye diseases cause negative changes in a patient's mental, emotional, and
physical health 4,5. A patient may lose their ability to perform visual functions, such as
contrast sensitivity, color perception, and adaptation to light, due to eye disease. The
progression of eye disease also affects the extent of their visual perceptions and
adaptation to general life negatively. For instance, patients tend to lose self-reliance, selfsufficiency, and social status when they suffer visual impairment. Such changes in their
visual capabilities cause damage to their life experiences by reducing their mobility,
strengths, and experiential learning 6. The result is a lack of satisfaction with their visual
capabilities and a subsequent loss of their general functionality. In the end, they face
restrictions in all areas of their life leading to a lower quality of their daily life experience.
The assessment of VRQoL also reveals the prevalence of different eye diseases
and their influence on patients’ daily lives. Vision impairment includes various eyerelated defects or diseases, such as eye swelling, thyroid eye disease, glaucoma, diplopia,
and blindness 7. These eye conditions and many others are a global concern because of
their significant impacts on the physical and mental capabilities of patients. Eye disease is
a common burden among adult patients above the age of 65 years whose medical history
incorporates ophthalmological conditions 8. The age-specific prevalence of eye disease is
likely to increase due to aging and multiple incapacitating conditions, such as depression,
anxiety, and frustration. The result is a progression in eye damage and increased chronic
conditions that require medical or surgical treatment. Such conditions reflect the impacts
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of eye disease on general health that lead to the reduction of patient’s performance and
general life experience.
Through measuring the QoL among eye disease patients, the current thesis seeks
to portray the relevance of research in the health-related issue. It provides an objective
clinical measure of eye disease among patients with ophthalmologic conditions. It also
identifies the relationship between eye disease and the multiple conditions associated with
the patient’s QoL 9. Vision impairment is associated with negative health, social, and
functional outcomes that reduce the patients’ QoL. Patient-reported outcomes are
important instruments for identifying the relationship between eye disease and the QoL
among patients with chronic conditions10. Therefore, the current research project will
provide important measures for gathering data and information about the large impact of
eye disease on a patient’s QoL.
Overall, a general view of the global research on the QoL reveals the impacts of
eye health on the quality of a patient’s life. This chapter uses the definitions of eye
disease and QoL to enhance the understanding of the relationship between visual
impairment and a patient's QoL. Research findings from this thesis will depict the
relationship between various types of eye diseases and the QoL scores of patients with
various ophthalmological conditions.
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Chapter 2 Literature Review
2 Introduction
This thesis explores the quality of life (QoL) in patients with eye diseases in
general and specifically seniors with eye diseases during the coronavirus disease 2019
(COVID-19) pandemic. Therefore, understanding the many aspects of QoL, including
feelings of depression and anxiety, sleep quality, and social support to vision-related
quality of life (VRQoL) and health-related quality of life (HRQoL) is critical.

2.1 Background of Quality of Life
Exploration of the domains of QoL can help ascertain the impact of illness on a
patient's life 1. QoL plays an integral role in understanding a patient's perception of their
health, well-being, and life satisfaction. It is stated that the World Health Organization
(WHO) defines QoL as "an individual's perception of one’s position in life in the context
of the culture and value systems in which one lives and about one’s goals, expectations,
standards and concerns.” 2. The WHO goes further to use the dimensions of physical
health, social relationships, psychological health, and the immediate environment of
individuals in the society to establish the QoL across the varied social groups and diverse
cultures.
The environmental aspect measures the quality of air, presence of pollution,
ambient noise, and damage to property since it determines the health of an individual 3.
Low QoL is indicated by the presence of pollution in both air and environment, resulting
in the spread of certain diseases and infections. The social and cultural aspects explore the
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beliefs, practices, and belief systems of individuals in society and how they affect access
to healthcare. Notably, there are some societies where accessing mental health services is
perceived as a sign of weakness, which affects the QoL of individuals in society 1,3.
Additionally, health-promoting behaviors and the physical health of an individual play an
integral role in supporting people's health. For instance, hiking trails, playgrounds, and
the safety of the social infrastructure in society enhance mental health, reduce stress, and
promote healthy living 4. Furthermore, physical health, translated as having no infections
or the lack of illness, enhances the QoL.
Mental health is a critical element of the QoL. The WHO defines it as a state in
which individuals can realize their capabilities, work fruitfully and productively, cope
with stress in life, and contribute positively to society 5. The mental health of an
individual is measured by the capacity to overcome depression, anxiety, and low sleep
quality while experiencing enhanced community integration and social support 3,5–7. In
essence, individuals who experience mental health disorders such as anxiety, depression,
and distress have a low QoL. To promote patients' well-being and health, it is critical to
comprehend the many factors that impact the QoL of an individual.

2.2 Health-related Quality of Life
HRQoL relates to the multi-dimensional concepts that explore the domains
associated with the mental, physical, social functioning and emotional health of an
individual 8. The measures transcend the direct standards that explore life expectancy,
population health, and causes of health, focusing on enhancing the health status of
individuals in society. The measurement of HRQoL seeks to establish the burden of
preventable injuries, diseases, and disabilities while offering valuable new insights on the
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correlation between risk factors and HRQoL 6. In essence, measuring HRQoL provides an
opportunity to monitor the process of a nation in the realization of health objectives. The
approach is critical in enhancing the QoL of individuals since it explores the life burden,
socio-economic status, cultural, social support, and demographical factors. In essence, the
element explores the impacts of culture, nationality, life attitudes, spirituality, gender, and
age concerning the quality and access to medical care. HRQoL and QoL are interrelated
as they seek to ensure that an individual's quality care and well-being are enhanced 8.
However, HRQOL focuses more on disease burden, while the QoL explores elements
such as environmental effects on individuals' health and well-being. HRQoL can measure
various elements that include life expectancy, survival, psychological state, pain, physical
function, ambulation and mobility, and sexual function 9. It can also measure elements
like disability, impairments, handicaps, and cognitive functions such as depression and
anxiety, just like QoL.

2.3 Vision-Related quality of life
VRQoL measures the degree to which vision impacts an individual’s economic
well-being, emotional and social status, and ability to perform daily activities. The
measure of VRQoL entails exploring the impairment degree that affects the ability of an
individual to perform activities that rely on their sight 9. Moreover, VRQoL measures the
ability of an individual to feel satisfied with their visual capabilities. Like the other types
of QoL discussed above, VRQoL also explores how one’s visual capability affects one’s
psychological state, physical health, social relationships, and level of independence 10.
Arguably, vision affects the ability of an individual to perform daily chores, improve their
social life, and take part in functional activities. As a result, visual impairments restrict
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the life of individuals, including participating in religious activities, daily routines,
recreation, mobility, and intense visual tasks. Like HRQoL, poor VRQoL impacts an
individual's mental well-being and health as it causes frustration, depression, and anxiety
11

. Thus, it is of great value to assess the social participation, emotional state, mobility,

and daily activity of a person about their VRQOL.

2.4 How to measure the different Qualities of Life
2.4.1 Measuring specific correlates of Quality of Life
The increased prevalence of depressive signs concerns social workers as it
correlates with adverse health outcomes and QoL, cognitive disability, medical illnesses,
suicide, and increased economic burden on patients and their families. Researchers and
healthcare workers alike are faced with the challenges of measuring depressive symptoms
owing to a lack of standardized measures; thus, they seek valid and brief indicators 1,4,12.
Among the available indicators is the Center for Epidemiologic Studies Depression Scale
(CES-D), which is a 20-item adapted for large-scale surveys critical in measuring the
depressive symptomology in older patients 13. The CES-D presents a valuable tool in the
assessment of subthreshold depression. According to Jiang et al. 14 CES-D entails high
reliability and validity in subthreshold depression, which is adequate to measure
depressive disorders. The CES-D was primarily designed for use in epidemiologic
studies, specifically in assessing the prevalence of depressive symptoms and determining
the at-risk population for depression among the general population. The recommended
criteria for determining the existence of subthreshold depression among individuals is a
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score of 16 out of the self-rating 20-item scale 14. Thus, the CES-D provides an adequate
tool for assessing depressive symptoms among individuals.
The Hospital Anxiety and Depression Scale (HADS) is considered an influential
instrument that measures states of depression and anxiety in hospital outpatient clinics.
The tool is a reliable instrument as it has seven items that measure depression and anxiety
levels 15,16. When a patient scores more than eight points from the total of 21 points, the
patient likely has a case of depression or anxiety depending on the subscale with the
score.
As aforementioned, understanding the sleep quality among patients is critical in
improving their QoL. As such, tools such as Pittsburgh Sleep Quality Index Questionnaire
(PSQI) play a role in assessing the presence of sleep disturbances 17. In the scoring of
PSQI, seven components are evaluated based on their level of difficulty. The final score is
evaluated based on a range of 0 to 21 with higher scores indicating poor quality of sleep.
According to Backhaus et al. 18, the PSQI has a high test-retest reliability and has good
validity for patients experiencing primary insomnia. The tool measures the disturbances
and quality of patients' sleep in the clinical population for one month. The PSQI contains
seven elements: sleep duration, sleep latency, subjective sleep quality, sleep disturbances,
daytime dysfunction, and habitual sleep efficiency.
In addition to sleep quality, social relationships are an essential aspect of QoL. As
such, measures like the Community Integration Questionnaire (CIQ) measure the ability
of an individual to interact, integrate, and develop relations with people in the society
19,20

. Integration is defined broadly in social networks, home, school, employment, or

volunteering work. According to Hirsh et al. 21, the CIQ measurement entails a 15-item
inventory which is used to measure the levels of community integration of individuals
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who have recently suffered brain injuries. The overall questionnaire score ranges from 0
to 29, however it can be further divided into three sub-scores, corresponding to
integration in the home, social integration, and productivity. Higher scores indicate higher
integration and social support 22.

2.4.2 Measuring Health-Related Quality of Life
2.4.2.1 Direct Preference Elicitation Techniques
While the previously mentioned questionnaires exist to measure different
correlates of QoL, HRQoL can be measured through a different set of means. HRQoL can
be measured using direct preference elicitation techniques like the time trade-off (TTO),
standard gamble (SG), and visual analog scale (VAS), with many users preferring these
techniques owing to their precision, reliability, ease of use, validity, and subjectivity.
These techniques produce utility scores which, in turn, can provide value to one’s
HRQoL. These scores generally take on values between 0 and 1, which reflects the
HRQoL of an individual. A value of 0 represents a state equal to being dead, while 1
represents a state of being in full health. Utility values are based on the normative rational
decision-making model under uncertainty 23. Utility scores explore the preference and
desirability that people express for their condition and health status.
The TTO approach seeks to elicit a response from an individual on the trade-offs
they are willing to make between one’s QoL and the length of one’s life 23. The patients
are asked about the proportion of their lives that they are willing to sacrifice to lead a
healthy life or be relieved of the health issue they face. The TTO approach is the
preferred method to evaluate the value of a health state in time 24,25. The use of TTO is
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mainly attributed to the widespread use of EuroQol-5D (EQ-5D) instruments, where the
value sets are typically obtained from the TTO 26. The TTO is also used by early
predecessors of EQ-5D tools such as the Assessment of Quality of Life-8D (AQol-8D)
and its earlier versions.
The SG approach measures the risk levels that individuals are willing to take for
the treatment to help realize optimal health. In framing the SG method, participants are
required to consider the choice between two options 27. In the first option, the respondent
is asked whether they are willing to live with a certain health problem under evaluation
for the remaining parts of their lives. In the second option, a risky treatment is initiated
with two possible results, including optimal health with a probability of p and immediate
death which has a probability of 1-p.
The VAS is considered a reliable, valid, and responsive tool that measures the
QoL compared to the other assessment tools. Using the VAS, individuals must indicate
where on the scale they consider their health state to be. At the top of the scale is a state
of perfect health, while at the bottom is a state of the worst possible health state.
However, VAS is generally considered inferior to the TTO and SG methods because the
VAS involves a rating task rather than a choice task. Moreover, the VAS is also criticized
because of scaling biases like the end-of-sale bias, where participants are less likely to
indicate health states at the top or bottom ends of the scales 23,27,28.

2.4.2.2 Generic Preference-Based Measures of Health
In addition to these preference elicitation techniques, generic preference-based
measures (GPBMs) of health are commonly used to measure HRQoL. EQ-5D is a widely
adopted tool that measures QoL with a focus on five dimensions such as self-care,
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mobility, discomfort/pain, depression/anxiety, and usual activities 29. The tool is critical
as it helps inform decision-making by organizations, providers, and healthcare authorities.
According to Fransen and Edmonds 30, the EQ-5D measurement has a high level of
reliability which is sufficient for aggregate data level and is comparable to the SF-36. The
scores for EQ-5D scores range between -0.59 and one where scores closer to one indicate
a higher QoL, while scores less than 0indicate states worse than death 31.
The 36-Item Short Form Survey (SF-36) health survey is a standardized
questionnaire used to assess patient health across eight dimensions: physical functioning,
role limitations due to physical problems,

general health perceptions, vitality, social

functioning, role limitations due to emotional problems, general mental health, and health
transition 32. The questionnaire consists of items or questions that present respondents
with choices about their perception of their health. The SF-36 does not lend itself to the
generation of an overall summary score however, each dimension score is transformed
onto a 0 to 100 scale, which is not comparable across dimensions 33. Higher scores
represent higher HRQoL. A physical component score (PCS) and mental component
score (MCS) can also be derived from the scale items 32. The Short-form Six-Dimension
(SF-6D) is derived from the SF-36, covering six dimensions: role limitation, physical
function, pain, social functioning, vitality, and mental functioning. The scoring for SF-6D
is derived from six dimensions, including role limitations, mental health and vitality,
physical functioning, pain, and social functioning. The scoring criteria use weights
obtained from a sample of the general population within the UK derived using the SG
method. The SF-6D method exhibits a high level of test-retest reliability 34. On the other
hand, 12-Item Short Form Survey (SF-12) is a self-reported measure that explores the
effect of health on the life of individuals in the society to measure the QoL. Scoring using
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the SF-12 scale is conducted based on 0 to 100 criteria, with higher scores being an
indicator of better mental and physical functioning. A score of 42 and below on the SF-12
is an indicator of clinical depression 35. Based on previous studies, the SF-12 exhibits
high reliability and validity levels in measuring health status among the elderly 36.
The Health Utilities Index (HUI) questionnaire is a preference-based system and
health profile that measure an individual's health status, reports HRQoL, and generates
utility scores 37. HUI entails the HUI mark 1, 2, and 3. The HUI2 investigates the concept
of self-care in depth. This presents an evident benefit in a variety of applications,
including the therapy of Alzheimer's disease 38. The HUI2 measurement criteria include
seven elements: self-care, pain, mobility, emotion, cognition, sensation, and fertility –
each with three to five levels. The concepts of fear and anxiety are at the core of HUI2's
interpretation of the emotional experience. The HUI3 evaluates eight aspects of health,
including vision, emotion, ambulation, pain, hearing, speech, dexterity, cognition, and
discomfort with each characteristic having between five and six tiers. The various traits
and levels may be combined to produce 972 000 distinct health states 39. The HRQoL
score is determined using the utility function from preference scores measured according
to the von Neumann-Morganstern utility theory 37.

2.4.3 Measuring Vision-Related Quality of Life
On the other hand, vision-specific instruments such as the Visual Function Index
(VF-14), National Eye Institute Visual Function Questionnaire (NEI VFQ), Activities of
Daily Visual Scale (ADVS), and Visual Activities Questionnaire (VAQ) are designed to
measure the impact of visual functioning on patients. They are instrumental as they help
provide tools for comparison and greater sensitivity to the QoL related to patients' vision.
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Visual acuity can be converted to utility values as the values from ocular diseases shows a
strong correlation with visual acuity. The VAQ is a measure of low vision impairments
that can impact daily living in various categories, including visual acuity, visual search,
peripheral vision, and color vision. The original VAQ consists of 33 questions and eight
subscales 40. The Visual Function Index (VF-14) is a short questionnaire that measures
functional impairment in cataract patients. It comprises 18 questions that address 14
elements of visual function that are impacted by cataracts. The VF-14 has a good level of
internal consistency and is a valid, reliable tool that provides information not
communicated by measurements of visual acuity or general health condition 41. The
Activities of Daily Vision Scale (ADVS) was designed as a self-report questionnaire to
assess the necessity for surgery and the results following surgery in cataract patients.
The National Eye Institute Visual Function Questionnaire (NEI VFQ) measures
the perceptions of self-reported vision-targeted health status, most significant for people
experiencing chronic eye diseases. In particular, the 25-item version of the National Eye
Institute Visual Function Questionnaire (NEI VFQ-25) presents reliable and valid criteria
to assess the influence of visual impairments on HRQoL 42. The content for NEI VFQ-25
is derived from the focus groups with multiple conditions. The NEI VFQ-25 includes
multi-item subscales to rate overall health on a 5-level scale that ranges from excellent to
poor and overall vision on a 6-level scale that ranges from excellent to blind. It also
includes multi-item subscales to assess difficulty with near vision activities, difficulty
with distance vision activities, limitations in social functioning due to vision, role
limitations due to vision, dependency on others due to vision, mental health symptoms
due to vision, future expectations for vision, driving difficulties, and pain and discomfort
in or around the eyes. Finally, the NEI VFQ-25 also includes single items to assess
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limitations with peripheral vision and color vision. All subscales and the total
questionnaire score are scored from 0 to 100. On this scale, 100 is the best possible score
and higher scores indicate higher levels of VRQoL while 0 represents the worst possible
score and lower scores indicate lower levels of VRQoL 43.

2.5 Quality of life during COVID-19
The COVID-19 outbreak caused untold suffering from families and individuals in
families as lockdowns, curfews, and social distancing rules were adopted, resulting in loss
of employment and job opportunities and depression, anxiety, and isolation 44. The many
health protocols exacerbated, the loss of a family member or a friend, the anxiety of
getting infected, and the stress from all these events affected the lives of many
individuals. The restriction on movements resulted in an increased sedentary life, low
physical activity, and conflicts in homes. Moreover, during the pandemic families
grappled with the loss of their friends or relatives, freedom of movement, ability to
provide, and negative impact on mental health 45. These events reflect the general health
and HRQoL of people in the society during the pandemic conditions.
However, it should also be noted that studies showed that masks played an
integral role in reducing the stress and fear among the population, while information
about medical treatment, healthy lifestyles, and keeping contact helped eliminate anxiety
46

. Understanding the measures that individuals take to eliminate stress is critical in

helping society make better decisions in the future. Furthermore, QoL is a crucial
indicator of insistence in individuals' well-being and overall health. Studies show that
COVID-19 impacted the health domains of individuals, including social functioning,
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physical condition, and health domains 47. For instance, the implementation of preventive
measures affected the ability of individuals to care for their families, health, and wellbeing as they were unable to exercise or access basic needs such as food and medication.

2.6 Quality of Life of Seniors aged 65+
The QoL for older adults, especially those above 65 years of age, appeared to be
affected heavily as social distancing, isolation, and loss of physical contact with their
guardians and family members increased loneliness and anxiety. Since the older people
are a vulnerable population, they were scarcely visited by the healthy younger population
resulting in isolation and depression 48. The elderly in rehabilitation homes and those
confined in their homes away from their relatives experienced a low QoL.
In general, older people describe a high QoL as being healthy, having peace,
living in harmony, feeling happy, being satisfied with life, and keeping oneself busy,
whether with hobbies, volunteer service, or work49. It also meant preserving interpersonal
relationships and receiving support from family, friends, and neighbors. In a study by
Emrani et al. 50, utility scores using the EQ-5D of older individuals without a spouse,
either divorced or widowed, were significantly lower than married individuals. Thus, the
research indicates a higher quality perception of life by individuals as one with a high
support system, either from spouses or friends.

2.7 Quality of life of people with eye diseases
Loss of vision affects the QoL of a person and their functions as they are unable to
care for themselves and family members. People's QoL with eye diseases is lower as
mental health and mood are affected 51. Patients suffering from eye diseases also tend to
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experience short sleep duration, insomnia, poor sleep quality, sleep disorders, and sleep
apnea 51. Sleep disorders increase stress levels as hormones such as cortisol cause
dehydration. Sleep latency and quality are critical elements in sleep, disrupted by eye
diseases 52. Ultimately, individuals with eye diseases experience lower cognitive control
and functions that reduce their QoL.
The HRQoL for an individual with peripheral vision loss is known for diseases
like glaucoma affecting the peripheral vision. Additionally, HRQoL in diseases like agerelated macular degeneration (ARMD) and cataracts affect central vision is also known.
Both peripheral and central vision loss appear to negatively impact QoL to a similar
extent 53. The relationship between QoL and various eye diseases is essential to
understand in clinical practice when assessing the visual function, the patient's wellbeing, and level of satisfaction with their care. Thus, as glaucoma severity increases, the
impacts of HRQoL rise in a similar function. In addition, patients with cataracts also
exhibit a low VRQoL. According to a study by Amedo et al.54, cataract surgery improves
the VRQoL in many aspects, including enhanced engagement in social activities and
elimination of limitations to work-related activities. Furthermore, dry eye disease (DED)
is a significant public health problem that causes ocular pain, tiredness, and visual
disturbances that negatively impact QoL, including social, physical, and psychological
functioning, daily activities, and professional productivity 55. Finally, Slakter and Stur 56
acknowledge that ARMD can significantly affect QoL. They also establish that growing
vision loss is connected with a worsening of QoL, and that vision loss is a common cause
of depression.
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2.8 Gaps in the Literature and the Objectives of the Thesis
Despite numerous studies exploring the impact of eye diseases on the QoL of
patients with eye diseases, there is yet to be a study that summarizes the HRQoL of
patients with various eye diseases in terms of measures such as direct preference
elicitation techniques and GPBMs. Moreover, despite numerous studies exploring the
impact of COVID-19 on the QoL of people in society, no research has been conducted on
the effects of COVID-19 on the QoL for seniors with eye diseases after the health
protocols were introduced.
Thus, this thesis aims to explore the HRQoL of patients with various eye diseases
evaluated using direct preference elicitation techniques and GPBMs, to provide important
information to policymakers to make evaluations and resource allocation decisions.
Moreover, this thesis aims to characterize the HRQoL, VRQoL, depression and anxiety
symptoms, sleep quality, and social support and community integration of seniors aged 65
and above with various eye diseases during the COVID-19 pandemic. This thesis strives
to improve patients' overall care for eye diseases through accomplishing these aims.
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Chapter 3 Health-related Quality of Life of North American
Patients with Eye Diseases
3 Abstract
Background: Health-related Quality of Life (HRQoL) values determined using direct
elicitation methods and generic preference-based measures are important for economic
evaluations of healthcare interventions.
Objective: This study systematically identifies and summarizes the HRQoL of patients
with a variety of eye diseases.
Methods: A systematic review of the literature identified North American studies that
quantified HRQoL of eye disease patients. Database searches were conducted through
MEDLINE, EMBASE, National Institute for Health Research Economic Evaluation
Database, Cochrane Libraries, and Web of Science. Risk of Bias Assessment was
performed using the assessment tools by CLARITY Group of McMaster University.
Results: Of the 3481 articles identified, 39 articles met the inclusion criteria. The time
trade-off technique was used in nine of the included studies, while the SG technique was
used in two studies. Fifteen studies used the SF-36, five studies used the SF-12, and 3
studies used the SF-6D. Two studies used the HUI2, and three studies used the HUI3.
Fourteen studies used the EQ-5D. Utility values across collective patients with glaucoma,
age-related macular degeneration (ARMD), diabetic retinopathy (DR), cataracts, uveitis,
and dry eye disease (DED) ranged from 0.89 to 0.94, 0.74 to 0.81, 0.77 to 0.88, 0.66 to
0.85, 0.67 to 0.84, and 0.78 to 0.82, respectively.
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Conclusions: HRQoL across patients with glaucoma, ARMD, DR, cataracts, uveitis, and
DED was similar using the SF-12 and SF-36. Utility values across patients with ARMD,
DR, uveitis, and DED appear to be similar while the values in patients with glaucoma
appear to be higher.

3.1

Introduction
A commonly used definition of health is that “Health is a state of complete

physical, mental and social well-being, and not merely the absence of disease and
infirmity” provided by the World Health Organization 1. An important feature of health is
that it includes domains such as pain, feelings, and various other symptoms that are
experienced by an individual2. A similarly related concept to health is health-related
quality of life (HRQoL).
HRQoL can be defined as how well a person functions in their daily life and their
perceived wellbeing across physical, mental, and social domains of health3. Here,
functioning refers to a person’s ability to perform some pre-defined activities, while
wellbeing refers to a person’s subjective feelings3,4. Moreover, HRQoL also refers to
aspects of self-perceived well-being that are related to the presence of disease or response
to treatment5. This definition is sometimes stated in a narrower version, where HRQoL is
used to identify the sub-set of the important or most common ways in which health or
health care impacts a person’s well-being6. However, HRQoL can also be defined in
terms of the level of health as perceived by the individual experiencing the health state7.
These values are also known as utilities and are used to calculate quality-adjusted lifeyears (QALYs) which can be used to measure the benefits of health technologies. In
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general, utility values are on a scale where zero is equal to death and one is equal to full
health. Values less than one are meant to reflect the loss of quality of life (QoL) because
of living in ill health7.
The standard gamble (SG), time trade-off (TTO), and the visual analogue scale
(VAS) are three main techniques for valuing health states, often called direct preference
elicitation techniques2,8. However, in addition to these preference elicitation techniques,
generic preference-based measures (GPBMs) of health are also commonly used methods
for measuring health states2,8. These GPBMs frequently make use of the direct preference
elicitation techniques above to estimate utility values for each health state defined by the
GBPM. GPBMs are relatively simple to use and widely accepted by policymakers
concerned with using economic assessments of cost-effectiveness around the world.
There are a number of GPBMs used in practice, and they all have a description of
health status and a set of values to assign to each health state defined by the descriptive
system. Each measure has a health state classification with multilevel dimensions that
together describe many health states. From these questionnaires, a preference-based
single utility value can be generated, which is estimated from a survey of the general
population who were asked to provide values for a set of states defined by the instrument.
These measures are designed to be relevant to most patient groups including the general
population and provide a means of making comparisons across different disease areas.2
Some of the most well-known GPBMs include the EuroQol-5D (EQ-5D), Short-form SixDimension (SF-6D), 36-Item Short Form Survey Instrument (SF-36), 12-Item Short Form
Survey (SF-12), and Health Utilities Index (HUI) questionnaires.
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Eye diseases and ophthalmological conditions can have a negative impact on
one’s HRQoL. However, their effect on one’s HRQoL can vary depending on the eye
disease and one’s visual acuity9,10. A previous systematic review noted that using utility
values that decreased visual acuity levels tend to have an obvious negative impact on the
HRQoL in patients with diabetic retinopathy (DR) and age-related macular degeneration
(ARMD)11. Another systematic review previously noted that the impact of glaucoma and
ARMD on QoL was similar across most domains of the SF-36. However, it appeared that
the weighted mean scores across the “role limitations caused by physical problems” and
“general health” domains appeared to be lower among patients with ARMD while the
score across the “social functioning” domain appeared to be lower in patients with
glaucoma 12. While these previous systematic reviews provide important insight on the
HRQoL of patients with these eye diseases, they tend to focus on specific eye conditions.
In short, there is need for a comprehensive review that identified HRQoL across all eye
conditions, using either direct or indirect elicitation methods.
In performing a systematic review to explore the QoL of patients in a variety of
eye diseases evaluated using preference elicitation techniques and GPBMs, we will be
able to inform economic evaluations and resource allocation decisions, and, ultimately,
improve the overall care of patients with different eye diseases. As such, the purpose of
this current systematic review is to systematically identify studies reporting the values of
HRQoL of patients with eye diseases from North America. This was accomplished by
summarizing summary scores and utility values reported for eye disease patients.
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3.2

Methods
A systematic review was conducted following the Preferred Reporting Items for

Systematic Reviews and Meta-Analyses (PRISMA) statements13.

3.2.1

Data sources and searches
Database searches were conducted through MEDLINE, EMBASE, National

Institute for Health Research Economic Evaluation Database (NHS EED), Cochrane
Libraries, and Web of Science. In both MEDLINE and EMBASE, search strategies were
designed to retrieve pertinent articles up to January 28, 2022. In NHS EED, Cochrane
Library, and Web of Science search strategies were designed to retrieve pertinent articles
up to February 6, 2022.
The search strategies were designed to include various keywords, terms, and
subject headings synonymous with the following concepts: quality of life, time trade-off,
visual analog scale, standard gamble, and eye disease. GPBMs including the EQ-5D, SF36, SF-12, SF-6D, and HUI was used as search terms. Additionally, specific eye diseases
including glaucoma, retinal vein occlusion, cataracts, macular degeneration, macular
edema, macular hole, retinal detachment, dry eye disease (DED), thyroid eye disease,
amblyopia, strabismus, and uveitis were used as search terms. Full search strategies for
each database can be found in Appendix H.

3.2.2

Inclusion/Exclusion criteria
We included any type of observational and experimental study performed in North

America on adults (18 years and older) clinically diagnosed with any type of eye disease.
We included studies using direct preference elicitation methods of time trade-off or

33

standard gamble or studies using the EQ-5D, SF-6D, SF-36, SF-12, or HUI
questionnaires to evaluate HRQoL. We included studies that provided utility scores or
summary scores from the direct elicitation methods or GPBMS mentioned above for the
reported eye diseases. However, studies were required to have an English full text.

3.2.3

Screening and Selection of studies
The results found through the database searches were imported into Covidence

systematic review software (Covidence, Inc)14. Duplicates were removed, and systematic
screening was done by two independent reviewers (B.Y and H.J). Level one (title and
abstract) screening occurred first, and Cohen’s Kappa statistics and raw percentage
agreement were calculated before conflicts were resolved. Conflicts at each level of
screening were resolved by consensus. If consensus could not be reached, then a third
reviewer was required to arbitrate. The remaining studies then proceeded to level two
(full text) screening where their full texts had been uploaded and Cohen’s Kappa statistics
and raw percentage agreement were calculated, once again, following the screening
process.

3.2.4

Risk of Bias (RoB)Assessment
The Risk of Bias (RoB) assessment tools by CLARITY Group of McMaster

University was used to assess the risk of bias in the included studies15. Given the variation
in study design, we employed a number of quality tools based on the type of study.
Specifically, the Instrument for Cross-Sectional Surveys of Attitudes and Practices, Tool
to Assess Risk of Bias in Cohort Studies, Tool to Assess Risk of Bias in Randomized
Controlled Trials, and Tool to Assess Risk of Bias in Longitudinal Symptom Research
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Studies Aimed at the General Population were all chosen as the tools to assess the study
quality.

3.2.5

Data extraction
Data extraction was completed by two independent reviewers (B.Y and T.W) onto

standardized data sheets that were checked for accuracy by two other independent
reviewers (S.A and M.M). Information extracted from the studies included author(s)
names, study year, publication, study design, geographical location of study, study
objectives, study period and duration, sampling methods, total sample size, and study
settings. Additionally, information pertaining to the participants of the studies including
gender, age, eye diseases, non-ocular comorbidities, visual acuity, education level, as well
as race/ethnicity were also extracted. Finally, information on the questionnaires and
elicitation methods used, mode of administration, domain scores, summary scores, and
utility scores of the elicitation methods were also extracted. The outcome data of all
studies pertaining to the Multicenter Uveitis Steroid Treatment (MUST) trial were
merged as one to prevent the duplication of study data16–18. Similarly, the outcome data of
the studies by Feeny et al.19 and Groessl et al.20 were also merged to prevent the
duplication of study data.

3.2.6

Data Synthesis
All included studies were described qualitatively in terms of the study and

participant characteristics, elicitation methods used, and HRQoL scores across each eye
disease.
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3.3

Results
The flow of literature is represented in the PRISMA flowchart (Figure 3-1). The

search strategy resulted in 5856 records that were potentially relevant to the review
including from 1246 MEDLINE, 3114 from EMBASE, 160 from NHS EED, 653 from
Cochrane Libraries, and 683 from Web of Science. After the removal of duplicates, 3481
records remained and were then subject to level one screening. After the two independent
reviewers completed level one screening, 3012 records were removed as they did not
contain relevant information pertaining to QoL in patients with eye diseases. This resulted
in 469 records remaining and sought for retrieval; however, 11 reports were irretrievable.
As such, 458 reports then proceeded on to level two screening. 419 reports were then
excluded leaving 39 reports. The reasons for excluding the 419 reports are listed in Figure
3-1.
The Cohen’s Kappa statistics for level one and level two screening were 0.73 and
0.58, respectively (Appendix I). These scores indicate substantial and moderate
agreement respectively21. However, of note, the raw percentage agreement scores for
level one and level two screening were 94% and 90%, respectively.

3.3.1

Characteristics of Included Studies
The characteristics of the included studies can be seen in Table 1 and the

characteristics of the participants in the included studies can be seen in Table 2. Of the
total 39 included studies, 10 were from Canada22–31, 21were from the United States of
America (USA) 19,20,32–50, and one included participants from both Canada and the USA51.
The remaining seven studies included countries outside of North America, in addition to
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either Canada, the USA, or both16–18,52–55. Twenty-two studies followed a cross-sectional
study design22,25,28–31,33,35–40,42,45,47,49–53,55. Four studies had a cohort design24,26,32,48 while
six studies followed a longitudinal survey design19,20,23,27,34,43. Seven studies followed a
randomized controlled trial (RCT) design16–18,41,44,46,54. Of the 22 studies that followed a
cross-sectional design, 3 of the studies were abstract-only publications22,30,42. The TTO
technique was used in nine of the included studies29–31,34–37,49,50, while the SG technique
was used in two studies35,36. Sixteen studies used the SF-36 16–18,23,25,27,32,42–45,47,48,51,52,54,
five studies used the SF-1225,33,38,40,41, and 3 studies used the SF-6D19,20,54. Two studies
used the HUI219,20, and three studies used the HUI319,20,22. Finally, 14 studies used the
EQ-5D16–20,24,26,28,39,46,51,53–55.
The mode of administration was self-administered in 19 studies16–
20,25,27,32,33,35,39,41,42,44,50,51,53,55,56

38,40,46,47,52

, interviewer-administered in 12 studies23,26,29,30,34,36–

, and self-administered using an assistant in two studies28,31. Seven of the

included studies focused on patients with glaucoma28,30–33,40,44. Eight studies focused on
patients with ARMD25,27,36–38,47,50,55. Seven studies focused on patients with
DR25,29,30,35,37,43,45. Six studies focused on patients with cataracts19,20,23,26,41,48. Five studies
focused on DED39,42,49,51,53. Five studies focused on patients with uveitis 16–18,24,54 and one
each on patients with retinal vein occlusion22, strabismus34, diabetic macular edema46,
posterior vitreous detachment25, and retinal detachment25.

3.3.2

Risk of Bias Assessment
The results of the RoB assessment can be seen in Appendix C. Of the 22 studies

using a cross-sectional design assessed using the Instrument for Cross-Sectional Surveys
of Attitudes and Practices, 10 studies were deemed to be of low risk25,28,29,31,35–38,40,53, nine
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studies were deemed to be of moderate risk33,39,45,47,49–52,55, and three were deemed to be
of high risk22,30,42. All five studies using a cohort design assessed by the Tool to Assess
Risk of Bias in Cohort Studies were deemed to be of moderate risk18,24,26,32,48. Of the five
studies using a RCT design assessed using the Tool to Assess Risk of Bias in
Randomized Controlled Trials, one study was deemed to be of low risk46, three studies
were deemed to be of moderate risk41,44,54, and one study was deemed to be of high risk17.
Finally, of the seven studies using a longitudinal survey design assessed using the Tool to
Assess Risk of Bias in Longitudinal Symptom Research Studies Aimed at the General
Population, five studies were deemed to be of low risk16,20,23,27,43, one study was deemed
to be of moderate risk19, and one study was deemed to be of high risk34.

3.3.3

HRQoL in Patients with Glaucoma
Table 3-3a presents the outcome data in studies pertaining to patients with

glaucoma. In the seven studies focused on patients with glaucoma, there were two studies
with a specific focus on primary open-angle glaucoma (POAG), four of the studies
focused on glaucoma in general, and the remaining one investigated open-angle glaucoma
(OAG).

There was a total of three different GPBMs that were used in the studies
pertaining to patients with glaucoma (Table 3-3a.). The SF-12 was used in two studies,
the SF-36 was used in two studies, and the EQ-5D 5L was used in one study. Moreover,
there were two studies that applied the TTO elicitation technique. Using the SF-12,
Balkrishanan et al.33 similarly reported a mean (SD) of 39.9 (12.0) for the PCS and 52.2
(9.9) for the MCS for all patients in their study. Serbin et al.40 also used the SF-12,
however they demonstrated a mean (SD) of 41.8 (12.6) for the PCS and 52.2 (9.9) for the
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MCS for all patients in their study. Serbin et al.40 also reported the PCS and MCS by
patients with and without select physical or mental comorbidity (SPMC) noting that the
scores were higher among patients without SPMC. The study by Bailey et al.32 reported a
mean (SD) of 45.6 (10.6) for the physical component score (PCS) and 54.2 (7.4) for the
mental component score (MCS) using the SF-36 for all patients in their study. Javitt et
al.44 used the SF-36 and reported baseline means and ranges for the PCS and MCS by
treatment group. In the brimonidine group, the mean PCS is 52.4 and its range is 23.5 to
64.7 while the mean MCS is 63.1 and its range is 38.7 to 74.8. Similarly, in the timolol
group, the mean PCS is 53.8 and its range is 21.4 to 64.0 while the mean MCS is 62.9 and
its range is 32.2 to 73.8.
The study by Montemayor et al.28, showed a mean utility score of 0.89 with a
range from -0.08 to 1.00 using the EQ-5D 5L for all patients in their study. Finally, using
the TTO method, Thomas et al.30 demonstrated a mean (SD) utility score of 0.94 (0.15)
for patients with glaucoma while Uruthiramoorthy et al.31 reported a mean (SD) utility
score of 0.91 (0.18) for all patients through also using the TTO method.

Overall, based on the SF-12, the mean PCS values ranged from 39.2 to 44.67 and
the mean MCS values ranged from 48.7 to 52.2. Based on the SF-36, the mean PCS
values ranged from 45.6 to 53.8 and the mean MCS values ranged from 54.2 to 63.1.
These scores generally suggest average physical health and mental health among patients
with glaucoma. The mean utility values of patients with glaucoma were between 0.89 to
0.94. However, these scores appear to suggest a good HRQoL among patients with
glaucoma.

39

3.3.4

HRQoL in Patients with Age-related Macular Degeneration
Table 3-3b presents the outcome data in studies pertaining to patients with

ARMD. Analysis of ARMD was covered in eight studies with a total of 1295
respondents. Seven of the studies focused on ARMD in general, while one study focused
specifically on wet ARMD.
Of the eight studies focused on ARMD, two used the SF-12, three used the SF-36,
and one used the EQ-5D (Table 3-3b). In terms of the direct preference elicitation
methods that were used, three studies used the TTO, and one study used the SG. The
study by Choudhury et al.38 presented mean PCS and MCS scores by disease severity
using the SF-12. Patients with early ARMD had mean a PCS and MCS of 46.8 (95% CI:
42.2, 51.4) and 49.8 (95% CI: 44.2, 55.2) respectively. Similarly, patients with late
ARMD group had a mean PCS and MCS of 44.0 (95% CI: 38.1, 49.8) and 50.9 (95% CI:
43.9, 58.0) respectively38. Globe et al.25 presented PCS and MCS scores for all patients
using both the SF-12 and SF-36. The SF-12 found a mean (SD) PCS of 46.0 (11.0) and a
mean (SD) MCS of 50.0 (12.0) while the SF-36 found a mean (SD) PCS of 45.0 (10.0)
and a mean (SD) MCS of 50.0 (11.0)25. Between the seven severity groups, Mackenzie et
al.27 found mean PCS scores ranging from 41.0 to 47.0 and mean MCS scores ranging
from 38.0 to 53.0. Mackenzie et al.27 and Mangione et al. 47 both used the SF-36 and
reported mean (SD) scores for each domain by disease severity which can be seen in
further detail in Appendix K.
The study by Brown et al.36 showed a mean utility score of 0.72 (95% CI: 0.66,
0.78) using TTO method and 0.81 (95% CI: 0.76, 0.86) using the SG method for all
patients in their study. Another study by Brown et al.37 also showed, for all study patients,
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a mean (SD) utility score of 0.74 (0.23) using TTO method. Both studies by Brown et
al.36 and Brown et al.37 also provide utility scores across patients grouped by visual acuity
(Table 3-3b). In a study by Brown et al.36, mean utility scores across all visual acuity
groups range from 0.40 to 0.96. However, in another study by Brown et al.37, the mean
utility values range from 0.59 to 0.84. In both studies, a general trend of higher utility
values with better visual acuity and lower utility values can be seen with worse visual
acuity. The study by Soubrane et al.55 showed a mean utility score of 0.95 (95% CI: 0.90,
0.99) for all patients with wet ARMD. Finally, using the EQ-5D, the study by Stein et
al.50 presented their results across disease severity where the mild, moderate, and severe
groups had mean utility scores of 0.83 (95% CI: 0.76, 0.90), 0.73 (95% CI: 0.67, 0.80),
and 0.57 (95% CI: 0.49, 0.65), respectively.
Overall, based on the SF-12, the mean PCS values ranged from 44.0 to 46.8 and
the mean MCS values ranged from 49.8 to 50.9. Based on the SF-36, the mean PCS
values ranged from 41.0 to 47.0 and the mean MCS values ranged from 38.0 to 52.0.
These scores appear to suggest generally average physical and mental health among
patients with ARMD. However, it is worth noting that the lower limits of the ranges are
likely indicative of a poorer quality of physical and mental health among patients with
more severe forms of ARMD. The mean utility values of patients with ARMD were
between 0.40 to 0.96. Overall, these scores suggest a variable HRQoL from poor to good
among patients with ARMD. However, once again, it should be noted that patients with
more severe forms of ARMD or with worse visual acuity appear to have poorer HRQoL.
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3.3.5

HRQoL in Patients with Diabetic Retinopathy
Table 3-3c presents the outcome data in studies pertaining to patients with DR.

There were seven studies that focused on patients with DR. Out of the seven studies, one
study applied both the SF-12 and SF-36, while two studies applied only the SF-36. It can
also be noted that two studies applied both the TTO and SG, while the other two studies
applied only the TTO.
Using the SF-12, a mean (SD) PCS of 46.0 (9.0) and a mean (SD) MCS of 51.0
(9.0) was reported. Globe et al.25 reported mean (SD) PCS and MCS using both the SF-12
and SF-36 for all patients in their study. Similarly, using the SF-36 a mean (SD) PCS of
46.0 (10.0) and a mean (SD) MCS of 50.0 (9.0) were also reported25. The study by Hirai
et al.43 reported mean (SD) PCS and MCS of 49.6 (9.6) and 51.6 (8.3) respectively using
the SF-36 for all study patients. Furthermore, Hirai et al.43 also reported 10-year followup PCS and MCS scores of 46.2 (11.1) and 52.9 (8.9), respectively. Additionally, Hirai et
al.43 and Lewis et al.45 both reported scores for each domain of the SF-36 which can be
seen in further detail in Appendix K.
The study by Brown et al.35 showed mean utility scores of 0.77 (95% CI: 0.73,
0.81) and 0.88 (95% CI: 0.84, 0.92) using the TTO and SG methods respectively for all
study patients. Another study by Brown et al.37 showed a utility score of 0.79 (0.20) using
the TTO method for all patients with DR. Both studies by Brown et al.35,37 provided
utility scores across patients grouped by visual acuity (Table 3-3c). In study by Brown et
al.35, mean utility scores across all visual acuity groups range from 0.59 to 0.92. However,
in the study by Brown et al.37, the mean utility values range from 0.60 to 0.86. Once
again, in both studies, a general trend of higher utility values with better visual acuity and
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lower utility values can be seen with worse visual acuity. Similarly, the study by Thomas
et al.30 showed a mean (SD) utility score of 0.81 (0.33) and Sharma et al. showed a mean
(SD) utility score of 0.79 (0.23) while both using the TTO method for all patients in their
respective studies.
Overall, based on the SF-12, the mean PCS value was 46.0 and the mean MCS
values ranged from 51.0. Based on the SF-36, the mean PCS values ranged from 46.2 to
46.0 and the mean MCS values ranged from 50.0 to 52.9. Overall, these scores suggest
generally average physical and mental health among patients with DR. The mean utility
values of patients with DR were between 0.59 to 0.92. These scores suggest a variable
HRQoL from poor to good among patients with DR. However, it should be noted that
patients with worse visual acuity appear to have poorer HRQoL.

3.3.6

HRQoL in Patients with Cataracts
Table 3-3d presents the outcome data in studies pertaining to patients with

cataracts. One study used the SF-12, three of the studies used the SF-36, another study
used the EQ-5D, HUI2, HUI3, and SF-6D, and another used only EQ-5D. Espindle et
al.41 provided mean (SD) PCS and MCS by intervention group using the SF-12 at
baseline prior to administering the interventions. The mean (SD) PCS and MCS were
43.2 (11.2) and 54.0 (9.1) respectively in the blue light-filtering intraocular lens (IOL)
group. In the clear IOL group, the mean (SD) PCS and MCS were 43.2 (11.3) and 54.0
(9.1) respectively41. Boisjoly et al.23 reported the median and interquartile range (IQR)
PCS and MSC for two cohorts with cataracts using the SF-36. The first cohort had a
median (IQR) PCS and MCS of 75.0 (50.0, 90.0) and 76.0 (56.0, 88.0) respectively, while
the second cohort had a median (IQR) PCS and MCS of 75.0 (50.0, 90.0) and 76.0 (64.0,
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80.0) respectively23. Owsley et al.48 reported the baseline mean (SD) PCS and MCS
across two intervention groups as well using the SF-36. In the surgery group, the mean
(SD) PCS and MCS were 45.9 (14.4) and 81.2 (16.1) respectively. Similarly, in the no
surgery group, the mean (SD) PCS and MCS were 45.9 (15.8) and 82.1 (11.1)
respectively48. Lee et al.52 reported mean (SD) scores for each domain in the SF-36 for all
patients (Appendix K).
The study by Feeny et al.19 showed a mean (SD) utility score of 0.83 (0.17) for the
EQ-5D, 0.79 (0.17) for the HUI2, 0.66 (0.27) for HUI3, and 0.74 (0.12) for the SF-6D for
all study patients. Finally, the study by Lim et al.26 showed a mean (SD) utility score of
0.85 (0.14) using the EQ-5D for all patients preoperatively.
Overall, based on the SF-12, the mean PCS values ranged from 43.2 to 46.1 and
the mean MCS values ranged from 54.0 to 54.6. These scores suggest generally average
physical and mental health among patients with cataracts. Based on the SF-36, the central
tendencies of PCS values ranged from 45.9 to 75.0 and the mean MCS values ranged
from 76.0 to 82.1. These scores suggest generally average to good physical health and
good mental health among patients with cataracts. The mean utility values of patients
with cataracts were between 0.66 to 0.85. These scores suggest fair to good HRQoL
among patients with cataracts.

3.3.7

HRQoL in Patients with Uveitis
Table 3-3e presents the outcome data in three studies pertaining to patients with

uveitis. One study by Chan et al.24 dealt with anterior uveitis, the other one by Naik et
al.54 investigated uveitis in general, and the combined study by The Multicenter Uveitis
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Steroid Treatment Trial Research Group16–18 dealt with intermediate uveitis and pan
uveitis.
All studies in patients with uveitis applied a different variety of GPBMs. The first
study by Chan et al.24 used EQ-5D (5L), the second one by Naik et al.54 applied both SF36 and SF-6D, and the last one by The Multicenter Uveitis Steroid Treatment Trial
Research Group16–18 used EQ-5D and SF-36. Naik et al.54 reported a mean (SD) PCS and
MCS score of 47.4 (12.2) and 47.6 (12.7) respectively. The Multicenter Uveitis Steroid
Treatment Trial Research Group 16–18 reported median (IQR) PCS and MCS scores of
55.0 (45.0, 55.0) and 52.0 (40.0, 57.0) for all patients with virtually identical scores
being reported among patients with intermediate and pan uveitis. Further information on
each domain score from both studies can be found in Appendix K.
Among patients with anterior uveitis, the study by Chan et al.24 showed a mean
(SD) utility score of 0.72 (0.21) for patients who also presented with inflammatory back
pain and 0.82 (0.16) for patients without inflammatory back pain. However, the study by
Naik et al.54 showed a mean (SD) utility score of 0.67 (0.11) and 0.84 (0.13) using the SF6D and EQ-5D respectively. In addition, the Multicenter Uveitis Steroid Treatment Trial
Research Group16–18 showed median (IQR) utility scores of 0.8 (0.8, 1.0) for all patients,
for patients with intermediate uveitis, and for patients with pan uveitis. Further scores by
stratification on follow-up time by treatment group can be found in Appendix K.
Overall, based on the SF-36, the measures of central tendency for PCS values
ranged from 47.4 to 50.0 and MCS values ranged from 47.6 to 52.0. These scores suggest
generally average physical and mental health among patients with uveitis. The measures
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of central tendency for utility values of patients with uveitis were between 0.67 to 0.84.
These scores suggest fair to good HRQoL among patients with uveitis.

3.3.8

HRQoL in Patients with Dry Eye Disease
Table 3-3f presents the outcome data in studies pertaining to patients with DED.

There were five studies conducted on patients with DED. The included studies that were
conducted on patients with DED used different sets of GPBMs. Two of the studies by
Dana et al.39 and Messmer et al.53 used the EQ-5D 5L, the study by Farrand et al.42 used
the SF-36, and lastly, the EQ-5D 3L and SF-36 were used by Rajagopalan51. Schiffman et
al.49 was the only study that used the TTO elicitation method.
The study by Farrand et al.42 reported PCS and MCS scores across patients with
diagnosed DED and symptomatic participants with undiagnosed DED. The mean (SD)
PCS and MCS scores were 45.3 (10.6) and 48.1 (22.4) respectively in the patients
diagnosed with DED. Similarly, the mean (SD) PCS and MCS scores were 45.3 (10.6)
and 48.1 (22.4) respectively in the participants who were symptomatic and undiagnosed
with DED42. Rajagopalan et al.51 showed mean (SD) PCS and MCS scores of 47.1 (0.9)
and 51.0 (0.8) respectively for all patients in their study.
The study by Dana et al.39 showed a mean (SD) utility value score of 0.82 (0.13)
for all patients with DED. Messmer et al.53 showed a mean utility value score of 0.78 for
all patients with DED. However, the study by Rajagopalan et al.51 showed a mean (SD)
utility score of 0.82 (0.02) for all their study patients. The study by Schiffman et al.49
reported mean (SD) utility scores across the severity of DED among their patients.
Patients who were asymptomatic, had mild, moderate, severe, and DED requiring surgery
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revealed mean (SD) scores of 0.78 (0.23), 0.81 (18), 0.78 (0.19), 0.72 (0.23), and 0.62
(0.26) respectively.
Overall, based on the SF-36, the mean PCS values ranged from 45.3 to 48.8 and
MCS values ranged from 44.6 to 51.0. These scores suggest generally average physical
and mental health among patients with DED. The mean utility values of patients with
DED were between 0.62 to 0.82. These scores suggest fair to good HRQoL among
patients with DED. However, it should be noted that patients with worse disease severity
had lower HRQoL.

3.3.9

HRQoL in Patients with other eye diseases
The current review involved a number of other eye diseases, including central

retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) in the study by
Balshaw et al.22, diabetic macular edema (DME) in the study by Loftus et al.46, both
posterior vitreous detachment (PVD) and retinal detachment in the study by Globe et
al.25, and strabismus in the study by Beauchamp et al.3425 (Table 3-3g).
The GPBMs that were applied were different as well. The HUI3 was used in the
study pertaining to CRVO and BRVO, the EQ-5D (3L) was used in the study on DME,
and the SF-12 and SF-36 were used in the study on PVD and retinal detachment (Table 33g). The study on adult strabismus by Beauchamp et al.34 used the TTO method. Globe et
al.25 presented mean (SD) PCS and MCS for both the SF-12 and SF-36. Among all
patients with PVD, the SF-12 showed mean (SD) PCS and MCS of 51.0 (9.0) and 52.0
(9.0) respectively. The SF-36 showed mean (SD) PCS and MCS of 51.0 (9.0) and 52.0
(9.0) respectively for patients with PVD as well. For retinal detachment, the SF-12
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showed mean (SD) PCS and MCS of 49.0 (8.0) and 48.0 (11.0) respectively.
Furthermore, the SF-36 showed mean (SD) PCS and MCS of 50.0 (7.0) and 48.0 (11.0)
respectively for patients with retinal detachment.
The study by Balshaw et al.22 showed a mean (SD) utility score of 0.80 (0.42) for
patients with CRVO and BRVO together using the HUI3. The study by Beauchamp et
al.34 showed a mean (SD) utility value score of 0.85 (0.20) using TTO method for all
patients with strabismus preoperatively. Finally, the study by Loftus et al.46 presented
baseline mean utility scores by treatment group for patients with DME; the Pegaptanib
group had a score of 0.74 and the Sham group had a score of 0.76.

48

Figure 3-1. PRISMA flowchart of the study selection process.
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Table 3-1. Characteristics of the included studies.

First Author
and Year of
Publication

Country

Bailey 2016

USA

Balkrishnan 2003

USA

Balshaw 2012

Canada

Beauchamp 2006

USA

Boisjoly 2010

Canada

Brown 1999

Study Design

Sampling Method

Study Setting

Elicitation
Method**

Mode of
Administration

Prospective
cohort
Cross-sectional

Cumulative
incidence
Convenience

Not specified

SF-36

Tertiary healthcare

SF-12

Not specified

Not specified

HUI3

Convenience

Tertiary healthcare

TTO

Intervieweradministered

Convenience

Tertiary healthcare

SF-36

USA

Cross-sectional
(Abstract only)
Prospective
survey and cost
utility analysis
Prospective
survey
Cross-sectional

Convenience

Tertiary healthcare

TTO, SG

Brown 2000

USA

Cross-sectional

Convenience

Tertiary healthcare

TTO, SG

Brown 2002

USA

Cross-sectional

Convenience

Tertiary healthcare

TTO

Chan 2012

Canada

Random

USA

Not specified

Community and
tertiary healthcare
Community

EQ-5D 5L

Choudhury 2016

Retrospective
cohort
Cross-sectional

Dana 2020

USA

Cross-sectional

Not specified

Community

EQ-5D 5L

Espindle 2005

USA

RCT

Convenience

Tertiary healthcare

SF-12

Farrand 2016

USA

Not specified

Community

SF-36

Feenya 2012

USA

Cross-sectional
(Abstract only)
Longitudinal
survey

Not specified

Tertiary healthcare

Globe 2002

Canada

Cross-sectional

Convenience

Tertiary healthcare

EQ-5D 3L,
HUI2, HUI3,
SF-6D
SF-12, SF-36

Intervieweradministered
Selfadministered
Intervieweradministered
Intervieweradministered
Selfadministered
Intervieweradministered
Selfadministered
Selfadministered
Selfadministered
Selfadministered

Hirai 2012

USA

Not specified

Tertiary healthcare

SF-36

Javitt 2000

USA

Longitudinal
survey
RCT

Convenience

Tertiary healthcare

SF-36

Lee 2003

USA, Korea

Cross-sectional

Convenience

Tertiary healthcare

SF-36

Lewis 2017
Lim 2021

USA
Canada

Not specified
Convenience

Tertiary healthcare
Tertiary healthcare

SF-36
EQ-5D

Loftus 2011

USA

Cross-sectional
Prospective
cohort
RCT

Not specified

Tertiary healthcare

EQ-5D 3L

Mackenzie 2002

Canada

Prospective case

Convenience

Tertiary healthcare

SF-36

SF-12

Selfadministered
Selfadministered
Not specified

Selfadministered
Not specified
Selfadministered
Intervieweradministered
Not specified
Intervieweradministered
Intervieweradministered
Self-
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series
Cross-sectional

Convenience

Tertiary healthcare

SF-36

USA,
Australia,
Germany,
UK
Canada

Cross-sectional

Convenience

Tertiary healthcare

EQ-5D 5L

Cross-sectional

Convenience

Tertiary healthcare

EQ-5D 5L

USA,
Canada,
Brazil,
Czech
Republic,
France,
Germany,
Greece,
Australia,
Austria,
Israel, India,
South
Africa,
Korea,
Poland,
Portugal,
Spain,
Switzerland,
UK
USA

RCT

Not specified

Tertiary healthcare

SF-36, SF-6D,
EQ-5D

Prospective
cohort
Cross-sectional

Convenience

Tertiary healthcare

SF-36

Not specified

Convenience

Tertiary healthcare

Cross-sectional
Cross-sectional

Convenience
Not specified

Tertiary healthcare
Community

SF-36, EQ-5D
3L
TTO
SF-12

Selfadministered
Not specified
Intervieweradministered
Intervieweradministered
Selfadministered

Mangione 1999

USA

Messmer 2019

Montemayor
2001

Naik 2013

Owsley 2007
Rajagopalan 2005

administered
Intervieweradministered
Selfadministered

Selfadministered
with assistance
in person
Not specified

Schiffman 2003
Serbin 2020

USA,
Canada
USA
USA

Sharma 2003

Canada

Cross-sectional

Convenience

Tertiary healthcare

TTO

Soubrane 2007

Canada,
France,
Germany,
Spain, UK
USA

Cross-sectional

Convenience

Tertiary healthcare

EQ-5D

Cross-sectional

Community and
Tertiary healthcare

TTO

Selfadministered

USA,
Canada,
Australia,
UK

RCT

Convenience for
ARMD, Random
for general public
Not specified

Tertiary healthcare

EQ-5D, SF-36

Selfadministered

Canada

Cross-sectional

Convenience

Tertiary healthcare

TTO

Interviewer-

Stein 2002

The Multicenter
Uveitis Steroid
Treatment Trial
Research Groupb
2015
Thomas 2015
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Uruthiramoorthy
2017

Canada

(Abstract only)
Cross-sectional

Convenience

Tertiary healthcare

TTO

administered
Selfadministered
with assistance
in person

**EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures, TTO
and SG are direct elicitation methods; ARMD: age-related macular degeneration; DED: dry eye
disease; USA: United States of America; UK: United Kingdom; RCT: randomized controlled
trial; a: Groessl et al. was merged with this study; b: Frick et al. and Sugar et al. were merged with
this study

Table 3-2. Characteristics of the participants of the included studies.
First Author
and
Year of
Publication
Bailey 2016

Male: n
(%)

Female: n
(%)

Not
specified

317
(100%)

Balkrishnan
2003

111
(31.0%)

247
(69.0%)

Balshaw 2012

Not
specified

Not
specified

Beauchamp
2006

14
(40.0%)

21 (60.0%)

Boisjoly 2010

Cohort
1: 168
(33.0%)

Cohort 1:
341
(67.0%)

Cohort
2: 76
(36.9%)
37
(38.9%)

Cohort 2:
130
(63.1%)
58 (61.1%)

Brown 2000

24
(33.3%)

48 (66.7%)

Brown 2002

Diabetic
retinopat
hy: 146

Diabetic
retinopathy
: 188

Brown 1999

Age

Mean (SD):
64.0 (6.4)

Sample Size

Education Level

Race/ethnicity: n (%)

317 POAG

Education: N (%)

Not specified

Range: 65 to
89
Mean (SD):
75.8 (7.3)
Range: 39 to
92
Median: 72
Range: 19 to
75
Mean: 49
Median
Cohort1: 73
Median
Cohort2: 72

589 POAG

Graduate School: 28
(8.8%)
Not specified

Not specified

202 Total
75 CRVO
127 BRVO
35 Strabismus

Not specified

Not specified

Not specified

Not specified

715 Cataracts
509 Cohort 1
206 Cohort 2

Not specified

Not specified

Range: 28 to
87
Mean (SD):
63 (11)
Median: 64
Range: 56 to
85
Mean: 74.4
Mean
diabetic
retinopathy:

100 Diabetic
retinopathy

Mean (SD) number
of years of formal
education after
kindergarten: 13.0
(3.0)
Mean (SD) number
of years of education:
12.8 (3.2)
Not specified

Not specified

80 ARMD

617 Total
333 Diabetic
retinopathy

White: 72 (100%)

Diabetic retinopathy:
White: 302 (90.4%)
Non-white: 32 (9.6%)
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Chan 2012

(43.7%)

(56.3%)

62.2

ARMD:
83
(33.7%)
Back
pain: 22
(33.3%)

ARMD:
163
(66.3%)
Back pain:
44 (66.7%)

Mean
ARMD: 73.2

No back
pain: 42
(56.0%)

No back
pain: 33
(44.0%)

Mean (SD)
back pain:
45.6 (13.4)
Mean (SD)
no back
pain: 51.4
(16.0)
Mean (SD):
54.8 (10.7)

Choudhury 2016

2001
(41.0%)

2875
(59.0%)

Dana*2020

351
(35.0%)

652
(65.0%)

Mean (SD):
56.0 (14.7)
Median: 60

Espindle 2005

Blue
Light–
Filtering
IOL: 36
(27.5%)

Blue
Light–
Filtering
IOL: 95
(72.5%)

Blue Light–
Filtering
IOL:
Mean (SD):
72.5 (6.71)

Clear
IOL: 53
(42.1%)
35566
(48.0%)

Clear IOL:
73 (57.9%)

Clear IOL:
Mean (SD):
72.0 (6.14)
Mean (SD):
48 (17)

154
(41.0%)

222
(59.0%)

Farrand 2016

Feenya 2012

38529
(52.0%)

Age group:
N (%)
35 to 44: 5
(1.3%)
45 to 64:
115 (30.6%)
65 to 91:
256 (68.1%)

246 ARMD
38 Excluded

167 Anterior uveitis

ARMD
White: 245 (99.6%)
Non-white: 1 (0.4%)
Not specified

Back pain:
White: 55 (83.3%)
No back pain:
White: 49 (65.3%)

4876 Total
4402 No ARMD
474 ARMD
2009 Total
1003 DED
1006 no DED

Not specified

Latino: 2001 (100.0%)

Not specified

291 Cataracts

Not specified

White: 907 (90.4%)
Hispanic/Latino: 63 (6.3%)
Black/African American:
46 (4.6%)
Asian: 38 (3.8%)
Other: 28 (2.8%)
Preferred not to answer: 6
(0.6%)
Blue Light–Filtering IOL:
White: 126 (96.2%)
Clear IOL:
White: 123 (97.6%)

74095 Total
5,042 DiagnosedDED
1,785 UndiagnosedDED
67,268 non-DED
536 total
376 Cataracts
160 Heart failure

Not specified

Not specified

Education: n (%)

White: 328 (87.2%)
Black: 12 (3.2%)
Asian: 19 (5.0%)
Other: 4 (1.1%)
Missing: 13 (3.5%)

< High school: 21
(5.6%)
High School
graduate: 60 (16.0%)
Some college: 78
(20.7%)
2-year assoc: 27
(7.2%)
4-year college grad:
90 (23.9%)
Master’s degree: 57
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Globe 2002

409
(48.7%)

430
(51.3%)

Mean (SD):
55.7 (17.3)

Hirai 2012

256
(49.3%)
Brimoni
dine: 52
(49.1%)

264
(50.7%)
Brimonidi
ne: 54
(50.9%)

Mean (SD):
39.2 (9.4)
Brimonidine
: Range: 29
to 87
Mean: 59

Timolol:
41
(39.0%)

Timolol:
64 (61.0%)

28
(53.8%)

24 (46.2%)

Javitt 2000

Lee 2003

Timolol:
Range: 21 to
80
Mean: 56
Mean (SD):
72.04 (8.19)

1081 Total
126 ARMD
106 Diabetic
retinopathy
89 Retinal
detachment
79 PVD
498 Other retinal
disease
183 Excluded
520 Diabetic
retinopathy
219 OAG

132 Cataracts
84 Korean
65 American

(15.2%)
Doctorate/professiona
l: 34 (9.0%)
Missing: 9 (2.4%)
Not specified

Mean (SD) years in
school: 14.2 (2.5)
Not specified

Education: n (%)
Graduated high
school or higher
education: 46
(88.0%)
Not specified

Lewis 2017

18
(36.0%)

32 (64.0%)

Range: 26 to
87
Mean (SD):
63.9 (13.9)

100 Total
50 Healthy controls
50 Diabetic
retinopathy

Lim 2021

136
(43.5%)

177
(56.5%)

Range: 42 to
84
Mean: 69.07

320 Cataracts

Education: n (%)

Pegaptanib:
Range: 28 to
83
Mean (SD):
62.3 (9.3)

260 DME

< High school: 48
(15.3%)
High school: 84
(26.8%)
Apprenticeship: 16
(5.1%)
College: 65 (20.8%)
University: 100
(31.9%)
Not specified

Loftus 2011

Pegapta
nib: 81
(60.9%)

Pegaptanib
: 52
(39.1%)

Sham:

Sham: 59

White: 622 (74.1%)
Asian: 181 (21.6%)
Black: 0
Indo-Pakistani: 36 (4.3%)

Unclear
Brimonidine:
White: 67 (63.2%)
Black: 33 (31.1%)
Other: 6 (5.6%)
Timolol:
White: 52 (49.5%)
Black: 50 (47.6%)
Other: 3 (2.9%)
Not specified

White: 4 (8.0%)
Black: 16 (32.0%)
Hispanic: 29 (58.0%)
Other: 1 (2.0%)
Africa: 12 (3.9%)
Americas: 87 (27.7%)
Asia: 88 (28.0%)
Europe: 127 (40.5%)

Pegaptanib:
Caucasian/white: 104
(78.2%)
Asian: 13 (9.8%)
Black: 3 (2.3%)
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68
(53.5%)

(46.5%)

Median: 62

Hispanic: 8 (6.0%)
Other: 5 (3.8%)

Sham:
Range: 20 to
80
Mean (SD):
62.5 (10.2)
Median: 63

Mackenzie 2002

61
(38.4%)

98 (61.6%)

Mean (SD):
75 (9)

159 ARMD

Not specified

Mangione 1999

74
(36.8%)
58
(34.1%)

127
(63.2%)
112
(65.9%)

201 ARMD

Not specified

160 DED
40 USA
40 Australia
40 Germany 40 UK

Not specified

Not specified

Montemayor
2001

113
(50.4%)

111
(49.6%)

224 Glaucoma

Not specified

Not specified

Naik 2013

82
(36.6%)

142
(63.4%)

Mean (SD):
71 (10)
Age group:
N (%)
21 to 30: 17
(10%)
31 to 40: 22
(12.9%)
41 to 50: 32
(18.8%)
51 to 60: 46
(27.1%)
61 to 70: 34
(20.0%)
71 to 80: 15
(8.8%)
Range: 24 to
92
Mean (SD):
64.3 (14.4)
Mean (SD):
44.6 (14.3)

Sham:
Caucasian/white: 107
(84.3%)
Asian: 15 (11.8%)
Black: 2 (1.6%)
Hispanic: 3 (2.4%)
Other: 0
Caucasian: 132 (83.0%)
Asian: 21 (13.2%)
East Indian: 6 (3.8%)
Not specified

Not specified

White:135 (60.3%)

Owsley 2007

Surgery:
8
(26.7%)

Surgery:
22 (73.3%)

224 Total
180 Intermediate
uveitis
44 Posterior uveitis
45 Cataracts

Education: n (%)

Surgery:
African American: 7
(23.3%)
White, non-Hispanic: 23
(77.7%)

Messmer 2019

No
surgery:
2
(13.3%)

No
surgery: 13
(86.7%)

Surgery:
Mean (SD):
81 (8)
No surgery:
Mean (SD):
87 (6)

Surgery:
Attended school but
not a high school
graduate: 19 (63.3%)
High school graduate:
4 (13.3%)
At least some
college: 7 (23.3%)

No surgery:
Attended school but
not a high school

No surgery:
African American:3
(20.0%)
White, non-Hispanic: 12
(80.0%)
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graduate: 8 (53.3%)
High school graduate:
5 (33.3%)
At least some
college: 2 (13.3%)
Highest level of
education: n (%)
High school diploma
or less: 23 (18%)
Some college: 47
(36%)
College degree: 29
(22%)
Graduate/postgraduat
e: 31 (24%)
Mean (SD) number
of years of education:
14.5 (2.8)

Caucasian: 106 (81.5%)
African American: 12
(9.2%)
Hispanic/Spanish
American: 5 (3.9%)
Asian/Oriental/Pacific
Islander: 6 (4.6%)
Other: 1 (0.8%)

Rajagopalan*
2005

27
(20.8%)

103
(79.2%)

Range: 22 to
89
Mean (SD):
55.18
(15.26)

210 Total
130 Non-SS KCS
32 SS
48 Controls

Schiffman 2003

11
(19.3%)

46 (80.7%)

57 DED

Serbin 2020

1220
(41.7%)

1708
(58.3%)

Range: 22 to
77
Mean (SD):
52.7 (13.9)
Mean (SD):
65.09
(15.84)

2982 Glaucoma

Education: n (%)

Not specified

Mean (SD):
63.5 (12.5)
Median: 67
Age group: n
(%)
0 to 50: 32
(14.5%)
51 to 60: 47
(21.3%)
61 to 70: 66
(29.9%)
71 to 80: 68
(30.8%)
> 80: 8
(3.6%)
Range: 53 to
95
Mean (SD):
78.1 (6.9)

221 Diabetic
retinopathy

No education: 21
(0.7%)
≤ High school: 1243
(42.5%)
1 to 3 years of
college: 368 (12.6%)
4 years of college:
250 (8.5%)
> 4 years of college:
216 (7.4%)
Unreported/not
ascertained: 830
(28.3%)
Highest education
level: n (%)

White: 217 (98.2%)
Other: 4 (1.8%)

Sharma 2003

Soubrane* 2007

114
(51.6%)

140
(70.0%)

107
(48.4%)

260
(30.0%)

White: 35 (61.4%)
Black: 22 (38.6%)

< High school: 112
(50.7%)
High school: 60
(27.1%)
> High school: 49
(22.2%)

872 Wet ARMD

Not specified

White: 397 (99.0%)
Black: 0
Asian: 0
Other: 2 (0.5%)
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Median: 79
Mean (SD):
75.1 (7.92)

Stein* 2002

42
(35.3%)

77 (64.7%)

The Multicenter
Uveitis Steroid
Treatment Trial
Research
Groupb 2015
Thomas 2015

64
(25.1%)

191
(74.9%)

Mean (SD):
46.3 (15.0)
Median: 47

Unclear

Unclear

Unclear

Uruthiramoorthy
2017

Unclear

Unclear

Mean (SD):
72.9 (10.2)

339 Total
15 Excluded
115 ARMD
142 General public
62 Providers
255 Uveitis

Not specified

White: 118 (99.2%)
Other: 1 (0.8%)

Not specified

50 Glaucoma +
Diabetic
retinopathy
250 Glaucoma

Not specified

White: 142 (55.7%)
Hispanic/Latino: 33
(12.9%)
Black: 66 (25.9%)
Other: 14 (5.5%)
Not specified

Education: n (%)
Completed high
school or less: 122
(48.8%)
Completed more than
high school: 128
(51.2%)

Caucasian: 199 (79.6%)
East Asian: 3 (1.2%)
Black: 4 (1.6%)
First Nations: 3 (1.2%)
Other: 41 (16.4%)

ARMD: age-related macular degeneration; BRVO: branch retinal vein occlusion; CRVO: central
retinal vein occlusion; DED: dry eye disease; DME: diabetic macular edema; SS: Sjögren’s
Syndrome; KCS: Keratoconjunctivitis Sicca; PVD: posterior vitreous attachment; USA: United
States of America; UK: United Kingdom; IOL: intraocular lens; OAG: open-angle glaucoma;
POAG: primary open-angle glaucoma; SD: standard deviation; *: data only pertains to patients
with the respective eye disease; a: Groessl et al. was merged with this study; b: Frick et al. and
Sugar et al. were merged with this study

Table 3-3a. Health-related quality of life outcomes in patients with glaucoma.
First Author
and
Year of
Publication
Bailey 2016

Eye
disease (s)

Elicitation
method**

Utility values

POAG

SF-36

Not reported

Balkrishnan
2003
Javitt 2000

POAG

SF-12

Not reported

OAG

SF-36

Not reported

Montemayor
2001

Glaucoma

EQ-5D 5L

Mean (Range): 0.89 (0.08 to 1.00)

Summary scores on preference-based measures

Mean (SD) PCS: 45.6 (10.6)
Mean (SD) MCS: 54.2 (7.4)
Mean (SD) PCS: 39.3 (12.0)
Mean (SD) MCS: 52.2 (9.9)
Treatment group:
PCS: Mean (Range)
MCS: Mean (Range)
Brimonidine:
Timolol:
PCS: 52.4 (23.5 to 64.7)
PCS: 53.8 (21.4 to 64.0)
MCS: 63.1 (38.7 to 74.8)
MCS: 62.9 (32.2 to 73.8)
Not reported

57

Serbin 2020

Glaucoma

SF-12

Not reported

Patient group:
PCS: Mean (SD)
MCS: Mean (SD)
All patients:
PCS: 41.79 (12.55)
MCS: 50.17 (10.56)

Thomas 2015
Uruthiramoort
hy 2017

Glaucoma
Glaucoma

TTO
TTO

Mean (SD): 0.94 (0.15)
Mean (SD): 0.91 (0.18)

Patients With SPMC:
PCS: 39.22 (12.76)
MCS: 48.74 (11.22)
Patients Without
SPMC:
PCS: 44.67 (11.66)
MCS: 51.79 (9.51)

Not applicable
Not applicable

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; BCVA: best-corrected visual acuity; MCS: mental
component score; PCS: physical component score; POAG: primary open-angle glaucoma; SD:
standard deviation SPMC: select physical or mental comorbidity
Table 3-3b. Health-related quality of life outcomes in patients with age-related macular
degeneration.
First
Author and
Year of
Publication
Brown 2000

Eye
disease(s)

ARMD

Elicitation
method**

TTO, SG

Utility values

Visual acuity: n (%)
Mean (95% CI)
All patients: 72
(100%)
TTO: 0.72 (0.66,
0.78)
SG: 0.81 (0.76, 0.86)
20/20 to 20/25: 21
(29.2%)
TT0: 89 (0.82, 0.96)
SG: 0.96 (0.92, 1.00)

Brown 2002

ARMD

TTO

20/30 to 20/50: 23
(31.9%)
TTO: 0.81 (0.73,
0.89)
SG: 0.88 (0.83, 0.93)
Visual acuity: n (%)
Mean (SD)

Summary scores on preference-based
measures

Not applicable

20/60 to 20/100: 11
(15.3%)
TTO: 0.57 (0.47, 0.67)
SG: 0.69 (0.52, 0.86)
20/200 to 20/400: 12
(16.7%)
TTO: 0.52 (0.38, 0.66)
SG: 0.71 (0.57, 0.85)
CF to LP: 4 (4.2%)
TTO: 0.40 (0.29, 0.50)
SG: 0.55 (0.36, 0.74)

Not applicable
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Choudhury
2016

ARMD

SF-12

All patients: 263
(100%)
0.74 (0.23)

20/50 to 20/100: 57
(21.7%)
0.71 (0.22)

20/20 to 20/25: 60
(22.8%)
0.84 (0.21)

≤ 20/200: 65 (24.7%)
0.59 (0.22)

20/30 to 20/40: 65
(24.7%)
0.80 (0.19)
Not reported

Early ARMD: Mean (95% CI)
PCS: 46.8 (42.2, 51.4)
MSC: 49.8 (44.2, 55.2)
Late ARMD: Mean (95%CI)
PCS: 44.0 (38.1, 49.8)
MCS: 50.9 (43.9, 58.0)
SF-12: Mean (SD)
SF-36: Mean
PCS: 46 (11)
(SD)
MCS: 50 (12)
PCS: 45 (10)
MCS: 50 (11)
Severity of ARMD:
Grade 4:
SF-36: Mean (SD)
PCS: 47 (7.5)
MCS: 52 (8.5)
Grade 1:
PCS: 47 (10)
Grade 5:
MCS: 49 (12)
PCS: 44 (13)
MCS: 38 (16)
Grade 2:
PCS: 46 (11)
Grade 6:
MCS: 53 (12)
PCS: 41 (15)
MCS: 52 (10)
Grade 3:
PCS: 46 (11)
Grade 7:
MCS: 50 (11)
PCS: 42 (13)
MCS: 51 (9)

Globe 2002

ARMD

SF-12, SF-36

Not reported

Mackenzie
2002

ARMD

SF-36

Not reported

Soubrane
2007
Stein 2002

Wet
ARMD
ARMD

EQ-5D

Mean (95% CI): 0.95 (0.90, 0.99)

Not applicable

TTO

Severity of ARMD: n
(%)
Mean (95%CI)

Moderate ARMD: 47
(40.9%)
0.732 (0.669, 0.795)

Not applicable

Mild ARMD: 34
(29.6%)
0.832 (0.762, 0.901)

Severe ARMD: 37
(32.2%)
0.566 (0.487, 0.645)

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; CI: confidence interval; MCS: mental component
score; PCS: physical component score; SD: standard deviation
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Table 3-3c. Health-related quality of life outcomes in patients with diabetic retinopathy.
First Author
and
Year of
Publication
Brown 1999

Eye
disease(s)

Diabetic
retinopathy

Elicitation
method**

TTO, SG

Utility values

Visual acuity: n (%)
TTO: mean (95%CI)
SG: mean (95%CI)
All patients: 95 (100%)
TTO: 0.77 (0.73, 0.81)
SG: 0.88 (0.84, 0.92)
20/20 to 20/25: 15
(15.8%)
TTO: 0.85 (0.75, 0.95)
SG: 0.90 (0.83, 0.97)

Brown 2002

Diabetic
retinopathy

TTO

20/30 to 20/50: 48
(50.5%)
TTO: 0.78 (0.72, 0.84)
SG: 0.92 (0.88, 0.96)
Visual acuity: n (%)
Mean (SD)
All patients: 354
(100%)
0.79 (0.20)
20/20 to 20/25: 72
(20.3%)
0.86 (0.17)

20/60 to 20/100: 21
(22.1%)
TTO: 0.78 (0.70, 0.86)
SG: 0.84 (0.72, 0.96)

Summary scores on preferencebased measures

Not applicable

20/200 to 20/400: 7
(7.4%)
TTO: 0.64 (0.53, 0.75)
SG: 0.71 (0.58, 0.84)
CF to HM: 4 (4.2%)
TTO: 0.59 (0.23, 0.95)
SG: 0.70 (0.29, 1.11)

20/30 to 20/40: 130
(36.7%)
0.80 (0.19)

Not applicable

20/50 to 20/100: 95
(26.8%)
0.77 (0.18)
≤ 20/200: 36 (10.2%)
0.60 (0.19)

Globe 2002

Diabetic
retinopathy

SF-12, SF-36

Not reported

SF-12: Mean
(SD)
PCS: 46 (9)
MCS: 51 (9)

SF-36: Mean
(SD)
PCS: 46 (10)
MCS: 50 (9)

Hirai 2012

Diabetic
retinopathy

SF-36

Not reported

10-year follow
up SF-36: Mean
(SD)
PCS: 46.2
(11.1)
MCS: 52.9 (8.9)

Sharma 2003

Diabetic
retinopathy
Diabetic
retinopathy

TTO

Mean (SD): 0.79 (0.23)

Baseline SF36: Mean (SD)
PCS: 49.6
(9.6)
MCS: 51.6
(8.3)
Not applicable

TTO

Mean (SD): 0.81 (0.33)

Not applicable

Thomas 2015

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; CF: counting fingers; HM: hand motions; MCS:
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mental component score; NLP: no light perception; NPDR: non proliferative diabetic
retinopathy; PCS: physical component score
Table 3-3d. Health-related quality of life outcomes in patients with cataracts.

First
Author and
Year of
Publication
Boisjoly
2010

Espindle
2005

Feenya 2012

Eye
disease(s)

Cataracts

Cataracts

Cataracts

Elicitation
method**

SF-36

SF-12

EQ-5D,
HUI2,
HUI3, SF6D

Utility values

Not reported

Cohort:
SF-36: Median (IQR)
Cohort 1:
PCS: 75 (50, 90)
MCS: 76 (56, 88)
Treatment group:
SF-12: Mean (SD)

Not reported

Baseline:
Mean (SD) EQ-5D:
0.83 (0.17)
Mean (SD) HUI2:
0.79 (0.17)
Mean (SD) HUI3:
0.66 (0.27)
Mean (SD) SF-6D:
0.74 (0.12)

Lim 2021

Cataracts

EQ-5D

Preoperative mean
(SD) 0.85 (0.14)

Owsley
2007

Cataracts

SF-36

Not reported

Summary scores on preference-based
measures

One month
postoperatively:

Blue Light–Filtering
IOL:
PCS: 43.21 (11.28)
MCS: 53.99 (9.13)
Not applicable

Cohort 2
PCS: 75 (50,
90)
MCS: 76 (64,
88)
Clear IOL:
PCS: 46.10
(10.04)
MCS: 54.60
(7.97)

Mean (SD) EQ5D: 0.84 (0.16)
Mean (SD) HUI2:
0.81 (0.19)
Mean (SD) HUI3:
0.72 (0.28)
Mean (SD) SF6D: 0.73 (0.12)
Postoperative
mean (SD): 0.88
(0.12)

Not applicable

Baseline Group:
SF-36: Mean (SD)
Surgery:
PCS: 45.9 (14.4)
MCS: 81.2 (16.1)
No surgery:
PCS: 45.9 (15.8)
MCS: 82.1 (11.1)

Follow up
group:
SF-36: Mean
(SD)
Surgery:
PCS: 44.0
(14.2)
MCS: 85.3
(13.5)
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No surgery:
PCS: 45.6
(14.3)
MCS: 86.5
(7.0)

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; IQR: interquartile range; IOL: intraocular lens; MCS:
mental component score; PCS: physical component score; SD: standard deviation; a: Groessl et
al. was merged with this study.
Table 3-3e. Health-related quality of life outcomes in patients with uveitis.
First Author
and Year of
Publication
Chan 2012

Eye
disease(s)
Anterior
uveitis

Elicitation
method**
EQ-5D 5L

Utility values

Summary scores on preference-based measures

Patient group: Mean (SD)

Not applicable

Back pain: 0.72 (0.21)

Naik 2013

Uveitis

SF-36, SF6D, EQ-5D

No back pain: 0.82 (0.16)
Mean (SD): SF-6D: 0.67 (0.11)
Mean (SD): EQ-5D: 0.84 (0.13)

The
Multicenter
Uveitis
Steroid
Treatment
Trial Research
Groupb 2015

Intermediate
uveitis, pan
uveitis

EQ-5D, SF36

Uveitis type: EQ5D Median (IQR)
All patients:
0.8 (0.8, 1.0)

Intermediate
uveitis:
0.8 (0.8, 1.0)
Pan uveitis:
0.8 (0.8, 1.0)

SF-36: Mean (SD)
PCS: 47.4 (12.2)
MCS: 47.6 (12.7)
Uveitis type: SF-36
health survey subscales
Median (IQR):

Intermediate uveitis:
PCS: 50 (41, 55)
MCS: 52 (43, 57)

All patients:
PCS: 50 (41, 55)
MCS: 52 (40, 57)

Pan uveitis:
PCS: 50 (41, 55)
MCS: 52 (37, 56)

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; ETDRS: Early Treatment Diabetic Retinopathy
Study; IQR: interquartile range; MCS: mental component score; PCS: physical component score;
SD: standard deviation; SE: standard error; b: Frick et al. and Sugar et al. were merged with this
study
Table 3-3f. Health-related quality of life outcomes in patients with dry eye disease.
First Author
and
Year of
Publication
Dana 2020
Farrand 2016

Messmer

Eye
disease(s)

DED
DED

DED

Elicitation
method**

EQ-5D 5L
SF-36

EQ-5D 5L

Utility values

Mean (SD): 0.82 (0.13)
Not reported

Severity of DED:

Moderate: 0.759

Summary scores on preference-based
measures

Not applicable
DED type: Mean
(SD)
Diagnosed-DED:
PCS: 45.3 (10.6)
MCS: 48.1 (11.4)
Not applicable

SymptomaticUndiagnosed DED:
PCS: 48.8 (9.5)
MCS: 44.6 (11.6)
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2019

Mean
Severe: 0.755
All patients: 0.777

Rajagopalan
2005

DED

SF-36, EQ-5D 3L

Mean (SD) EQ-5D: 0.82 (0.02)

SF-36: Mean
(SD)

Schiffman
2003

DED

TTO

Severity of DED:
Mean (SD)

Not applicable

Moderate: 0.78 (0.19)

PCS: 47.05 (0.90)
MCS: 51.00 (0.75)

Severe: 0.72 (0.23)
Asymptomatic:
0.78 (23)

Severe Requiring
Surgery: 0.62 (0.26)

Mild: 0.81 (18)

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; DED: dry eye disease; MCS: mental component
score; PCS: physical component score; SD: standard deviation
Table 3-3g. Health-related quality of life outcomes in patients with miscellaneous eye diseases.
First Author
and
Year of
Publication
Balshaw 2012

Eye
disease(s)

Elicitation
method**

Utility values

CRVO,
BRVO
Strabismus

HUI3

Mean (SD): 0.80 (0.42)

TTO

Globe 2002

PVD

SF-12, SF36

Mean (SD)
preoperative: 0.85
(0.20)
Not reported

Globe 2002

Retinal
detachment

SF-12, SF36

Not reported

Loftus 2011

DME

EQ-5D 3L

Baseline:

Week 54:

Mean Pegaptanib:
0.741

Mean Pegaptanib:
0.694

Mean Sham: 0.756

Mean Sham: 0.738

Beauchamp
2006

Summary scores on preferencebased measures

Not applicable
Mean (SD)
postoperative 5 or 8
weeks: 0.96 (0.11)

Not applicable

SF-12: Mean
(SD)
PCS: 51 (9)
MCS: 52 (9)

SF-36: Mean
(SD)
PCS: 51 (10)
MCS: 52 (10)

SF-12: Mean
(SD)
PCS: 49 (8)
MCS: 48 (11)

SF-36: Mean
(SD)
PCS: 50 (7)
MCS: 48 (11)

Not applicable

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; BRVO: branch retinal vein occlusion; CRVO: central
retinal vein occlusion; DME: diabetic macular edema; MCS: mental component score; PCS:
physical component score; PVD: posterior vitreous detachment; SD: standard deviation
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3.4

Discussion
The current review investigated the HRQoL in patients with a variety of eye

diseases including glaucoma, ARMD, DR, cataracts, uveitis, and DED. In doing so, it
provides an overview of the values of HRQoL associated with these eye diseases that can
be utilized in economic evaluations. In characterizing the GPBM summary scores, it was
shown that based on the SF-12, the mean PCS values ranged from 39.2 to 44.67 and the
mean MCS values ranged from 48.7 to 52.2. Similarly, based on the SF-36, the mean PCS
values ranged from 45.6 to 53.8 and the mean MCS values ranged from 54.2 to 63.1. In
patients with ARMD, the mean PCS values ranged from 44.0 to 46.8 and the mean MCS
values ranged from 49.8 to 50.9 based on the SF-12. The mean PCS values ranged from
41.0 to 47.0 and the mean MCS values ranged from 38.0 to 52.0 based on the SF-36.
Among the studies focusing on DR, the mean PCS value was 46.0 and the mean MCS
values ranged from 51.0. Similarly, based on the SF-36, the mean PCS values ranged
from 46.2 to 46.0 and the mean MCS values ranged from 50.0 to 52.9. For the studies
pertaining to patients with cataracts, the mean PCS values ranged from 43.2 to 46.1 and
the mean MCS values ranged from 54.0 to 54.6 based on the SF-12. However, based on
the SF-36, the central tendencies of PCS values ranged from 45.9 to 75.0 and the mean
MCS values ranged from 76.0 to 82.1. The included studies on patients with uveitis
reported PCS and MCS scores with measures of central tendency ranging from 47.4 to
50.0 and 47.6 to 52.0 respectively based on the SF-36. Finally, the studies focused on
DED reported mean PCS and MCS values ranging from 45.3 to 48.8 and 44.6 to 51.0
based on the SF-36 as well. Overall, across each eye disease, the measures of central
tendency of the scores generally appeared to be near 50. PCS and MCS values can range
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between 0 to 100, however a mean (SD) of 50 (10) has been noted to be the PCS and
MCS values of the US general population for both the SF-12 and SF-3657,58.

As per the analysis of the utility values of the patients with eye disease, the mean
utility values of patients with glaucoma were quite high between 0.89 to 0.94, indicating
that the QoL for glaucoma patients appears to be quite good. The mean utility values for
collective patients with ARMD were much more variable ranging from 0.74 to 0.81.
However, based on studies that reported utility values stratified by disease severity, mean
utility values as low as 0.40 and as high as 0.96 were reported among groups of patients
with more severe and less severe forms of ARMD respectively. Similarly, the mean
utility values of collective patients with DR ranged from 0.77 to 0.88. However, among
studies that reported utility values stratified by disease severity, mean utility values as low
as 0.59 and as high as 0.92 were reported among groups of patients with more severe and
less severe forms of DR respectively. The mean utility scores for patients with cataracts
ranged from 0.66 to 0.85. The measures of central tendency for utility values of patients
with uveitis ranged from 0.67 to 0.84. Finally, the mean utility values of collective
patients living with DED ranged from 0.78 to 0.82. However, among studies that reported
utility values stratified by disease severity, mean utility values as low as 0.62 and as high
as 0.81 were reported in patients with more severe and less severe forms of DED
respectively. Overall, the utility values across patients with ARMD, DR, uveitis, and
DED appear to be quite similar while the values in patients with glaucoma appear to be
higher.
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In previous systematic reviews of QoL in eye diseases, the typical focus is on the
relationship between vision impairment and QoL values9,11,59,60. Of note, a recent
systematic review by Assi et al.10 was an umbrella systematic review that examined the
association between vision impairment or specific eye diseases and reduced QoL and the
effectiveness that ophthalmic interventions can have on improving QoL. However, it did
not focus on the HRQoL values from direct preference elicitation methods or GPBMs.

Among systematic reviews of QoL in patients with eye diseases, is a systematic
review by Evans et al.12. In that review, the authors captured studies pertaining to the QoL
of diseases impairing peripheral and central vision including glaucoma, ARMD, and
cataracts. Evans et al.12 noted that in most QoL domains of the SF-36 and SF-12 the
difference between the impact of the two diseases was slight and unlikely to be clinically
significant. This finding appears to concur with the results of this systematic review since
the range of PCS and MCS scores across the different eye diseases were relatively
similar. Moreover, using weighted means, the authors found that ARMD had a greater
impact on the physical components than mental components of the SF-36 and SF-12. This
finding appears to contrast with the results of the current study. Additionally, Evans et
al12. noted that patients with glaucoma exhibited a similar degree of QoL impairment to
those with cataracts using EQ-5D. This finding does appear to agree with the results of
this systematic review that demonstrated an EQ-5D score of 0.89 in the study on
glaucoma patients and EQ-5D scores from 0.83 to 0.85 reported for patients with
cataracts. However, it should be noted that Evans et al.12 included studies from countries
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not restricted to North America that were published before July 13, 2007. Furthermore,
the characteristics of their included studies and study participants were unclear.
Another similar systematic review by Poku et al.11 on DR and ARMD focused on
the relationship between utility values and visual impairment. In their study, it was noted
that the mean utility of patients with DR overall was 0.79 across their included studies.
Furthermore, it was noted that the mean utility of patients with ARMD overall was 0.8111.
While the authors did not limit their included studies to a particular geographical region,
both of their results are similar to the findings of the current systematic review.

While this study provides valuable information on the HRQoL values assigned to
a variety of different eye diseases, this study is limited by the literature included. Five of
the 39 included studies were deemed to be of a high RoB upon assessment17,22,30,34,42.
These 5 studies imply low confidence that they present valid HRQoL values for their
respective diseases. However, the other 34 included studies were of moderate or low
RoB. As such, the majority of the included studies appear to be providing valid HRQoL
implying confidence in the results of the current review. Nonetheless, regardless of their
quality, all studies were included for analysis. Furthermore, this review captured studies
that were performed in North American countries. As such, these values may not
represent HRQoL values in other countries. Additionally, to systematically gather a
consistent data on HRQoL, a location restriction was placed. This restriction also resulted
in the exclusion of 92 other articles that measured HRQoL among other eye conditions
including but not limited to ocular toxoplasmosis, endophthalmitis, anophthalmus, or
macular holes. However, the key objective of this systematic review was to measure
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HRQoL in patients with various eye diseases in the North American continent.
Additionally, this review is also restricted to an adult patient group. As a result, this
review does not incorporate sufficient information on eye diseases that are much more
common in pediatric patient populations such as amblyopia and strabismus34,61. A future
study could incorporate a bigger variety of studies not restricted to North America to
provide a more comprehensive summary on HRQoL of eye diseases from a more global
perspective. Furthermore, a future study could also focus more on eye diseases that affect
the pediatric population.

3.5

Conclusions
This systematic review has shown that HRQoL across patients with glaucoma,

ARMD, diabetic retinopathy, cataracts, uveitis, and DED was similar using the SF-12 and
SF-36. Furthermore, their summary scores appear to suggest normal HRQoL. This
systematic review has also shown that the utility values across patients with ARMD, DR,
uveitis, and DED appear to be similar, while the values in patients with glaucoma appear
to be higher. However, further studies need to be done to better understand the QoL for
patients with other visual conditions among different populations.
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Chapter 4 Quality of Life of Seniors with Eye Diseases During
COVID-19
4 Abstract
Background: The ophthalmology clientele is vulnerable to psychological stressors in the
context of the coronavirus disease 2019 (COVID-19) pandemic.
Objective: To assess health-related quality of life (HRQoL), vision-related quality of life
(VRQoL), depression and anxiety symptoms, and social support and community
integration of seniors with eye diseases. To identify important predictor variables of the
outcomes above.
Methods: A cross-sectional survey study was conducted among seniors with eye diseases
(n=90). Linear regression analysis with backward stepwise selection was used to predict
the value of the outcomes of eye disease. Through leave-one-out cross-validation, the
predictive performance of each model was assessed with root mean squared error and
mean absolute error. Further, model assumptions for each backwards stepwise regression
model were tested.
Results: Based on the analysis, preference-based HRQoL of the study patients with eye
diseases during the pandemic is likely good with a mean utility value of 0.88. VRQoL
and sleep quality appeared to be good as well. Depression and anxiety symptoms
appeared to be low, while community integration and social support were moderate.
Furthermore, the presence of retinal disease, number of non-ocular comorbidities, and
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education appeared to have significant negative effects on social support and community
integration. The presence of retinal disease and the number of non-ocular comorbidities
both appeared to negatively impact VRQoL. The use of a mobility aid appeared to
negatively affect depressive symptoms and sleep quality.
Conclusions: The overall quality of life and wellness among seniors with eye diseases
appeared to be good during the COVID-19 pandemic. However, the presence of retinal
disease and the number of non-ocular comorbidities both appeared to negatively impact
VRQoL and social support and community integration. Education appeared to impact
social support and community integration negatively. The use of a mobility aid appeared
to negatively affect depressive symptoms and sleep quality.

4.1 Introduction
Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1. This disease has
been reported to be able to cause severe acute respiratory infection with an incubation
period of 1–14 days 2. Many of the common symptoms of COVID-19 include fever, dry
cough, as well as fatigue 3. The SARS-CoV-2 virus has been reported to be transmitted
via respiratory droplets; however, it can also be spread through various discharges, feces,
aerosol, and conjunctiva4.
The first reported outbreak occurred in Wuhan, China in 2019. At the beginning
of 2020 February, it was reported by the National Health Commission of the People’s
Republic of China that 3,387 healthcare workers have confirmed COVID-19 infections.
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However, even before February 2020, COVID-19 had already made its way to Canada in
Ontario; in late January 2020, the first imported case of COVID-19 was reported.
Following this case, community transmission was then documented within British
Colombia on March 1, 20205. As the virus continued to spread throughout Canada and the
rest of the globe, on March 11 of 2020, the World Health Organization (WHO) decided to
declare the COVID-19 outbreak a pandemic 2. Later, in April of 2020, over 2,000,000
people from 210 countries were reported to have been infected with the death toll being
over 140,000 people worldwide 1.
The burden brought on by the COVID-19 pandemic has affected many groups of
individuals on a global level. One vulnerable group of individuals who have been greatly
impacted by the pandemic are patients with ophthalmological conditions. Patients in this
group are particularly vulnerable in the context of the COVID-19 pandemic because of
their age and pre-existing comorbid conditions; specifically, elderly patients aged 65 and
above with eye diseases like glaucoma, age-related macular degeneration, or diabetic
retinopathy require regular follow-ups and commonly suffer from additional
comorbidities 6. These additional conditions include anxiety and depression which have
been shown to be exacerbated throughout the ongoing pandemic 7,8. Even if these
individuals do not currently have such comorbidities, they are extremely susceptible to
developing mental health issues 9.
Further, the negative impact of the COVID-19 pandemic has been shown to be
pronounced among elderly individuals through public media outlets portraying COVID19 as a disease that is particularly devastating to the elderly. This spread of
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misinformation, in turn, has resulted in the development of social stigma and
discrimination causing additional distress to elderly individuals, their families, and their
caregivers 9. Moreover, because of their age, elderly individuals are at a high risk of
mortality upon being infected by COVID-19. This information compounds their worry
about being infected with the virus and not having access to proper healthcare. In addition
to the vulnerabilities imposed by their age group, because of the proximity between the
patient and health care personnel during ophthalmological examinations, the risk of
transmission can be perceived as being relatively high among seniors with
ophthalmologic conditions. As such, the delicate balance between the risk of exposure to
COVID-19 and visual loss in delaying cases is a psychological stressor to both patients
and clinicians 10,11.
The present pandemic has led officials to rethink the management of patient lists
and to restrict the patients to be assessed or treated based on the urgency of their
condition in accordance with ministerial guidelines 12,13. These restrictions may have
potentially resulted in many delays in clinical visits which, in turn, may increase the risk
of visual loss not only by delaying necessary care but also by making patients less likely
to follow their physician’s guidance for their conditions. Moreover, due to the inability to
attend clinical visits, patients themselves might decide to become nonadherent and
interrupt their treatment or postpone their visit for fear of contracting SARS-CoV-2.
Furthermore, the COVID-19 pandemic conditions have created even more difficulty to
access medications that are high in demand and have made it difficult to make changes to
treatments when necessary14. Additionally, visual loss can accompany depressive
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symptoms and deteriorate the quality of life (QoL) 15 in addition to the difficulties already
present due to their ocular diseases and potential comorbidities. Thus, it is necessary to
characterize and document the quality of life and mental well-being of patients with
various ophthalmologic conditions during the COVID-19 pandemic.
In documenting the QoL and wellness of patients during the COVID-19
pandemic, we can quantify the collateral impact of COVID-19 beyond the direct impact
of the virus. Furthermore, this will help to improve the future quality of care during nonCOVID-19 conditions and even during potential future pandemic situations. Therefore,
the goal of this study is to characterize the preference-based health-related quality of life
(HRQoL), vision-related QoL (VRQoL), depression and anxiety symptoms, sleep quality,
and social support and community integration of seniors aged 65 and above with various
eye diseases during the COVID-19 pandemic. Furthermore, this study also aims to
identify important predictor variables for the aforementioned measures.

4.2 Methods
4.2.1 Study design and Sampling Procedures
The study followed a cross-sectional design. A convenience sample of 90 patients
who were identified as having an underlying ocular disease were recruited from four
ophthalmic practices at the Ivey Eye Institute, St. Josephs’s Health Care London, Ontario.
The clinical protocol was conducted in accordance with the Western Research Ethics
Manager (WREM) at the University of Western Ontario. All patients were sequentially
recruited from November 2021 to May 2022 using convenience sampling. The eligibility
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of the patients who were attending their regular ophthalmology visits was determined by
the ophthalmologist on staff. Inclusion criteria included patients who were age 65 and
above and diagnosed with an eye disease by an experienced ophthalmologist. Exclusion
criteria included patients who were unable to provide valid informed consent, who had
significant communication barriers or lack of English proficiency that prevents
participants from completing the questionnaires, or who had irreversible vision loss that
prevented them from completing the questionnaires.
All participants received a complete explanation of the purpose and procedures
involved in the study and patient concerns were addressed prior to study participation.
Both verbal and electronically written informed consent were obtained from all
participating patients. The study was initiated after approval by WREM (refer to
Appendix A for the approval letter) and Lawson Health Research Institute’s Clinical
Research Impact Committee.

4.2.2 Data Collection
All data were collected through electronic questionnaires accompanied by face-toface interviews for assistance. All data were recorded electronically using the UWO
Qualtrics questionnaires that were set up in advance. Data from Qualtrics were then
imported to a password-protected and encrypted spreadsheet on the password-protected
local computer in the principal investigator’s (M.M) office at St. Joseph’s Healthcare.
Data were coded to protect participant confidentiality. The code key with identifying data
(Master data) was also stored in a password-protected and encrypted spreadsheet on the
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password-protected local computer in the principal investigator’s office. For analysis
purposes, the de-identified study data not containing patient information was stored in a
password-protected and encrypted spreadsheet on the St. Joseph’s Hospital OneDrive.
Data quality checks were performed at random.
Following clinical examination of the patients, the ophthalmologists at the Ivey
Eye Institute identified and referred participants to the research assistant on duty based on
the inclusion and exclusion criteria. The questionnaires were presented to the patients
using a combination of self-administered and interviewer-assisted modes. Participants
provided informed consent and completed the 30-minute questionnaire. The questionnaire
included the Time Trade-Off (TTO) questionnaire, the 25-item version National Eye
Institute Visual Function Questionnaire (NEI VFQ-25), Hospital Anxiety and Depression
Scale – Anxiety subscale (HADS-A), Center for Epidemiologic Studies – Depression
scale (CES-D), Pittsburgh Sleep Quality Index (PSQI), and Community Integration
Questionnaire (CIQ). Demographic characteristics on patients’ age, socioeconomic status
(SES), ethnicity, education level, living arrangement, city of residence, and use of
mobility aid were also collected. All of which were provided by patients themselves in
the electronic questionnaires.
The TTO was used to obtain utility scores to calculate patients’ preference-based
HRQOL. Preference-based HRQOL is a frequently used measure calculated with utility
values on a scale from 0 to 1, where 0 represents a health state equal to death and 1
represents a state of perfect health16. In the current study, the utility score using the TTO
method was calculated by dividing the number of years a patient was willing to trade in
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return for perfect vision by the estimated number of years of life remaining and
subtracting this number from 1.
VRQOL measures the impact of vision on an individual’s daily living, as well as
one’s satisfaction and attitudes towards their vision. The NEI VFQ-25 is divided into 12
subscales: general health, general vision, near vision, distance vision, driving, peripheral
vision, color vision, ocular pain, role limitations, dependency, social function, and mental
health. The NEI VFQ-25 was also shown to have high validity and reliability 17.
The HADS-A is a 7-item self-report subscale for measuring symptoms of anxiety.
Each item on the questionnaire is scored from 0 to 3, with total scores ranging from 0 to
21. Higher scores represent higher levels of psychological distress18. The HADS-A has
been used in a previous study on the impact of low vision on the QoL, depression,
anxiety, and social support 19. A score ≥ 8 on the HADS-A has a sensitivity of 0.9 and
specificity of 0.79 for identifying patients with anxiety20. The HADS-A has been
demonstrated to have adequate internal consistency with a Cronbach’s alpha value of 0.87
when administered in older adults 21.
The CES-D is a brief self-report scale designed to measure self-reported
symptoms associated with depression experienced in the past week. The CES-D includes
twenty items comprising six scales reflecting major facets of depression. The possible
range of CES-D scores is 0 to 60, with the higher scores indicating the presence of more
depressive symptomatology. A CES-D score ≥ 16 has high sensitivity and specificity
rates for identifying subjects with depressive disorder. The CES-D has been demonstrated
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to be reliable with coefficient alpha estimates of 0.90 in clinical older adults. It has also
been demonstrated to have high construct validity when administered to older adults22.
The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month
time interval. The measure consists of 19 individual items, creating 7 components that
produce one global score 23. Higher PSQI scores indicate worse sleep quality. A PSQI
score > 5 has sensitivity and specificity rates of 89.6% and 86.5%, respectively, for
identifying cases with sleep disorder 24. The PSQI has been shown to have a high testretest reliability and a good validity 25.
The CIQ is a 15-item inventory designed to measure levels of community
integration. The overall score ranges from 0 to 29, and can be further divided into three
sub-scores, corresponding to integration in the home, social integration, and productivity.
A higher CIQ score represents greater integration26. Previous research has demonstrated
adequate test-retest reliability and internal consistency27.
All patients were interviewed under standardized conditions. The interviews were
conducted by four interviewers who all received standardized training prior to
administering the questionnaires. All questionnaires were completed by the patient in an
electronic format on an electronic tablet through the UWO Qualtrics link containing the
questionnaires. While completing the questionnaires, a research assistant was present to
assist by answering any questions or concerns about the questionnaires, if patients had
any, as well as to administer the questionnaires.
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4.2.3 Statistical analysis
All statistical analyses were performed using STATA 17.0. The descriptive
statistics were computed for all demographic variables while univariate analysis was
computed for all questionnaire outcome measures. To understand the central tendency
and distribution of continuous variables, means, and standard deviations were calculated.
Associations between predictor variables were also assessed using Pearson
correlations between continuous predictor variables, The Pearson correlation coefficient
threshold absolute value of 0.6 was used as a cut-off indicating a strong association
between the variables28. If a threshold above 0.6 was identified, then a significance test
was conducted to confirm the association. Chi-square tests were used to assess the
association between pairs of categorical predictor variables. The significance of the
relationship between the predictor variables was defined at p<0.050. T-tests and one-way
ANOVA were used to assess the associations between pairs of continuous and categorical
predictor variables. Again, statistical significance was determined at p<0.050.
Bivariate analysis was performed to assess the unadjusted effect estimates and
check whether each predictor variable and outcome were associated. Each of the predictor
variables (age, number of non-ocular comorbidities, number of ocular comorbidities, use
of a mobility aid, SES during COVID-19, living arrangements, education, presence of
retinal disease, presence of glaucoma, and presence of cataracts) was individually
investigated for association with all six outcomes, using simple linear regression analyses.
Linear regression models were also created with the questionnaire scores as the
dependent variables using backwards stepwise multiple regression. In backwards stepwise
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regression, all predictor variables are first used in the model. Following this, tests are then
performed to determine the least significant predictor variable that is to be removed.
Predictor variables continue to be removed until all remaining predictors are determined
to be relevant predictors of the outcome in the model. Regression coefficients were
deemed to be significant if the associated p-values were <0.050.
To assess the backwards stepwise linear regression models’ ability to accurately
predict each outcome, leave-one-out cross-validation (LOOCV) of each model. In
LOOCV, a single observation is used for the testing set while n-1 observations are used
for the training set29. This process is repeated until each observation has been a part of the
testing set. LOOCV evaluates a model based on prediction and is used for estimating the
test error. The root mean squared error (RMSE) and mean absolute error (MAE) were
determined for each multivariable model.
Further, model assumptions for each multivariable model were tested. Namely,
the constant variance of the residuals was tested using residuals versus fitted values plots.
The normality of the residuals was assessed using quantile-quantile (Q-Q) plots. Linearity
between the predictors and outcomes was assessed using component-plus-residual plots.
The variance inflation factor (VIF) was used to test for multicollinearity. A VIF of 10 was
used as the rule of thumb to indicate an acceptable level of multicollinearity30.
We believed the missing data were missing at random conditioned on the other
variables (i.e., education). Then non-response rate was 0.06% (n=5), 0% (n=0), 0% (n=0),
0.02% (n=2), 0% (n=0), and 0.02% (n=2) for the TTO, NEI VFQ-25, CES-D, HADS-A,
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PSQI, and CIQ, respectively. Considering the nonresponse rate was small, these
individuals were excluded from all relevant analyses.

4.3 Results
4.3.1 Participants and Participant Characteristics
A total of 128 patients were approached by the attending clinicians and asked to
participate in the study. Of the 128 patients, 115 agreed to participate, however, 25 of
these patients did not pass the inclusion/exclusion criteria. As such, a total of 90
participants consented and were included in the study. To summarize the characteristics
of these included participants, univariate analyses were conducted. The participants’
characteristics can be seen in Table 4-1. The mean age of the participants was 77.8 years
with a standard deviation of 8.0 years. In terms of the ethnicities of the participants, 86
identified as being white, two participants identified as being Black, one participant
identified as being Arab, and one participant did not indicate his or her ethnicity. Of the
included participants, 37 participants completed high school or less and 53 participants
had additional training or higher education. It was also noted that 23 participants had an
income of $25,000 or less. Moreover, 67 participants lived at home with their family,
spouse, or caregiver, while 22 participants lived at home alone and only one participant
lived in a nursing home. Finally, 15 participants reported using a mobility aid such as a
cane, walker, wheelchair, or motorized scooter.
The participants’ clinical characteristics can be seen in Table 4-2. Of the 90 total
participants, the mean number of non-ocular comorbidities was 1.6 with a standard
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deviation of 1.7. Of the 77 participants who reported their eye disease(s), the mean
number of ocular comorbidities was 1.2 with a standard deviation of 0.5. In terms of the
eye diseases with which participants presented, 22 participants had only retinal disease,
31 participants had only glaucoma, 8 participants had only cataracts, 1 participant had
only dry eye disease (DED), 1 participant had only uveitis, and 1 participant had only
asteroid hyalosis. However, 3 participants had both retinal disease and glaucoma, 5
participants had both retinal disease and cataracts, and 4 participants had glaucoma and
cataracts.

4.3.2 Associations between predictor variables
4.3.2.1 Association between continuous predictor variables
The results of the associations between continuous predictor variables are
presented in Appendix L. Pearson correlations did not reveal any strong linear
associations between the continuous predictor variables: age, number of non-ocular
comorbidities, and number of ocular comorbidities.

4.3.2.2 Association between pairs of categorical predictor variables
The chi-square test results of the associations between categorical predictor
variables are also presented in Appendix L. Significant associations were observed
between the presence of retinal disease and glaucoma. Among patients who had a retinal
disease, 90% did not also have glaucoma. Significant associations were also observed
between the presence of glaucoma and cataracts. Among patients with glaucoma, 90% did
not also have cataracts.
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4.3.2.3 Association Between Pairs of Continuous Predictor Variables
Finally, the t-test and one-way ANOVA results for the associations between
continuous and categorical predictor variables are also presented in Appendix L. The use
of a mobility aid was significantly associated with age, the number of non-ocular
comorbidities, and the number of ocular comorbidities. On average, patients who used a
mobility aid were older, had more non-ocular comorbidities, and had more ocular
comorbidities. The presence of retinal disease was significantly associated with age.
Patients who had retinal disease appeared to be older, on average. The presence of
glaucoma was also significantly associated with age, however, it appeared that on average
patients without glaucoma were older. Finally, the presence of cataracts was significantly
associated with the number of non-ocular comorbidities. On average, patients with
cataracts appeared to have a greater number of non-ocular comorbidities.

4.3.3 Preference-based HRQoL
The TTO utility score measures the preference-based quality of life on a scale
from 0 to 1, in which a score of 0 represents a state of death and 1 represents perfect
visual health. In our study population (n=90), the average TTO utility score was 0.88 with
a standard deviation of 0.23 (Table 4-3). Thus, the majority of the patients were willing to
trade 12% of their remaining life for perfect vision.
The bivariate analyses for preference-based HRQoL with the demographic and
clinical variables is presented in Table 4-4. No variables were significantly associated
with preference-based HRQoL.
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On average, patients who have completed more than high school in their
education have an average difference in their TTO score of 0.05 (95% CI: -0.05, 0.15) as
compared to patients who have completed high school or less. The use of a mobility aid,
on average, increases the TTO score by 0.02 (95% CI: -0.11, 0.16). For each increase in
the number of ocular comorbidities, the TTO score increases by 0.07 (95% CI: -0.06,
0.19). On average, the presence of glaucoma increases the TTO score by 0.04 (95% CI: 0.08, 0.15). The presence of retinal disease changes the TTO score by -0.06 (95% CI: 0.17, 0.05). The presence of cataracts changes the TTO score by -0.09 (95% CI: -0.22,
0.05).
Patients with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000,
$75,001 - $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have
TTO scores with a difference of -0.12 (95% CI: -0.40, 0.16), -0.17 (95% CI: -0.45, 0.11),
-0.06 (95% CI: -0.35, 0.22), 0.01 (95% CI: -0.31, 0.32), -0.10 (95% CI: -0.44, 0.23), and 0.33 (95% CI: -0.70, 0.04) respectively as compared to patients with a SES of less than
$10,000.
The backwards stepwise regression did not produce a model with any variable
predictive of the TTO utility score. This is similar to the results of the bivariate analysis
in that no variable was found to be significantly associated with the TTO score.

4.3.4 VRQoL
The NEI VFQ-25 score measures vision-related quality of life on a total scale
from 0 to 100, in which a score of 0 represents the worst possible score and 100
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represents the best. In our study population (n=90), the average NEI VFQ-25 score was
84.71 with a standard deviation of 11.61 (Table 4-3).
The bivariate analyses for the VRQoL with the demographic and clinical variables
is presented in Table 4-5. The following variables were significantly associated with
VRQoL: education (p=0.027), number of ocular comorbidities (p=0.042), and the
presence of retinal disease. Patients who have completed more than high school in their
education have an average difference in their NEI VFQ-25 score of 5.46 (95% CI: 0.62,
10.29) as compared to patients who have completed high school or less. For each increase
in the number of ocular comorbidities, the NEI VFQ-25 score changes by -6.31 (95% CI:
-12.23, -0.24) The presence of retinal disease changes the NEI VFQ-25 score by -7.56
(95% CI: -12.58, -2.55).
On average, for every year increase in age, the NEI VFQ-25 score changes by 0.28 (95% CI: -0.58, 0.03). Patients living at home with others are expected to have a NEI
VFQ-25 score difference of 3.87 (95% CI: -1.68, 9.42) as compared to patients living
alone or in a nursing/retirement home. Use of a mobility aid, on average, changes the NEI
VFQ-25 score by -6.31 (95% CI: -12.83, 0.21). On average, for each increase in the
number of non-ocular comorbidities, the NEI VFQ-25 score changes by -1.23 (95% CI: 2.64, 0.17). On average, the presence of glaucoma increases the NEI VFQ-25 score by
2.88 (95% CI: -2.44, 8.19). The presence of cataracts increases the NEI VFQ-25 score by
1.22 (95% CI: -5.26, 7.69).
Patients with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000,
$75,001 - $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have
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NEI VFQ-25 scores with a difference of -6.54 (95% CI: -20.58, 7.49), -4.63 (95% CI: 18.52, 9.24), -0.29 (95% CI: -14.38, 13.79), 5.53 (95% CI: -10.11, -21.17), 3.57 (95% CI:
-12.46, 19.56), and -0.50 (95% CI: -17.81, 16.81) respectively as compared to patients
with a SES of less than $10,000.
Upon assessment of the backwards stepwise multivariable linear regression
model, the component-plus-residual plot and Q-Q plot did not confirm the assumption of
linearity and normality, respectively. However, the residual versus fitted values plot and
VIFs confirmed the assumption of homoscedasticity and multicollinearity, respectively
(Appendix M). The backwards stepwise multivariable regression model revealed that the
presence of retinal disease and number of non-ocular comorbidities were predictive of
NEI VFQ-25 score (Table 4-10). Adjusting for the number of non-ocular comorbidities,
on average, the presence of retinal disease significantly (p=0.002) changed the NEI VFQ25 score by -7.92 (95% CI: -12.81, -3.05). For each increase in the number of non-ocular
comorbidities, the NEI VFQ-25 score significantly (p=0.033) changes by -1.66 (95% CI:
-3.01, -0.31).

4.3.5 Presence of depressive symptoms
The CES-D score measures self-reported symptoms associated with depression
experienced in the past week on a scale from 0 to 60, in which higher scores indicate the
presence of more depressive symptomatology. In our study population (n=90), the
average CES-D score was 6.79 with a standard deviation of 6.39 (Table 4-3).
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The bivariate analyses for the presence of depressive symptoms with the
demographic and clinical variables is presented in Table 4-6. The following variable was
significantly associated with the presence of depressive symptoms. Use of a mobility aid,
on average, increases the CES-D score by 4.35 (95% CI: 0.85, 7.86).
On average, patients who have completed more than high school in their
education have an average difference in their CES-D score of 1.98 (95% CI: -0.72, 4.69)
as compared to patients who have completed high school or less. Patients living at home
with others are expected to have a CES-D score difference of -0.05 (95% CI: -3.13, 3.03)
as compared to patients living alone or in a nursing/retirement home. For each increase in
the number of ocular comorbidities, the CES-D score increases by 2.10 (95% CI: -1.33,
5.53). On average, the presence of glaucoma changes the CES-D score by -1.99 (95% CI:
-4.95, 0.98). The presence of retinal disease increases the CES-D score by 2.74 (95% CI:
-0.18, 5.67). The presence of cataracts changes the CES-D score by -0.43 (95% CI: -4.06,
3.20).
Patients with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000,
$75,001 - $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have
CES-D scores with a difference of -4.42 (95% CI: -12.61, 3.77), -3.13 (95% CI: -11.23,
4.98), -4.51 (95% CI: -12.73, 3.71), -1.24 (95% CI: -10.37, -7.89), -8.00 (95% CI: -17.35,
1.35), and -3.42 (95% CI: -13.52, 6.69) respectively as compared to patients with a SES
of less than $10,000.
Upon assessment of the backwards stepwise multivariable linear regression
model, Q-Q plot did not confirm the assumption of normality. However, the residual-
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versus-fitted values plot and the VIFs confirmed the assumption of homoscedasticity and
multicollinearity, respectively (Appendix M). The backwards stepwise multivariable
regression model revealed that the presence of retinal disease and the use of a mobility
aid were predictive of CES-D score (Table 4-10). On average, adjusting for the use of a
mobility aid, the presence of retinal disease increased the CES-D score by 2.50 (95% CI:
-0.43, 5.43), however, this increase was not significant (p=0.094). Adjusting for the
presence of retinal disease, the use of a mobility aid significantly (p=0.028) increased the
CES-D score by 4.20 (95% CI: 0.46, 7.94).

4.3.6 Presence of anxiety symptoms
The HADS-A subscale measures symptoms of anxiety in the past week each using
a scale from 0 to 21 in which higher scores represent higher levels of anxiety. In our study
population (n=88), the average HADS-A score was 2.83 with a standard deviation of 2.56
(Table 4-3).
The bivariate analyses for the presence of anxiety symptoms with the
demographic and clinical variables is presented in Table 4-7. No variables were
significantly associated with the presence of anxiety symptoms.
On average, patients living at home with others are expected to have a HADS-A
score difference of 0.71 (95% CI: -0.52, 1.94) as compared to patients living alone or in a
nursing/retirement home. Use of a mobility aid, on average, increases the HADS-A score
by 0.58 (95% CI: -0.87, 2.04). On average, for each increase in the number of non-ocular
comorbidities, the HADS-A score increases by 0.11 (95% CI: -0.21, 0.42). For each
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increase in the number of ocular comorbidities, the HADS-A score increases by 0.53
(95% CI: -0.83, 1.89). On average, the presence of glaucoma changes the HADS-A score
by -0.12 (95% CI: -1.32, 1.07). The presence of retinal disease increases the HADS-A
score by 0.84 (95% CI: -0.33, 2.02). The presence of cataracts changes the HADS-A
score by -0.71 (95% CI: -2.15, 0.73).
Patients with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000,
$75,001 - $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have
HADS-A scores with a difference of -0.05 (95% CI: -3.30, 3.20), 0.21 (95% CI: -3.00,
3.42), 0.37 (95% CI: -2.89, 3.63), -1.43 (95% CI: -5.05, -2.19), -0.83 (95% CI: -4.54,
2.87), and -1.50 (95% CI: -5.51, 2.51) respectively as compared to patients with a SES of
less than $10,000.
Upon assessment of the backwards stepwise linear regression model, the Q-Q plot
did not confirm the assumption of normality, but the residual-versus-fitted values plot
confirmed the assumption of homoscedasticity (Appendix M). The backwards stepwise
regression model revealed that the use of a mobility aid was the only variable predictive
of HADS-A score (Table 4-10). Once again, this model displays that, on average, the use
of a mobility aid increases the HADS-A score by 0.58 (95% CI: -0.87, 2.04), however,
this change is not significant (p=0.428).

4.3.7 Sleep Quality
The PSQI score measures sleep quality over a 1-month time interval on a global
scale from 0 to 21, in which higher scores indicate worse sleep quality. In our study
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population (n=90), the average PSQI score was 6.58 with a standard deviation of 3.00
(Table 4-3).
The bivariate analyses for sleep quality with the demographic and clinical
variables is presented in Table 4-8. The following variables were significantly associated
with sleep quality: use of a mobility aid (p=0.044), and SES during COVID-19. Use of a
mobility aid, on average, increases the PSQI score by 1.73 (95% CI: 0.05, 3.41). Patients
with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000, $75,001 $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have PSQI
scores with a difference of -3.26 (95% CI: -7.00, 0.48), -3.26 (95% CI: -6.95, 0.43), -3.47
(95% CI: -7.21, 0.26), -4.43 (95% CI: -8.58, -0.28), -4.67 (95% CI: -8.92, -0.41), and 2.50 (95% CI: -7.10, 2.10) respectively as compared to patients with a SES of less than
$10,000.
On average, for every year increase in age, the PSQI score changes by -0.01 (95%
CI: -0.09, 0.08). Patients who have completed more than high school in their education
have an average difference in their PSQI score of 0.82 (95% CI: -0.48, 2.11) as compared
to patients who have completed high school or less. Patients living at home with others
are expected to have a PSQI score difference of -1.17 (95% CI: -2.62, 0.29) as compared
to patients living alone or in a nursing/retirement home. On average, for each increase in
the number of non-ocular comorbidities, the PSQI score increases by 0.22 (95% CI: 0.15, 0.59). For each increase in the number of ocular comorbidities, the PSQI score
increases by 0.36 (95% CI: -1.18, 1.90). On average, the presence of glaucoma changes
the PSQI score by -0.56 (95% CI: -1.94, 0.81). The presence of retinal disease increases
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the PSQI score by 0.57 (95% CI: -0.82, 1.95). Finally, the presence of cataracts changes
the PSQI score by -0.28 (95% CI: -1.97, 1.42).
Upon assessment of the backwards stepwise linear regression model, the Q-Q plot
did not confirm the assumption of normality, but the residual-versus-fitted values plot
confirmed the assumption of homoscedasticity (Appendix M). The backwards stepwise
regression model revealed that the use of a mobility aid was the only variable predictive
of PSQI score (Table 4-10). Once again, this model displays that, on average, the use of a
mobility aid significantly (p=0.044) increases the PSQI score by 1.73 (95% CI: 0.05,
3.41).

4.3.8 Social Support and Community Integration
The CIQ score measures social support and community integration on a scale
from 0 to 29, in which a higher score represents more complete community integration
and a higher level of social support. In our study population (n=88), the average CIQ total
score was 14.46 with a standard deviation of 4.07 (Table 4-3).
The bivariate analyses for social support and community integration with the
demographic and clinical variables is presented in Table 4-9. The following variables
were significantly associated with social support and community integration: number of
non-ocular comorbidities (p=0.047), and presence of retinal disease (p=0.001). On
average, for each increase in the number of non-ocular comorbidities, the CIQ score
changes by -0.50 (95% CI: -1.00, -0.01). The presence of retinal disease changes the CIQ
score by -3.06 (95% CI: -4.82, -1.30).
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On average, for every year increase in age, the CIQ score changes by -0.10 (95%
CI: -0.21, 0.02). Patients who have completed more than high school in their education
have an average difference in their CIQ score of -1.23 (95% CI: -2.98, 0.53) as compared
to patients who have completed high school or less. Patients living at home with others
are expected to have a CIQ score difference of -0.67 (95% CI: -2.67, 1.33) as compared to
patients living alone or in a nursing/retirement home. Use of a mobility aid, on average,
changes the CIQ score by -1.22 (95% CI: -3.54, -1.10). The presence of glaucoma
increases the CIQ score by 0.80 (95% CI: -1.14, 2.73). The presence of cataracts changes
the CIQ score by -0.07 (95% CI: -2.45, 2.31). On average, for each increase in the
number of ocular comorbidities, the CIQ score changes by -1.51 (95% CI: -3.70, 0.68).
Patients with a SES of $10,001 - $25,000, $25,001 - $50,000, $50,001 - $75,000,
$75,001 - $100,000, $100,001 - $125,000, and greater than $150,000 are expected to have
CIQ scores with a difference of -0.02 (95%CI: -5.30, 5.25), 0.33 (95% CI: -4.88, -5.54),
0.13 (95% CI: -5.15, 5.40), 3.38 (95% CI: -2.48, 9.24), 0.92 (95% CI: -5.09, 6.92), and
1.67 (95% CI: -4.82, 8.15) respectively as compared to patients with a SES of less than
$10,000.
Upon assessment of the backwards stepwise multivariable linear regression
model, the component-plus-residual plot, Q-Q plot, residual-versus-fitted values plot and
the VIFs confirmed the assumption of linearity, normality, homoscedasticity, and
multicollinearity, respectively (Appendix M). The backwards stepwise multivariable
regression model revealed that the presence of retinal disease, number of non-ocular
comorbidities, and education were predictive of CIQ score (Table 4-10). Adjusting for all
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other predictors, on average, the presence of retinal disease significantly (p<0.001)
changed the CIQ score by -3.10 (95% CI: -4.77, -1.43). For each increase in the number
of non-ocular comorbidities, the CIQ score significantly (p=0.004) changes by -0.68
(95% CI: -1.15, -0.22). Finally, having education of more than high school significantly
(p=0.033) changes the CIQ score on average by -1.79 (95% CI: -3.44, -0.15).

4.3.9 Results of the LOOCV
The results of LOOCV assessment of the models in Appendix N demonstrate that
the backwards stepwise regression models for VRQoL, and social support and community
integration had generally similar MAEs as compared to a similar previous study by
Uruthiramoorthy et al36. The MAE of the VRQoL model in the current study is slightly
higher than the models in the previous study suggesting that the model in the current
study could be nearly as predictive as the previous models. However, the multivariable
model for social support and community integration in the current study had an even
lower value of MAE as compared to the study by Uruthiramoorthy et al36 indicating that it
may be more predictive of the outcome.
Table 4-1. Demographic characteristics of the included participants.
Characteristic

Full Sample
(N=90)
77.8 (8.0)

Age, mean (SD)
Ethnicity, n (%)
White
Black
Arab
Choice not listed
Education, n (%)
Some high school or less
Completed high school

86/90 (96%)
2/90 (2%)
1/90 (1%)
1/90 (1%)

8/90 (9%)
29/90 (32%)
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Additional training
College Degree
Undergraduate university
Postgraduate university
Advanced Professional degree

15/90 (17%)
18/90 (20%)
9/90 (10%)
8/90 (9%)
3/90 (3%)

Socioeconomic status, n (%)
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

3/83 (4%)
20/83 (24%)
24/83 (29%)
19/83 (23%)
7/83 (8%)
6/83 (7%)
0/83 (0%)
4/83 (5%)

Use of a mobility aid, n (%)
No
Yes

72/87 (83%)
15/87 (17%)

Living arrangements, n (%)
Nursing home
Home alone
Home with caregiver
Home with spouse
Home with family

1/90 (1%)
22/90 (24%)
1/90 (1%)
58/90 (64%)
8/90 (9%)

City of residence, n (%)
London
St. Thomas
Stratford
Woodstock
Rural

51/88 (58%)
6/88 (6%)
4/88 (5%)
2/88 (4%)
25/88 (29%)

Table 4-2. Clinical characteristics of the included participants.
Characteristic

Full Sample
(N=90)

Eye diseases, n (%)
None reported
Retinal only
Glaucoma only
Cataracts only
Dry eye only
Retinal and Glaucoma
Retinal and Cataracts
Glaucoma and Cataracts
Glaucoma and Dry eye
Uveitis only
Asteroid Hyalosis only

13/90 (18%)
22/90 (21%)
31/90 (34%)
8/90 (9%)
1/90 (1%)
3/90 (3%)
5/90 (6%)
4/90 (4%)
1/90 (1%)
1/90 (1%)
1/90 (1%)
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Number of ocular comorbidities, mean (SD)

1.2 (0.5)

Number of non-ocular comorbidities, mean (SD)

1.6 (1.7)

Table 4-3. Summary of questionnaire scores for all participants.
Minimum score

Maximum score

Number of

Questionnaire

Mean score (SD)

TTO

0.88 (0.23)

0

1.00

85

NEI VFQ-25

84.71 (11.61)

54.72

98.33

90

CES-D

6.79 (6.39)

0

27.00

90

PSQI

6.58 (3.00)

2.00

15.00

88

HADS-A

2.83 (2.56)

0

12.00

90

CIQ

14.46 (4.07)

2.00

23.75

88

respondents

Table 4-4. Unadjusted effects of variables with preference-based HRQoL.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities

Coefficient
-0.00

P-value
0.840

Ref
0.05

0.327

Ref
-0.01

0.854

Ref
0.02
0.01

0.740
0.399

0.07

0.305
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Glaucoma
No
Yes
Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

Ref
0.04

0.516

Ref
-0.06

0.281

Ref
-0.09

0.195

Ref
-0.12
-0.17
-0.06
0.01
-0.10

0.406
0.231
0.658
0.966
0.535

-3.27

0.084

Table 4-5. Unadjusted effects of variables with VRQoL.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities

Coefficient
-0.28

P-value
0.073

Ref
5.46

0.027

Ref
3.87

0.169

Ref
-6.31
-0.00

0.058
0.994

-6.24

0.042
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Glaucoma
No
Yes
Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

Ref
2.88

0.284

Ref
-7.57

0.004

Ref
1.22

0.709

Ref
-6.54
-4.64
-0.29
5.53
3.57

0.356
0.508
0.967
0.484
0.659

-0.50

0.954

Table 4-6. Unadjusted effects of variables with depressive symptoms.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities
Glaucoma

Coefficient
-0.01

P-value
0.918

Ref
1.98

0.149

Ref
-0.05

0.974

Ref
4.35
-0.00

0.016
0.994

2.10

0.227
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No
Yes
Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

Ref
-1.99

0.186

Ref
2.74

0.066

Ref
-0.43

0.812

Ref
-4.42
-3.13
-4.51
-1.24
-8.00

0.286
0.445
0.278
0.788
0.093

-3.42

0.503

Table 4-7. Unadjusted effects of variables with anxiety symptoms.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities
Glaucoma
No

Coefficient
-0.01

P-value
0.688

Ref
-0.01

0.989

Ref
0.71

0.253

Ref
0.58
0.11

0.428
0.492

0.53

0.438

Ref
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Yes
Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

-0.12

0.838

Ref
0.84

0.157

Ref
-0.71

0.328

Ref
-0.05
0.21
0.37
-1.43
-0.83

0.976
0.898
0.822
0.434
0.656

-1.50

0.458

Table 4-8. Unadjusted effects of variables with sleep quality.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities
Glaucoma
No
Yes

Coefficient
-0.01

P-value
0.831

Ref
0.82

0.212

Ref
-1.17

0.115

Ref
1.73
0.22

0.044
0.239

0.36

0.647

Ref
-0.56

0.417
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Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

Ref
0.57

0.416

Ref
-0.28

0.747

Ref
-3.26
-3.26
-3.47
-4.43
-4.67

0.086
0.083
0.068
0.037
0.032

-2.50

0.282

Table 4-9. Unadjusted effects of variables with social support and community
integration.
Variables
Age
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone/ Nursing/Retirement
home
Home with others
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Number of Non-ocular
Comorbidities
Number of Ocular Comorbidities
Glaucoma
No
Yes

Coefficient
-0.10

P-value
0.092

Ref
-1.23

0.169

Ref
-0.67

0.509

Ref
-1.22
-0.50

0.297
0.047

-1.51

0.173

Ref
0.80

0.415
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Retinal disease
No
Yes
Cataract
No
Yes
Socioeconomic status during
COVID-19
less than $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
$100,001 - $125,000
$125,001 - $150,000
Greater than $150,000

Ref
-3.06

0.001

Ref
-0.07

0.951

Ref
-0.02
0.33
0.13
3.38
0.92

0.993
0.900
0.962
0.254
0.762

1.67

0.610

TTO: Time Tradeoff; NEI VFQ-25: National Eye Institute 25-Item Visual Function
Questionnaire-25; CES-D: Center for Epidemiologic Studies Depression Scale; PSQI:
Pittsburg Sleep Quality Index; HADS-A: Hospital Anxiety and Depression Scale –
Anxiety; HADS-D: Hospital Anxiety and Depression Scale – Depression; CIQ:
Community Integration Questionnaire; SD: standard deviation
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Table 4-10. Coefficient Estimates (95% Confidence Interval) for the Backwards Stepwise Linear
Regression Models of the Questionnaire Outcomes.
Variables

NEI VFQ-25

CES-D

Retinal disease

-7.92 (-12.81, -3.05)

2.50 (-0.43, 5.43)

Number of non-

-1.66 (-3.01, -0.31)

PSQI

HADS-A

CIQ
-3.10 (-4.77, -1.43)
-0.68 (-1.15, -0.22)

ocular
comorbidities
Use of a mobility

4.20 (0.46, 7.94)

1.73 (.05, 3.41)

0.58 (-0.87, 2.04)

aid
Education

-1.79 (-3.44, -0.15)

NEI VFQ-25: National Eye Institute 25-Item Visual Function Questionnaire-25; CES-D: Center
for Epidemiologic Studies Depression Scale; PSQI: Pittsburg Sleep Quality Index; HADS-A:
Hospital Anxiety and Depression Scale – Anxiety; HADS-D: Hospital Anxiety and Depression
Scale – Depression; CIQ: Community Integration Questionnaire
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4.4 Discussion
In this cross-sectional study, the preference-based HRQoL, VRQoL, depression
and anxiety symptoms, and social support and community integration of seniors with
various eye diseases were assessed. A total of 90 participants were included in the study
and the results showed that the COVID-19 pandemic did not appear to have a large
impact on the QoL of seniors with eye diseases. This section provides a detailed analysis
and discussion of the results of the QoL assessment and the potential impact on healthrelated outcomes.
The present study revealed that the preference-based HRQoL of our study patients
with eye diseases during the pandemic is likely quite good with a mean utility value of
0.88. Moreover, it doesn’t appear that any of the potential predictors had a significant
level of impact on the HRQoL of seniors during the pandemic. The analysis of the present
study also showed that these seniors with eye disease appeared to have good vision and
only a slight loss in visual performance impacting their VRQoL during the pandemic.
However, it was also shown that the presence of retinal disease and the number of nonocular comorbidities had a significant negative impact on the participants' VRQoL.
Moreover, study participants appeared to have a low presence of depressive
symptomatology. The backwards stepwise multivariable regression analysis revealed that
the use of a mobility aid did appear to show a significant increase in depressive
symptomatology. The level of anxiety appeared to be normal, and the quality of sleep
appeared to be good overall among patients with eye diseases during the pandemic. Of
note, the use of a mobility aid was found to negatively affect sleep quality but not the
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presence of anxiety symptoms. Previously, sleep quality has been found to be associated
with physical disability in older adults which may explain this relationship between the
use of a mobility aid and poor sleep quality31. On the other hand, an analysis on the
levels of social support and community integration found that participants likely had
moderate social support and community integration during the pandemic. Furthermore, it
was revealed that the presence of retinal disease, number of non-ocular comorbidities, and
education appeared to have significant negative effects on social support and community
integration. Based on the key measures of QoL such as preference-based HRQoL,
VRQoL levels of depression and anxiety, and access to social support and community
integration, the above findings indicate that the QoL and wellness of the elderly with eye
diseases appears to be good.
However, it is important to note that there are studies conducted during this period
that highlighted the need for further research to ascertain the impact of COVID-19 on the
QoL of the elderly with eye diseases. For instance, a systematic review by Zaher et al.32
showed that there was a 36% increase in the fear of vision loss due to an increased risk of
missing appointments and a 48% increase in the fear of contracting the virus due to office
visits. Therefore, a future survey study focusing on gathering data about the fear of vision
loss due to an increased risk of missing appointments and fear of contracting the virus due
to office visits among eye disease patients would shed more light on the overall QoL of
patients during the ongoing pandemic. Further, a prospective cross-sectional comparative
study by Shalaby et al.33 found that the pandemic affected visually impaired people which
results in diminished QoL. Moreover, majority of seniors who have vision loss tend to
experience depressive symptoms 34. The results of our study resonate that community
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integration and social support appear to be the lowest among the study population. This
finding concurs with the view that containment measures of the pandemic such as
lockdowns, social distancing, and curfews may have potentially impacted the lives of
seniors with eye diseases.
Interestingly, the results of the preference-based HRQoL in this current study
seem to agree with those of previous studies performed in the same location and setting.
A previous study by Thomas et al.35 investigated the preference-based HRQoL among
patients with glaucoma and diabetic retinopathy. Another previous study by
Uruthiramoorthy et al.36 investigated the preference-based HRQoL among patients with
glaucoma. Both studies reported relatively high mean utility values from 0.89 to 0.94
which is similar to the value of 0.88 found in the current study using the same TTO
technique. These similarities may be suggestive that perhaps the QoL of the patients at
this location is relatively high due to the services and facilities provided by the Ivey Eye
Institute or due to the environment of London, Ontario in general.
Further, the study by Uruthiramoorthy et al36 found that living arrangements and
the use of a mobility aid were significant predictors of VRQoL. Additionally, the study by
Uruthiramoorthy et al36 found age, sex, income, living arrangement, and use of mobility
aids to be predictors of social support and community integration. The difference seen
between the predictor variables in the two studies may be due to a multitude of factors
such as the COVID-19 pandemic conditions, different time periods, general eye disease
patients versus glaucoma only patients, or the senior patient population.
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4.4.1 Limitations
While the current study provides valuable information on the QoL of seniors with
eye diseases, there were some limitations. A potential limitation stems from the use of
convenience sampling which is associated with sampling bias 37. Of note, many
participants in our study were identified as being white and not requiring the use of a
mobility aid; both of which are characteristics associated with a higher QoL38,39. As a
result, this means that the results may not be representative of the actual population and
that they are likely not entirely generalizable to other populations of seniors with eye
diseases40.
This study was also limited by the number of included participants. As with most
studies, more participants would allow for greater power and a greater ability to detect
differences that are present. As such, a greater number of participants may have resulted
in the detection of a significant impact on outcome measures like preference-based
HRQoL.
Two other limitations of this study are inherent to the cross-sectional design that
was used. The first of which is that in a cross-sectional design one cannot necessarily
determine whether the exposure did precede the outcome41. As such, in the current study
it is not entirely certain as to whether the study participants’ wellness was due to the
presence of the COVID-19 pandemic conditions. The second of which is length bias
which is systematic error due to selection of disproportionate numbers of long duration
cases41. With this limitation in mind, it may be that many participants recruited in the
current study were patients who have had their eye diseases for a long duration of time
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and been properly managed for a long time as well. As such, these patients may have
been more adapted to their conditions and reported better QoL and wellness.
The final potential limitation of the study stems from healthy volunteer bias.
Historically, volunteers in medical research tend to have a lower risk of mortality and
other health problems compared to those who are not volunteers42. Patients in the current
study participated on a voluntary basis. As a result, this may mean that the results of the
current study were biased in favor of higher QoL due to the study participants having
healthier lifestyles than those who did not volunteer to participate. However, it was noted
that of the 128 patients who were approached, 115 agreed to participate while 25 of these
patients did not pass the inclusion/exclusion criteria. This suggests that the probability of
such selection bias is likely low.
The current study has major implications, especially when it comes to focusing
healthcare resources on the most vulnerable groups of the population. However, future
studies in this area could focus on the relationship between QoL and eye diseases using
eye disease-specific questionnaires. For example, instruments such as the Ocular Surface
Disease Index for patients with DED and the Glaucoma Quality of Life-15 for patients
with glaucoma could be studied43,44. Generic preference-based measures of health to
measure HRQoL such as the EuroQoL-5D and 36-item Short Form Survey could be
used45,46. Moreover, future studies with larger sample sizes focused on the QoL of seniors
with eye diseases after the pandemic is completely over would be worthwhile conduct so
that a comparison can be made to better understand the impact of the pandemic conditions
on this population of patients.
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4.5 Conclusions
Overall, the current study has found that the QoL among seniors with eye diseases
appeared to be good. Measures of preference-based HRQoL and VRQoL appeared to be
high. Indications of depression and anxiety symptoms were likely low, while community
integration and social support appeared to be moderate. The presence of retinal disease
and the number of non-ocular comorbidities both appeared to negatively impact VRQoL
and social support and community integration. Education appeared to impact CIQ
negatively. The use of a mobility aid appeared to negatively affect depressive symptoms
and sleep quality.
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Chapter 5 Discussion
5 Introduction
This chapter begins with a statement of the overall goals of the thesis and each
individual study in Section 5.1. Section 5.2 presents a summary of the results and the
interpretations of each study’s results coinciding with each study’s objectives. Section 5.3
presents the strengths and limitations of each study. Section 5.4 discusses the future
directions. Finally, the conclusions are presented in Section 5.5.

5.1 Overall Goals of the Thesis
The overall goal of this thesis was to explore the quality of life (QoL) of patients
with eye diseases. This goal was accomplished through two research studies. The first
study was a systematic review in Chapter 3 which aimed to systematically identify and
summarize the health-related quality of life (HRQoL) values from direct preference
elicitation techniques and generic preference-based measures (GPBMs) in North
American patients with a variety of different eye diseases to provide important
information to be utilized for making evaluations and resource allocation decisions. The
second study was a cross-sectional survey study in Chapter 4 that aimed to characterize
the preference-based HRQoL, vision-related QoL (VRQoL), depression and anxiety
symptoms, sleep quality, social support, and community integration of seniors aged 65
and above with various eye diseases during the COVID-19 pandemic.
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5.2 Summary of Results
In characterizing the summary scores of the SF-36 and SF-12, the systematic
review showed that the mean physical component scores (PCS) ranged from 39.2 to 53.8
while the mean mental component scores (MCS) ranged from 48.7 to 62.9 in patients
with glaucoma. In patients with age-related macular degeneration (ARMD), PCS scores
ranged from 41.0 to 47.0 while MCS scores ranged from 38.0 to 52.0 across all severity
classifications. Among the studies focusing on diabetic retinopathy (DR), mean PCS
scores ranged from 46.0 to 49.6, and mean MCS scores ranged from 50.0 to 52.9. For the
studies pertaining to patients with cataracts, the mean PCS values ranged from 43.2 to
46.1, while the MCS scores had a larger range from 54.0 to 82.1. Similarly, the included
studies on patients with uveitis reported PCS and MCS scores with measures of central
tendency ranging from 47.4 to 50.0 and 47.6 to 52.0 respectively. Finally, the studies
focused on dry eye disease (DED) reported mean PCS and MCS values ranging from 45.3
to 48.8 and 44.6 to 51.0. Across each eye disease, overall physical component scores
ranged from 39.2 to 53.8 suggesting potentially poor to average physical health though
mental component scores ranged from 51.0 to 82.1 suggesting average to potentially good
mental health. However, most measures of the central tendency of the scores appeared to
be near 50 where PCS and MCS values can range between 0 to 100, and a mean (SD) of
50 (10) has been noted to be the PCS and MCS values of the US general population 1.

The systematic review also summarized the utility values of patients with eye
disease revealing that the mean utility values of patients with glaucoma appeared to be
consistent between 0.89 to 0.94. The mean utility values for collective patients with
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ARMD were more variable ranging from 0.74 to 0.81. Similarly, the mean utility values
of collective patients with DR ranged from 0.77 to 0.88. However, based on studies that
reported utility values stratified by disease severity, mean utility values as low as 0.40 and
as high as 0.96 were reported among groups of patients with more severe and less severe
forms of ARMD respectively. Similarly, among studies that reported utility values
stratified by severity of DR, mean utility values as low as 0.59 and as high as 0.92 were
reported among groups of patients with more severe and less severe forms respectively.
Mean utility scores for patients with cataracts were variable ranging from 0.66 to 0.85.
Likewise, measures of central tendency for utility values of patients with uveitis ranged
from 0.67 to 0.84. Finally, the mean utility values of collective patients living with DED
appeared to be less variable between 0.78 to 0.82. However, among studies that reported
utility values stratified by disease severity, mean utility values as low as 0.62 and as high
as 0.81 were reported in patients with more severe and less severe forms of DED
respectively. Of note, across non-stratified collective groups of patients with the eye
diseases mentioned above, utility values ranged from 0.74 to 0.94 suggesting overall fair
to good HRQoL. However, in general, the utility values across patients with ARMD, DR,
uveitis, and DED appeared to be quite similar while the values in patients with glaucoma
appear to be higher. This resonates with our results from the cross-sectional study.

The results of the cross-sectional study revealed that the overall QoL among
seniors with eye diseases appeared to be good during the COVID-19 pandemic. Results
from the data analysis showed that the outcomes of the HRQoL and VRQoL appeared to
be good with a mean utility value of 0.88 and a mean summary score of 84.71. Sleep
quality also appeared to be good with a mean summary score of 6.58. In addition, the
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assessment of the depression and anxiety symptoms appeared to be low with mean
summary scores of 6.79 and 2.56 respectively. The community integration and social
support appeared to be moderate with a mean summary score of 14.46. The results also
revealed that the presence of retinal disease and the number of non-ocular comorbidities
both appeared to negatively impact VRQoL and social support and community
integration. Greater education also appeared to impact social support and community
integration negatively. Additionally, the use of a mobility aid appeared to negatively
affect depressive symptoms and sleep quality. This could suggest patients with less
mobility could have poor sleep quality and depressive symptoms.
The systematic review from Chapter 3 focuses on preference-based HRQoL of all
eye disease patients in North America while the cross-sectional study from Chapter 4
looks at the wellness and more general QoL of a specific group of patients with eye
diseases at a specific time (seniors during the COVID-19 pandemic). Together they
provide a better picture of the QoL of patients with eye diseases. The findings from both
Chapters 3 and 4 generally seem to indicate that the QoL among patients with eye disease
appears to be good. In particular, the mean utility score of 0.88 was found in the crosssectional study of Chapter 4. This utility score is relatively similar to those for glaucoma,
DR, and some forms of ARMD in the systematic review of Chapter 3. Notably, a score of
0.88 appears to be high. This may be because while most patients in the cross-sectional
study had glaucoma, retinal diseases, or cataracts, 40 of included patients reported having
glaucoma making glaucoma the most prevalent disease in the study sample. Moreover, as
shown in Chapter 3, the score of the utility values for glaucoma were also quite high from
0.89 to 0.94. As such, it may be due to the high prevalence of glaucoma in the study
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sample that this mean utility score was quite high. Moreover, the results of the crosssectional study indicating the low presence of depression and anxiety symptoms within
the study sample seem to agree with the finding of suggesting average to potentially good
mental health from the systematic review.

5.3 Strengths and Limitations
In conducting the systematic review to explore the QoL of North American
patients with a variety of eye diseases, the outcomes of Chapter 3 could provide important
information to policymakers to make economic assessments to improve the overall care
of patients with different eye diseases. This is particularly a significant undertaking since
sight is an important part of the health and wellbeing of senior citizens who tend to be the
majority of individuals affected by eye diseases since it not only prevents health risks
such as falls but also psychological disorders such as anxiety, stress, and depression that
are known to have a negative impact on their QoL2. Additionally, in documenting and
assessing the QoL among senior patients during the COVID-19 pandemic, the outcomes
of Chapter 4 have the potential to determine the overall impact of the pandemic,
especially in relation to health and wellbeing of seniors. Furthermore, the findings from
Chapter 4 could provide a reservoir of information to help improve the future quality of
care during non-COVID-19 conditions and potential future pandemic situations.
However, while both studies provide valuable information, both have certain
limitations. Regarding the systematic review, of the 39 included studies, 16 were deemed
to be of a low risk of bias. Regardless of their quality, all studies were included in the
review due to the limited availability of evidence. Another limitation of the systematic
review stems from the fact that a location restriction of North America was placed to
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systematically gather consistent data on HRQoL. Thus, the values of HRQoL from the
systematic review may not be representative of those in other countries and articles that
measured HRQoL among other eye conditions were excluded from the review.
Additionally, the review had a restriction of adult patients and as a result, the review does
not include information on eye diseases that are much more common in pediatric
populations. Though, it should be emphasized that the key objective of this systematic
review was to determine and summarize the HRQoL values in adult patients with various
eye diseases in North America.
Regarding the cross-sectional study assessing QoL among seniors during the
COVID-19 pandemic, one of its limitations was the use of a convenience sampling
technique. This limits the generalizability of the findings to other populations of seniors
with eye diseases as well as it is possible that there are other factors that may influence an
individual’s QoL during COVID-193. The study may have also been limited by healthy
volunteer bias. This is a type of bias that occurs when a study participant is at a lower risk
of developing the disease because they are in fact healthy4. Nonetheless, it was noted that
of the 128 patients who were approached, 115 agreed to participate, while 25 of these
patients did not pass the inclusion/exclusion criteria. This suggests that the probability of
such selection bias is likely low.

5.4 Future Directions
One of the key areas of consideration for future research is the need for more data
to be extracted from a large sample of patients specific to each eye disease and disease
severity to increase the generalizability of the findings as well as to improve the power of
the study. In this regard, there is a need for more data to be collected to gain a better
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understanding of the impact of the pandemic on the QoL among seniors with different age
groups, specific eye diseases as well as disease severity. This also highlights another area
of consideration; that is to use different data collection tools when assessing QoL among
the target population. While the current cross-sectional study used a plethora of tools such
as the time trade-off technique, 25-item version National Eye Institute Visual Function
Questionnaire, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale–
Anxiety Subscale, and Center for Epidemiologic Studies – Depression scale, there are
many other tools that can be used to measure QoL as highlighted in the systematic
review. As such, additional measures such as the EuroQoL-5D, 36-item and 12-item
Short Form Surveys, and Health Utility Index questionnaires may be used to provide a
more comprehensive understanding of the overall health status of seniors with eye
diseases.
Another area of consideration for future research is the need to improve the health
and wellbeing of patients with eye diseases. As noted by previous studies, eye disease
among elderly patients is associated with poor health, low HRQoL, and increased
mortality5. Moreover, worse QoL is typically found among people with more severe
forms of eye diseases with worse visual acuity6. As such, while the current studies
provide evidence of the QoL among general patients with eye diseases and seniors with
eye diseases during pandemic times, future studies could apply the findings to develop
further interventions to improve the health and wellbeing of patients with eye diseases,
with a specific focus on wellness. Generally, wellness refers to the state of being
physically, mentally, and socially fit and healthy7. Wellness can also be defined as a state
of physical, mental, social, and spiritual health that enables individuals to effectively cope
with the demands of everyday life 8. Future studies could assess different aspects that
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affect wellness such as other mood disorders including bipolar disorder along with
anxiety- and depression-like in this cross-sectional study. Furthermore, future studies
could also take a greater focus on assessing spiritual health as a part of wellness.
Finally, future studies focusing on determining how the QoL of older adults is
affected more specifically by each case of an ophthalmological condition such as
glaucoma and DED could use relevant measures. Questionnaires designed to determine
how the QoL of patients with specific eye diseases could be used. For example, future
studies could use instruments like the Glaucoma Quality of Life-15 for patients with
glaucoma and the Ocular Surface Disease Index for patients with DED9,10, new
instruments like the Glaucoma Utility Instrument which is more tailored towards patients
with glaucoma unlike the traditional preference elicitation methods and can also yield
utility values for economic evaluations11. Doing so may provide a better understanding of
the overall QoL of older adults with these specific eye diseases.

5.5 Conclusions
Overall, the QoL of patients with eye diseases in North America appears to be good.
The HRQoL among patients with various eye diseases was generally similar. In
particular, there was similar HRQoL across patients with glaucoma, ARMD, diabetic
retinopathy (DR), cataracts, uveitis, and dry eye disease (DED) based on the SF-12 and
SF-36. Utility values across patients with ARMD, DR, cataracts, uveitis, and DED also
provided similar results, however, the values in patients with glaucoma appeared to be
higher. Moreover, QoL among seniors with eye diseases appeared to be generally good
during the COVID-19 pandemic. HRQoL, VRQoL, and sleep quality appeared to be
good. Depression and anxiety symptoms appeared to be low, while community
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integration and social support were moderate. The presence of retinal disease and the
number of non-ocular comorbidities both appeared to negatively impact VRQoL and
social support and community integration suggesting that retina patients with a number of
non-ocular comorbidities had poor vision-related QoL and poor social support and
community integration. Education appeared to impact CIQ negatively suggesting that
patients with education of more than high school had poorer social support and
community integration. The use of a mobility aid appeared to negatively affect depressive
symptoms and sleep quality.
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Appendix B. Time Trade-Off (TTO)

How many years do you expect to live? __________________years

Suppose there was a new technology that could restore your eyesight to perfectly healthy eyes.
The technology always works but decreases the length of time you live.

What is the maximum number of years, if any, that you would be willing to give up if you could
receive this technology and have perfect vision for your remaining years?

___________________years

Appendix C. National Eye Institute Visual Function Questionnaire (VFQ-25)
PART 1 - GENERAL HEALTH AND VISION
1. In general, would you say your overall health is: (Circle One)
Excellent............................... 1
Very Good............................ 2
Good...................................... 3
Fair......................................... 4
Poor........................................ 5
2. At the present time, would you say your eyesight using both eyes (with glasses or
contact
lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely
blind?
(Circle One)
Excellent............................... 1
Good...................................... 2
Fair......................................... 3
Poor........................................ 4
Very Poor.............................. 5
Completely Blind................ 6
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3. How much of the time do you worry about your eyesight? (Circle One)
None of the time............................. 1
A little of the time........................... 2
Some of the time............................ 3
Most of the time.............................. 4
All of the time?................................ 5
4. How much pain or discomfort have you had in and around your eyes (for example,
burning, itching, or aching)? Would you say it is: (Circle One)
None....................................... 1
Mild......................................... 2
Moderate............................... 3
Severe, or............................. 4
Very severe?........................ 5
PART 2 - DIFFICULTY WITH ACTIVITIES
The next questions are about how much difficulty, if any, you have doing certain
activities
wearing your glasses or contact lenses if you use them for that activity.
5. How much difficulty do you have reading ordinary print in newspapers? Would you
say you
have: (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight.... 5
Stopped doing this for other reasons or not interested
in doing this...................................... 6
6. How much difficulty do you have doing work or hobbies that require you to see well
up close,
such as cooking, sewing, fixing things around the house, or using hand tools? Would you
say:
(Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
7. Because of your eyesight, how much difficulty do you have finding something on a
crowded
shelf? (Circle One)

135

No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
8. How much difficulty do you have reading street signs or the names of stores?(Circle
One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this........................... 6
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or
curbs
in dim light or at night? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
10. Because of your eyesight, how much difficulty do you have noticing objects off to the
side
while you are walking along?(Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
11. Because of your eyesight, how much difficulty do you have seeing how people react
to things
you say? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
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12. Because of your eyesight, how much difficulty do you have picking out and matching
your
own clothes? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
13. Because of your eyesight, how much difficulty do you have visiting with people in
their
homes, at parties, or in restaurants? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
14. Because of your eyesight, how much difficulty do you have going out to see movies,
plays,
or sports events? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
15. Are you currently driving, at least once in a while? (Circle One)
Yes........................ 1 Skip To Q 15c
No ......................... 2
15a. IF NO: Have you never driven a car or have you given up driving? (Circle One)
Never drove........ 1 Skip To Part 3, Q 17
141
Gave up............... 2
15b. IF YOU GAVE UP DRIVING: Was that mainly because of your eyesight, mainly
for some
other reason, or because of both your eyesight and other reasons? (Circle One)
Mainly eyesight..................................... 1 Skip To Part 3, Q 17
Mainly other reasons ........................... 2 Skip To Part 3, Q 17
Both eyesight and other reasons .... 3 Skip To Part 3, Q 17
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15c. IF CURRENTLY DRIVING: How much difficulty do you have driving during the
daytime
in familiar places? Would you say you have: (Circle One)
No difficulty at all................................. 1
A little difficulty..................................... 2
Moderate difficulty............................... 3
Extreme difficulty................................. 4
16. How much difficulty do you have driving at night? Would you say you have: (Circle
One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
16A. How much difficulty do you have driving in difficult conditions, such as in bad
weather,
during rush hour, on the freeway, or in city traffic? Would you say you have: (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
PART 3: RESPONSES TO VISION PROBLEMS
The next questions are about how things you do may be affected by your vision. For each
one,
please circle the number to indicate whether for you the statement is true for you all,
most, some,
a little, or none of the time. (Circle One On Each Line)

All of
the time
17 Do you accomplish less
than you would like
because of your vision?
18 Are you limited in how
long you can work or do
other activities because

Most of
the time

Some
of the time

A little
of the time

None of
the time

1

2

3

4

5

1

2

3

4

5
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of your vision?
How much does pain or
discomfort in or around
your eyes, for example,
burning, itching, or
aching, keep you from
doing what you’d like to
19 be doing?

1

2

3

4

5
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For each of the following statements, please circle the number to indicate whether
for you the statement is definitely true, mostly true, mostly false, or definitely false
for you or you are not sure. (Circle One On Each Line)
Definitely Mostly

Not

Mostly Definitely

true

sure

false

true

false

20 I stay home most of the time
1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

because of my eyesight.
21 I feel frustrated a lot of the
time because of my eyesight.
22 I have much less control over
what I do, because of my
eyesight.
23 Because of my eyesight, I
have to rely too much on
what other people tell me
24 I need a lot of help from others
because of my eyesight.
25 I worry about doing things that
will embarrass myself or others,
because of my eyesight.
Appendix D. Hospital Anxiety and Depression Scale – Anxiety subscale (HADS-A)
Tick the box beside the reply that is closest to how you have been feeling in the past
week. Don’t take too long over you replies: your immediate is best.
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1. I feel
1 tense or 'wound up':
.

2. I feel
2 tense or 'wound up':
.

3. Worrying
3
thoughts go through my mind:
.

4. I can
3 sit at ease and feel relaxed:
.

5. I get
3 a sort of frightened feeling like 'butterflies' in the
stomach:
.

6. I feel
3 restless as I have to be on the move:
.

 o Most of the time
 o A lot of the time
 o From time to time, occasionally

Not at all

 o Very definitely and quite badly
 o Yes, but not too badly
 o A little, but it doesn't worry me

Not at all

 o A great deal of the time
 o A lot of the time
 o From time to time, but not too oft

Not at all

 o Definitely
 o Usually
 o Not Often

Not at all

 o Not at all
 o Occasionally
 o Quite Often

Very Often

 o Very much indeed
 o Quite a lot
 o Not very much
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7. I get
3 sudden feelings of panic:
.

Not at all

 o Very often indeed
 o Quite a lot
 o Not very often

Not at all

Appendix E. Center for Epidemiologic Studies – Depression scale (CES-D)
Instructions: Below is a list of the ways you might have felt or behaved. Please tell me
how often you have felt this way during the past week.

Rarely or none
of the time (less
than 1 day)

Some or a
little of the
time (1-2
days)

Occasionally
or a moderate
amount of
time (3-4
days)

Most or all
of the time
(5-7 days)

1. I was bothered by things that usually
don’t bother me.









2. I did not feel like eating; my appetite
was poor.









3. I felt that I could not shake off the
blues even with help from my family or
friends.









4. I felt I was just as good as other
people.









5. I had trouble keeping my mind on
what I was doing.









6. I felt depressed.
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7. I felt that everything I did was an
effort.









8. I felt hopeful about the future.









9. I thought my life had been a failure.









10. I felt fearful.









11. My sleep was restless.









12. I was happy.









13. I talked less than usual.









14. I felt lonely.









15. People were unfriendly.









16. I enjoyed life.









17. I had crying spells.









18. I felt sad.









19. I felt that people disliked me.









20. I could not get “going.”
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Appendix F. Pittsburgh Sleep Quality Index (PSQI)
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Appendix G. Community Integration Questionnaire (CIQ)
1. Who usually does the shopping for groceries or
other necessities in your household?
2. Who usually prepares meals in your household?

3. In your home who usually does the everyday
housework?

4. Who usually cares for the children in your home?

5. Who usually plans social arrangements such as
get-togethers with family and friends?
6. Who usually looks after your personal finances,
such as banking or paying bills
7. Approximately how many times a month do you
usually participate in shopping outside your
home?
8. Approximately how many times a month do you
usually participate in leisure activities such as
movies, sports, restaurants etc.
9. Approximately how many times a month do you
usually visit your friends or relatives?
10. When you participate in leisure activities do you
usually do this alone or with others?

11. Do you have a best friend with whom you
confide?
12. How often do you travel outside the home?

o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o

Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Not applicable
Yourself alone
Yourself and someone else
Someone else
Not applicable
Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Never
1-4 times
5 or more
Never
1-4 times
5 or more
Never
1-4 times
5 or more
Mostly alone
Mostly with friends
Mostly with family members
With a combination of family
and friends
Yes
No
Almost every day
Almost every week
Seldom/never (less than once
per week)
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13. Please choose the answer that best corresponds to
your current (during the past month) work
situation:

14. Please choose the answer that best corresponds to
your current (during the past month) school or
training program situation:

15. In the past month, how often did you engage in
volunteer activities

o Full-time (more than 20
hours/week)
o Part-time (less than or equal
to 20 hours/week)
o Not working, but actively
looking for work
o Not working, not looking for
work
o Not applicable (retired,
disability)
o Full-time
o Part-time
o Not attending school, or
training program
o Not applicable (retired,
disability)
o Never
o 1-4 times
o 5 or more

Appendix H. Search Strategies
Embase
#
1
2

3

4

Searches
"quality of life"/ or quality adjusted life year/
(quality of life or life quality or hql or hqol or qol or hrqol
or hr qol or health-related quality or health related
quality of life).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
(quality of wellbeing or quality of well being or quality of
well-being or qwb).mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
(qaly* or quality adjusted life year* or quality-adjusted
life year).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug

Results
563842
699058

679

37381

147

5

6

7

8

9

10

11

12

manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
(time trade off or time tradeoff or tto).mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
(visual analog scale* or VAS).mp. [mp=title, abstract,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
(standard gamble* or SG*).mp. [mp=title, abstract,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
(EQ-5D or eq5d or eq 5d or euroqol or euro qol or
euroqol-5d).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
(SF-36 or sf 36 or sf36 or sfthirtysix or sf thirtysix or sf
thirty six or short form 36 or short form thirty six or short
form thirtysix or shortform 36).mp. [mp=title, abstract,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
(SF-6D or sf 6d or sf6d or sf six d or short form 6d or short
form sixd or shortform 6d or shortform 6 d or Short-Form
Six-Dimension or Short Form Six Dimension).mp.
[mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword heading word, floating
subheading word, candidate term word]
(SF-12 or sf 12 or sf12 or sftwelve or sf twelve or short
form 12 or short form twelve or shortform 12).mp.
[mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword heading word, floating
subheading word, candidate term word]
(Health Utility Index or Health Utilities Index or HUI or
hui1 or hui2 or hui3).mp. [mp=title, abstract, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,

3128

113463

117943

25503

54052

1751

12975

4311

148

13

14

15

16

17

18

keyword heading word, floating subheading word,
candidate term word]
eye disease/ or Eye disease*.mp. or ocular disease*.mp.
or ophthal* disease.mp. or ophthal* condition.mp.
[mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer,
device trade name, keyword heading word, floating
subheading word, candidate term word]
glaucoma/ or low tension glaucoma/ or primary
glaucoma/ or open angle glaucoma/ or neovascular
glaucoma/ or secondary glaucoma/ or glaucoma.mp. or
open-angle glaucoma.mp. or open angel glaucoma.mp. or
primary open-angle glaucoma.mp. or primary open angle
glaucoma.mp. or OAG.mp. or POAG.mp. or low tension
glaucoma.mp. or low-tension glaucoma.mp. or AngleClosure Glaucoma.mp. or Angle Closure Glaucoma.mp. or
Normal-Tension Glaucoma.mp. or Normal Tension
Glaucoma.mp. or NTG.mp. [mp=title, abstract, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
retina macula age related degeneration/ or macular
degeneration/ or retina macula degeneration/ or agerelated macular degeneration.mp. or ARMD.mp. or
AMD.mp. or macular degeneration.mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
diabetic retinopathy/ or diabetic eye disease.mp. or
diabetic retinopathy.mp. or DR.mp. or retinopathy.mp. or
diabetic maculopathy.mp. [mp=title, abstract, heading
word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
retina macula edema/ or macular edema/ or macular
edema.mp. or diabetic macular edema.mp. or DME.mp.
or ME.mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
retina vein occlusion/ or retinal vein occlusion.mp. or
RVO.mp. or central retinal vein occlusion.mp. or
peripheral retinal vein occlusion.mp. or CRVO.mp. or

73881

115849

52221

341065

89590

10241

149

19

20

21

22

23

24

25

PRVO.mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
retina macula hole/ or macular hole*.mp. or retinal
hole*.mp. or retinal tear*.mp. or retinal break.mp. or
retinal breaks.mp. or retinal perforation*.mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
retina detachment/ or retinal detachment.mp. or
detached retina.mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
cataract/ or senile cataract/ or cataract*.mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
dry eye/ or keratoconjunctivitis sicca/ or dry eye*.mp. or
dry eye disease.mp. or dry eye syndrome.mp. or DED.mp.
or DES.mp. or keratoconjunctivitis sicca.mp. or KCS.mp. or
dysfunctional tear syndrome.mp. or lacrimal
keratoconjunctivitis.mp. or evaporative tear
deficiency.mp. or aqueous tear deficiency.mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
(thyroid eye disease or TED or Graves ophthalmopathy or
Graves Orbitopathy or GO).mp. [mp=title, abstract,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
amblyopia/ or Amblyopia.mp. or lazy eye.mp. [mp=title,
abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade
name, keyword heading word, floating subheading word,
candidate term word]
intermittent strabismus/ or strabismus/ or divergent
strabismus/ or vertical strabismus/ or convergent
strabismus/ or Strabismus.mp. or esotropia.mp. or
exotropia.mp. or Nystagmus.mp. [mp=title, abstract,

11031

4219

112954

545930

145516

14761

66919

150

31
32
33

heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name,
keyword heading word, floating subheading word,
candidate term word]
uveitis/ or autoimmune uveitis/ or endotoxin-induced
uveitis/ or intermediate uveitis/ or Uveitis.mp. or anterior
uveitis.mp. or posterior uveitis.mp. or intermediate
uveitis.mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword heading
word, floating subheading word, candidate term word]
1 or 2 or 3 or 4
5 or 6 or 7
8 or 9 or 10 or 11 or 12
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or
23 or 24 or 25 or 26
27 and 28
29 or 31
30 and 32

34

limit 33 to (human and english language)

26

27
28
29
30

41301

701521
232949
92067
1494120
26124
107571
3749
3114
01/28/2022

Medline
#
1

2

3

4

Searches
"Quality of Life"/ or Quality-Adjusted Life Years/ or "Value
of Life"/ or Health Status/ or Sickness Impact Profile/ or
Disability Evaluation/ or exp "Activities of Daily Living"/
(quality of life or life quality or hql or hqol or qol or hrqol
or hr qol or health-related quality or health related
quality of life).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
(quality of wellbeing or quality of well being or quality of
well-being or qwb).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating
sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
(qaly* or quality adjusted life year* or quality-adjusted

Results
442545

402993

520

22414

151

5

6

7

8

9

10

life year).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
(time trade off or time tradeoff or tto).mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(visual analog scale* or VAS).mp. [mp=title, abstract,
original title, name of substance word, subject heading
word, floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(standard gamble* or SG*).mp. [mp=title, abstract,
original title, name of substance word, subject heading
word, floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(EQ-5D or eq5d or eq 5d or euroqol or euro qol or
euroqol-5d).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
(SF-36 or sf 36 or sf36 or sfthirtysix or sf thirtysix or sf
thirty six or short form 36 or short form thirty six or short
form thirtysix or shortform 36).mp. [mp=title, abstract,
original title, name of substance word, subject heading
word, floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(SF-6D or sf 6d or sf6d or sf six d or short form 6d or short
form sixd or shortform 6d or shortform 6 d or Short-Form
Six-Dimension or Short Form Six Dimension).mp.

2094

70582

70953

13843

28325

951

152

11

12

13

14

15

[mp=title, abstract, original title, name of substance
word, subject heading word, floating sub-heading word,
keyword heading word, organism supplementary concept
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(SF-12 or sf 12 or sf12 or sftwelve or sf twelve or short
form 12 or short form twelve or shortform 12).mp.
[mp=title, abstract, original title, name of substance
word, subject heading word, floating sub-heading word,
keyword heading word, organism supplementary concept
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
(Health Utility Index or Health Utilities Index or HUI or
hui1 or hui2 or hui3).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating
sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
Eye Diseases/ or Eye disease*.mp. or ocular disease*.mp.
or ophthal* disease.mp. or ophthal* condition.mp.
[mp=title, abstract, original title, name of substance
word, subject heading word, floating sub-heading word,
keyword heading word, organism supplementary concept
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Glaucoma, Open-Angle/ or Glaucoma/ or Glaucoma,
Neovascular/ or Low Tension Glaucoma/ or glaucoma.mp.
or open-angle glaucoma.mp. or open angel glaucoma.mp.
or primary open-angle glaucoma.mp. or primary open
angle glaucoma.mp. or OAG.mp. or POAG.mp. or low
tension glaucoma.mp. or low-tension glaucoma.mp. or
Angle-Closure Glaucoma.mp. or Angle Closure
Glaucoma.mp. or Normal-Tension Glaucoma.mp. or
Normal Tension Glaucoma.mp. or NTG.mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Macular Degeneration/ or age-related macular
degeneration.mp. or ARMD.mp. or AMD.mp. or macular

6786

2153

56328

79056

31799

153

16

17

18

19

20

degeneration.mp. [mp=title, abstract, original title, name
of substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
Diabetic Retinopathy/ or diabetic eye disease.mp. or
diabetic retinopathy.mp. or DR.mp. or retinopathy.mp. or
diabetic maculopathy.mp. [mp=title, abstract, original
title, name of substance word, subject heading word,
floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Macular Edema/ or macular edema.mp. or diabetic
macular edema.mp. or DME.mp. or ME.mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Retinal Vein Occlusion/ or retinal vein occlusion.mp. or
RVO.mp. or central retinal vein occlusion.mp. or
peripheral retinal vein occlusion.mp. or CRVO.mp. or
PRVO.mp. [mp=title, abstract, original title, name of
substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
Retinal Perforations/ or macular hole*.mp. or retinal
hole*.mp. or retinal tear*.mp. or retinal break.mp. or
retinal breaks.mp. or retinal perforation*.mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Retinal Detachment/ or retinal detachment.mp. or
detached retina.mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating
sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary

153756

68310

6664

8987

28057

154

21

22

23

24

25

26

concept word, rare disease supplementary concept word,
unique identifier, synonyms]
Cataract/ or cataract*.mp. [mp=title, abstract, original
title, name of substance word, subject heading word,
floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Dry Eye Syndromes/ or Keratoconjunctivitis Sicca/ or dry
eye*.mp. or dry eye disease.mp. or dry eye syndrome.mp.
or DED.mp. or DES.mp. or keratoconjunctivitis sicca.mp.
or KCS.mp. or dysfunctional tear syndrome.mp. or
lacrimal keratoconjunctivitis.mp. or evaporative tear
deficiency.mp. or aqueous tear deficiency.mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Graves Ophthalmopathy/ or thyroid eye disease.mp. or
TED.mp. or Graves ophthalmopathy.mp. or Graves
Orbitopathy.mp. or GO.mp. [mp=title, abstract, original
title, name of substance word, subject heading word,
floating sub-heading word, keyword heading word,
organism supplementary concept word, protocol
supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Amblyopia/ or Amblyopia.mp. or lazy eye.mp. [mp=title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier,
synonyms]
Strabismus/ or Exotropia/ or Esotropia/ or
Strabismus.mp. or esotropia.mp. or exotropia.mp. or
Nystagmus.mp. [mp=title, abstract, original title, name of
substance word, subject heading word, floating subheading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
Uveitis, Anterior/ or Uveitis, Suppurative/ or Uveitis/ or

73694

393912

111356

9802

39175

25058

155

27
28
29
30
31
32
33
34

Uveitis, Posterior/ or Uveitis, Intermediate/ or Uveitis.mp.
or anterior uveitis.mp. or posterior uveitis.mp. or
intermediate uveitis.mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating
sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier, synonyms]
1 or 2 or 3 or 4
5 or 6 or 7
8 or 9 or 10 or 11 or 12
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or
23 or 24 or 25 or 26
27 and 28
29 or 31
30 and 32
limit 33 to (english language and humans)

598156
142646
48766
988352
15862
59087
1856
1246
01/28/2022

NHS EED
#
1

2
3
4
5
6
7
8
9
10
11

12

Searches
quality of life or life quality or hql or hqol or qol or
hrqol or hr qol or health-related quality or health
related quality of life
MeSH DESCRIPTOR Quality of Life EXPLODE ALL TREES
quality of wellbeing or quality of well being or quality
of well-being or qwb
qaly* or quality adjusted life year*or quality-adjusted
life year*
MeSH DESCRIPTOR Quality-Adjusted Life Years
EXPLODE ALL TREES
time trade off or time tradeoff or tto
visual analog* scale* or VAS
MeSH DESCRIPTOR Visual Analog Scale EXPLODE ALL
TREES
standard gamble* or SG*
EQ-5D or eq5d or eq 5d or euroqol or euro qol or
euroqol-5d
SF-36 or sf 36 or sf36 or sfthirtysix or sf thirtysix or sf
thirty six or short form 36 or short form thirty six or
short form thirtysix or shortform 36
SF-6D or sf 6d or sf6d or sf six d or short form 6d or
short form sixd or shortform 6d or shortform 6 d or

Results
3931

1466
60
2886
3345
367
141
2
347
738
242

55

156

13
14
15
16
17

18
19
20

Short-Form Six-Dimension or Short Form Six
Dimension
SF-12 or sf 12 or sf12 or sftwelve or sf twelve or short
form 12 or short form twelve shortform 12
Health Utility Index or Health Utilities Index or HUI or
hui1 or hui2 or hui3
Eye disease* or ocular disease* or ophthal* disease or
ophthal* condition
MeSH DESCRIPTOR Eye Diseases EXPLODE ALL TREES
glaucoma or open-angle glaucoma or open angel
glaucoma or primary open-angle glaucoma or primary
open angle glaucoma or OAG or POAG or low tension
glaucoma or low-tension glaucoma or Angle-Closure
Glaucoma or Angle Closure Glaucoma or NormalTension Glaucoma or Normal Tension Glaucoma or
NTG
MeSH DESCRIPTOR Glaucoma EXPLODE ALL TREES
MeSH DESCRIPTOR Glaucoma, Angle-Closure EXPLODE
ALL TREES
MeSH DESCRIPTOR Glaucoma, Neovascular EXPLODE
ALL TREES

37
144
29
270
64

55
0
0

21

MeSH DESCRIPTOR Glaucoma, Open-Angle EXPLODE
ALL TREES

32

22

MeSH DESCRIPTOR Low Tension Glaucoma EXPLODE
ALL TREES
age-related macular degeneration or ARMD or AMD or
macular degeneration
diabetic eye disease or diabetic retinopathy or DR or
retinopathy or diabetic maculopathy
MeSH DESCRIPTOR Diabetic Retinopathy EXPLODE ALL
TREES
macular edema or diabetic macular edema or DME or
ME
MeSH DESCRIPTOR Macular Edema EXPLODE ALL
TREES
retinal vein occlusion or RVO or central retinal vein
occlusion or peripheral retinal vein occlusion or CRVO
or PRVO
MeSH DESCRIPTOR Retinal Vein Occlusion EXPLODE
ALL TREES
macular hole* or retinal hole* or retinal tear* or
retinal break or retinal breaks or retinal perforation*
MeSH DESCRIPTOR Retinal Perforations EXPLODE ALL
TREES
retinal detachment or detached retina
MeSH DESCRIPTOR Retinal Detachment EXPLODE ALL

0

23
24
25
26
27
28

29
30
31
32
33

52
343
37
285

4

4
6
4
14
5

157

34
35
36

37
38
39
40
41
42
43
44
45
46
47
48

49
50
51

TREES
cataract*
MeSH DESCRIPTOR Cataract EXPLODE ALL TREES
dry eye* or dry eye disease or dry eye syndrome or
DED or DES or keratoconjunctivitis sicca or KCS or
dysfunctional
tear
syndrome
or
lacrimal
keratoconjunctivitis or evaporative tear deficiency or
aqueous tear deficiency
MeSH DESCRIPTOR Dry Eye Syndromes EXPLODE ALL
TREES
thyroid eye disease or TED or Graves ophthalmopathy
or Graves Orbitopathy or GO
Amblyopia or lazy eye
MeSH DESCRIPTOR Amblyopia EXPLODE ALL TREES
Strabismus or esotropia or exotropia or Nystagmus
MeSH DESCRIPTOR Strabismus EXPLODE ALL TREES
Uveitis or anterior uveitis or posterior uveitis or
intermediate uveitis
MeSH DESCRIPTOR Uveitis EXPLODE ALL TREES
1 or 2 or 3 or 4 or 5
6 or 7 or 8 or 9
10 or 11 or 12 or 13 or 14
15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or
34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
or 44
45 and 46
47 or 48
49 and 50

87
21
68

2
238
5
4
4
7
2
2
6382
902
1082
1052

715
1613
160
02/06/2022

Cochrane
ID
#1
#2

Search
MeSH descriptor: [Quality of
Life] this term only
"quality of life" or "life quality"
or "hql" or "hqol" or "qol" or
"hrqol" or "hr qol" or "healthrelated quality" or "health
related quality of life" or
"quality of wellbeing"
or "quality of well being" or
"quality of well-being" or
"qwb":ab,ti,kw

Hits
27524
135149

158

#3

#4

#5
#6
#7
#8
#9

#10

#11

#12

#13

#14
#15

MeSH descriptor: [QualityAdjusted Life Years] this term
only
qaly* or quality adjusted life
year*or quality-adjusted life
year*:ab,ti,kw
"time trade off" or "time
tradeoff" or "tto":ab,ti,kw
MeSH descriptor: [Visual
Analog Scale] this term only
"visual analog scale*" or
"VAS":ab,ti,kw
"standard gamble*" or
"SG":ab,ti,kw
"EQ-5D" or "eq5d" or "eq 5d"
or "euroqol" or "euro qol" or
"euroqol-5d":ab,ti,kw
"SF-36" or "sf 36" or "sf36" or
"sfthirtysix" or "sf thirtysix" or
"sf thirty six" or "short form
36" or "short form thirty six" or
"short form thirtysix" or
"shortform 36":ab,ti,kw
"SF-6D" or "sf 6d" or "sf6d" or
"sf six d" or "short form 6d" or
"short form sixd" or "shortform
6d" or "shortform 6 d" or
"Short-Form Six-Dimension" or
"Short Form Six
Dimension":ab,ti,kw
"SF-12" or "sf 12" or "sf12" or
"sftwelve" or "sf twelve" or
"short form 12" or "short form
twelve" or "shortform
12":ab,ti,kw
"Health Utility Index" or
"Health Utilities Index" or
"HUI" or "hui1" or "hui2" or
"hui3":ab,ti,kw
MeSH descriptor: [Eye
Diseases] this term only
"Eye disease*" or "ocular
disease*" or "ophthal*
disease" or "ophthal*
condition":ab,ti,kw

1421

4375

305
1010
65424
1739
11487

16523

369

3464

2320

628
2706

159
#16

#17

#18

#19

#20

#21

#22

#23

"glaucoma" or "open-angle
glaucoma" or "open angel
glaucoma" or "primary openangle glaucoma" or "primary
open angle glaucoma" or
"OAG" or "POAG" or "low
tension glaucoma" or "lowtension glaucoma" or "AngleClosure Glaucoma" or "Angle
Closure Glaucoma" or "NormalTension Glaucoma" or "Normal
Tension Glaucoma" or
"NTG":ab,ti,kw
"age-related macular
degeneration" or "ARMD" or
"AMD" or "macular
degeneration":ab,ti,kw
"diabetic eye disease" or
"diabetic retinopathy" or "DR"
or "retinopathy" or "diabetic
maculopathy":ab,ti,kw
"macular edema" or "diabetic
macular edema" or "DME" or
"ME":ab,ti,kw
"retinal vein occlusion" or
"RVO" or "central retinal vein
occlusion" or "peripheral
retinal vein occlusion" or
"CRVO" or "PRVO":ab,ti,kw
"macular hole*" or "retinal
hole*" or "retinal tear*" or
"retinal break*" or "retinal
perforation*":ab,ti,kw
"dry eye*" or "dry eye disease"
or "dry eye syndrome" or
"DED" or "DES" or
"keratoconjunctivitis sicca" or
"KCS" or "dysfunctional tear
syndrome" or "lacrimal
keratoconjunctivitis" or
"evaporative tear deficiency"
or "aqueous tear
deficiency":ab,ti,kw
"thyroid eye disease" or "TED"
or "Graves ophthalmopathy" or
"Graves Orbitopathy" or

9098

4154

32254

8243

1036

512

16840

11501

160

#24
#25

#26

#27
#28
#29
#30

#31

"GO":ab,ti,kw
"Amblyopia" or "lazy
eye":ab,ti,kw
"Strabismus" or "esotropia" or
"exotropia" or
"Nystagmus":ab,ti,kw
"Uveitis" or "anterior uveitis"
or "posterior uveitis" or
"intermediate uveitis":ab,ti,kw
#1 or #2 or #3 or #4
#5 or #6 or #7 or #8
#9 or #10 or #11 or #12 or #13
#14 or #15 or #16 or #17 or
#18 or #19 or #20 or #21 or
#22 or #23 or #24 or #25 or
#26
#27 and #28 and #29 and #30

763
2142

1485

137429
67282
31166
82512

653
02/06/2022

Grey Literature
Web of Science
#
31

Searches
#28 AND #30

Results
683
02/06/2022

30

#29 OR #27

69,220

29
28

#25 AND #26
#12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR
#24

11,847
212,423

27

#7 OR #8 OR #9 OR #10 OR
#11

62,166

26

#4 OR #5 OR #6

152,300

25

#1 OR #2 OR #3

429,102

24

AB=(Uveitis)

12,127

23

AB=(Strabismus )

6,446

161

22

AB=(Amblyopia )

4,030

21

AB=(dry eye*)

10,597

20

AB=(cataract*)

36,884

19

AB=(retinal detachment)

12,670

18

AB=(macular hole* or retinal
hole* )

3,851

17

AB=(retinal vein occlusion )

3,830

16

AB=(macular edema)

8,391

15

AB=(diabetic eye disease or
retinopathy )

37,040

14

AB=( macular degeneration )

19,288

13

AB=(glaucoma )

39,340

12

AB=(Eye disease* or ocular
disease* or ophthal* disease
or ophthal* condition )

82,059

11

AB=(Health Utility Index or
Health Utilities Index or HUI* )

11,887

10

AB=(SF-12 or sf 12 or
shortforms 12)

14,101

9

AB=(SF-6D or shortforms 6d or
Short Form Six Dimension)

1,158

8

AB=(SF-36 or sf 36 or short
form 36 )

32,430

7

AB=(EQ-5D or euroqol or
euroqol-5d)

12,223

6

AB=(standard gamble* or SG)

24,238

5

AB=(visual analog scale* or
VAS )

82,916

162

4

AB=(time trade off or time
tradeoff or tto )

46,037

3

AB=(qaly* or quality adjusted
life year*)

21,909

2

AB=(quality of wellbeing or
quality of well being or quality
of well-being)

61,200

1

AB=(quality of life or life
quality or health-related
quality or health related
quality of life )

395,244

Appendix I. Kappa Statistics Calculations

Kappa Statistics (Title and Abstract Screening)

Review Authors

Hyunsoo

Brian

Include

Exclude

Total

Include

371

77

448

Exclude

143

2890

3033

Total

514

2967

3481

163

164

Kappa Statistics (Full text Screening)
Review Authors

Hyunsoo

Brian

Include

Exclude

Total

Include

39

35

74

Exclude

10

374

384

Total

49

409

458
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Appendix J. Risk of Bias Assessment Tables
Risk of Bias Instrument for Cross-Sectional Surveys of Attitudes and Practices.
First Author and
Year of Publication

1. Is the source
population
representative of the
population of
interest?

2. Is the
response rate
adequate?

3. Is there little
missing data?

4. Is the
survey
clinically
sensible?

5. Is there any
evidence for the
reliability and
validity of the
survey
instrument?

Comments

Balkrishnan
2003

Definitely no (high
risk of bias)

Probably no

Definitely yes
(low risk of
bias)

Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)

Moderate
risk

Balshaw
2012
Brown
1999

Definitely no (high
risk of bias)

Definitely yes
(low risk of
bias)
Probably yes

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Probably yes

Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Brown
2000

Definitely no (high
risk of bias)

Brown
2002

Definitely no (high
risk of bias)

Choudhury
2016

Definitely yes (low
risk of bias)

Dana
2020

Probably yes

Probably no

Globe
2002

Definitely no (high
risk of bias)

Definitely yes
(low risk of
bias)
Definitely no
(high risk of
bias)

Definitely yes
(low risk of
bias)
Probably yes

Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Lee
2003

Definitely no (high
risk of bias)

Lewis
2017

Definitely no (high
risk of bias)

Definitely no
(high risk of

Definitely yes
(low risk of

Definitely
yes (low risk

Definitely yes
(low risk of

Definitely yes
(low risk of
bias)
Probably yes

Farrand
2016

Abstract
only, High
risk
Low risk

Low risk

Low risk

Low risk

Not entirely
clear about
sampling of
source
population,
Moderate
risk
Abstract
only, High
risk
Low risk

No
information
on response
rate,
Moderate
risk
No
information
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bias)

bias)

of bias)

bias)

Definitely no
(high risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely no
(high risk of
bias)

Probably yes

Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Mangione
1999

Definitely no (high
risk of bias)

Messmer
2019

Definitely no (high
risk of bias)

Montemayor
2001

Definitely no (high
risk of bias)

Rajagopalan
2005

Definitely no (high
risk of bias)

Schiffman
2003

Definitely no (high
risk of bias)

Definitely no
(high risk of
bias)

Probably yes

Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)

Serbin
2020

Definitely yes (low
risk of bias)

Probably yes

Probably yes

Sharma
2003

Definitely no (high
risk of bias)

Soubrane
2007

Definitely no (high
risk of bias)

Definitely yes
(low risk of
bias)
Definitely no
(high risk of
bias)

Definitely yes
(low risk of
bias)
Probably yes

Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)
Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Stein
2002

Definitely no (high
risk of bias)

Definitely no
(high risk of
bias)

Definitely yes
(low risk of
bias)

Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)

Definitely no (high
risk of bias)

Definitely yes
(low risk of
bias)

Definitely yes
(low risk of
bias)

Definitely
yes (low risk
of bias)

Definitely yes
(low risk of
bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Thomas
2015
Uruthiramoorthy
2017

on response
rate,
Moderate
risk
Moderate
risk
Low risk

Low risk

No
information
on response
rate,
Moderate
risk
No
information
on response
rate,
Moderate
risk
Low risk

Low risk

No
information
on response
rate,
Moderate
risk
No
information
on response
rate,
Moderate
risk
Abstract
only, High
risk
Low risk
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Tool to Assess Risk of Bias in Cohort Studies.
First
Author and
Year of
Publication

1. Was
selection of
exposed
and nonexposed
cohorts
drawn from
the same
population?

2. Can we
be
confident
in the
assessment
of
exposure?

3. Can we be
confident that
the outcome
of interest
was not
present at
start of study?

4. Did the study
match exposed
and unexposed
for all variables
that are
associated with
the outcome of
interest or did
the statistical
analysis adjust
for these
prognostic
variables?

5. Can we
be confident
in the
assessment
of the
presence or
absence of
prognostic
factors?

6. Can we
be
confident
in the
assessment
of
outcome?

7. Was
the follow
up of
cohorts
adequate?

8. Were cointerventions
similar
between
groups?

Comments

Bailey
2016

Definitely
yes (low
risk of bias)

Probably yes

Definitely no
(high risk of
bias)

Definitely
yes (low
risk of bias)

Probably no

Definitely no
(high risk of
bias)

Probably no

Definitely
yes (low
risk of
bias)
Probably
yes

Moderate
risk

Probably
yes

Probably no

Moderate
risk

Lim
2021

Definitely
yes (low
risk of bias)

Probably no

Definitely no
(high risk of
bias)

Probably no

Definitely
yes (low
risk of
bias)
Definitely
yes (low
risk of
bias)
Probably
yes

Probably no

Chan
2012

Probably
yes

Definitely
yes (low risk
of bias)

Moderate
risk

Owsley
2007

Definitely
yes (low
risk of bias)

Probably yes

Definitely no
(high risk of
bias)

Probably
yes

Probably no

Probably yes

Probably
yes

Definitely
yes (low
risk of
bias)
Probably
yes

Moderate
risk

Probably
yes

Definitely
yes (low
risk of
bias)
Probably
yes

Probably yes

Sugar
2020

Definitely
yes (low
risk of
bias)
Definitely
yes (low
risk of
bias)
Definitely
yes (low
risk of
bias)
Definitely
yes (low
risk of
bias)
Definitely
yes (low
risk of
bias)

Definitely
yes (low risk
of bias)

Moderate
risk
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Tool to Assess Risk of Bias in Randomized Controlled Trials.
First
Author
and
Year of
Publicat
ion

1. Was the
allocation
sequence
adequately
generated?

2. Was the
allocation
adequately
concealed?

3.a.
Were
patients
blinded?

3.b.
Were
health
care
provid
ers
blinde
d?

3.c. Were
data
collectors
blinded?

3.d. Were
outcome
assessors
blinded?

3.e.
Were
data
analysts
blinded?

4. Was loss
to follow-up
(missing
outcome
data)
infrequent?

5. Are
reports of
the study
free of
selective
outcome
reporting?

6. Was the
study
apparently
free of
other
problems
that could
put it at a
risk of
bias?
Probably
yes

Espindl
e
2005

Probably no

Definitely
no (high
risk of bias)

Definite
ly yes
(low
risk of
bias)

Defini
tely
yes
(low
risk of
bias)

Definitely
yes (low
risk of
bias)

Definitely
yes (low
risk of
bias)

Probabl
y yes

Definitely
yes (low
risk of bias)

Probably no

Javitt
2000

Probably no

Definitely
yes (low
risk of bias)

Definite
ly yes
(low
risk of
bias)

Defini
tely
yes
(low
risk of
bias)

Definitely
yes (low
risk of
bias)

Definitely
yes (low
risk of
bias)

Definite
ly yes
(low
risk of
bias)

Probably
yes

Definitely
no (high
risk of bias)

Probably
yes

Kempe
n
2015

Probably no

Probably
yes

Definite
ly no
(high
risk of
bias)

Defini
tely
no
(high
risk of
bias)

Definitely
no (high
risk of
bias)

Definitely
no (high
risk of
bias)

Definite
ly no
(high
risk of
bias)

Definitely
yes (low
risk of bias)

Definitely
yes (low
risk of bias)

Probably
yes

Loftus
2011

Probably no

Definitely
yes (low
risk of bias)

Definite
ly yes
(low
risk of
bias)

Defini
tely
yes
(low
risk of
bias)

Definitely
yes (low
risk of
bias)

Definitely
yes (low
risk of
bias)

Probabl
y no

Definitely
yes (low
risk of bias)

Probably no

Probably
yes

Naik
2013

Probably no

Probably
yes

Probabl
y yes

Proba
bly
yes

Probably
yes

Probably
yes

Probabl
y no

Probably no

Definitely
yes (low
risk of bias)

Probably
yes

Comments

Unclear
information
on
allocation
sequence
generation,
Moderate
risk
Unclear
information
on
allocation
sequence
generation,
Moderate
risk
Unclear
information
on
allocation
sequence
generation,
Open label,
High risk
Unclear
information
on
allocation
sequence
generation,
Low risk
Unclear
information
on
allocation
sequence
generation,
Moderate
risk
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Tool to Assess Risk of Bias in Longitudinal Symptom Research Studies Aimed at the General
Population.
First Author and
Year of Publication

1. Is the source
population (sampling
frame) representative
of the general
population?

2. Is the
assessment of the
outcome accurate
both at baseline
and at follow-up?

3. Is there little
missing data?

Comments

Beauchamp
2006

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

No information on
missing data, High risk

Boisjoly
2010

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Feeny
2012

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Definitely no
(high risk of
bias)
Definitely yes
(low risk of
bias)
Probably yes

Frick
2012

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Groessl
2013

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Hirai
2012

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Mackenzie
2002

Definitely no (high
risk of bias)

Definitely yes
(low risk of bias)

Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)
Definitely yes
(low risk of
bias)

Low risk

No information on
sampling method,
Moderate risk
No information on
sampling method, Low
risk
No information on
sampling method, Low
risk
No information on
sampling method, Low
risk
No information on
sampling method, Low
risk

Appendix K. Extra Data Extraction
Author and

Eye disease

Year of

Elicitation

Utility values

Summary scores on preference-based measures

method**

Publication
Mackenzie
2002

ARMD

SF-36

Not reported

ARMD Severity:

Grade 4:

SF-36: Mean (SD)

Physical functioning: 74
(22)
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Grade 1:

Role-physical: 65 (41)

Physical functioning:

Bodily pain: 80 (19)

80 (25)

General health: 69 (17)

Role-physical: 67 (41)

Vitality: 61 (14)

Bodily pain: 69 (25)

Social functioning: 90

General health: 64

(14)

(26)

Role-emotional: 80 (37)

Vitality: 57 (20)

Mental health: 75 (15)

Social functioning: 81
(25)

Grade 5:

Role-emotional: 75

Physical functioning: 57

(43)

(35)

Mental health: 72 (21)

Role-physical: 45 (51)
Bodily pain: 72 (29)

Grade 2:

General health: 55 (27)

Physical functioning:

Vitality: 56 (13)

71 (33)

Social functioning: 60

Role-physical: 70 (42)

(39)

Bodily pain: 74 (26)

Role-emotional: 40 (43)

General health: 73

Mental health: 48 (22)

(20)
Vitality: 57 (25)

Grade 6:

Social functioning: 85

Physical functioning: 66

(24)

(32)

Role-emotional: 86

Role-physical: 44 (42)

(30)

Bodily pain: 61 (30)

Mental health: 76 (22)

General health: 69 (27)
Vitality: 58 (25)

Grade 3: Physical

Social functioning: 79

functioning: 76 (27)

(25)

Role-physical: 71 (41)

Role-emotional: 63 (44)

Bodily pain: 70 (30)

Mental health: 79 (16)

General health: 65
(26)

Grade 7:

Vitality: 58 (25)

Physical functioning: 59

Social functioning: 82

(33)
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(23)

Role-physical: 51 (45)

Role-emotional: 74

Bodily pain: 81 (21)

(39)

General health: 68 (20)

Mental health: 74 (21)

Vitality: 52 (22)
Social functioning: 71
(33)
Role-emotional: 76 (36)
Mental health: 73 (18)

Mangione

ARMD

SF-36

Not reported

1999

ARMD Severity:

Bodily pain: 75 (3.1)

SF-36: Mean (SD)

General health: 68 (2.2)
Vitality: 59 (2.8)

Mild:

Social functioning: 92

Physical functioning:

(2.2)

79 (2.2)

Role–emotional: 87 (4.4)

Role–physical: 67

Mental health: 74 (2.5)

(3.7)
Bodily pain: 73 (2.2)

Severe:

General health: 68

Physical functioning: 79

(1.5)

(7.5)

Vitality: 61 (2.0)

Role–physical: 77 (12.6)

Social functioning: 92

Bodily pain: 82 (7.4)

(1.6)

General health: 63 (5.3)

Role–emotional: 82

Vitality: 66 (6.7)

(3.1)

Social functioning: 99

Mental health: 75 (1.7)

(5.3)
Role–emotional: 88

Moderate:

(10.5)

Physical functioning:

Mental health: 73 (5.9)

80 (3.2)
Role–physical: 76
(5.3)
Hirai 2012

Diabetic
retinopathy

SF-36

Not reported

Baseline SF-36: Mean

10-year follow up SF-36:

(SD)

Mean (SD)

Physical functioning:

Physical functioning:

85.7 (21.4)

77.9 (26.8)
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Role physical: 83.7

Role physical: 75.1

(30.7)

(36.2)

Bodily pain: 77.0

Bodily pain: 71.6 (23.8)

(22.5)

General Health: 63.3

General Health: 65.9

(24.2)

(21.3)

Vitality: 58.4 (21.4)

Vitality: 59.4 (19.4)

Social functioning: 88.2

Social functioning:

(20.4)

89.8 (17.2)

Role emotion: 82.6

Role emotion: 88.7

(30.6)

(26.6)

Mental health: 78.9

Mental health: 75.3

(16.6)

(16.2)
Lewis 2017

Diabetic

SF-36

Not reported

SF-36: Mean (SD)

retinopathy

Social Functioning: 75.0
Physical Functioning:

(30.4)

55.4 (30.7)

Vitality: 64.1 (23.0)

Physical Role

Bodily Pain: 57.6 (27.9)

Functioning: 66.1

General Health: 57.1

(29.1)

(25.6)

Emotional Role
Functioning: 81.3
(26.6)
Mental Health: 75.2
(22.5)
Lee 2003

Cataracts

SF-36

Not reported

SF-36: Mean (SD)

Role Limitation due to
Physical Health: 74.5

General Health: 61.2

(40.4)

(16.8)

Physical Function: 74.7

Mental Health: 71.2

(21.1)

(21.5) Role Limitation

Bodily Pain: 76.3 (23.4)

due to Emotional

Social Function: 78.1

Health: 80.1 (38.1)

(24.0)
Vitality: 59.8 (17.8)

The

Intermediate

EQ-5D,

Treatment

Treatment

Uveitis type: SF-36

Treatment group: SF-36

Multicenter

uveitis, pan

SF-36

group: EQ-

group EQ-5D

health survey

follow-up Mean (SE)
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Uveitis
Steroid

uveitis

5D Baseline

follow-up

subscales Median

Mean (SE)

Mean (SE)

(IQR)

Treatment
Trial
Research
b

Group 2015

Implant group:
PCS:

Implant

Implant group:

All patients:

12 mo: 47.26 (1.22)

group:

12 mo: 0.83

Physical functioning:

24 mo: 47.26 (1.21)

0.81 (0.02)

(0.02)

51 (42, 57)

36 mo: 47.26 (1.17)

Systemic

24 mo: 0.83

Role-physical: 49 (28,

48 mo: 46.47 (1.21)

group

(0.02)

56)

54 mo: 46.33 (1.15)

0.83 (0.02)

36 mo 0.83

Bodily pain: 54 (44,

(0.02)

63)

MCS:

48 mo: 0.84

General health: 48 (38,

12 mo: 51.30 (1.13)

(0.02)

55)

24 mo: 50.20 (1.18)

54 mo: 0.82

Vitality: 49 (40, 58)

36 mo 50.46 (1.19)

(0.02)

Social functioning: 52

48 mo: 49.63 (1.21)

(35, 57)

54 mo: 50.48 (1.29)

Systemic

Role-emotional: 55

group:

(45, 55)

12 mo: 0.80

Mental health: 50 (41,

Systemic group:

(0.02)

57)

PCS:

24 mo: 0.81

12 mo: 46.18 (1.15)

(0.02)

Intermediate uveitis:

24 mo: 46.37 (1.18)

36 mo: 0.81

Physical functioning:

36 mo: 46.68 (1.19)

(0.02)

51 (42, 55)

48 mo: 46.89 (1.12)

48 mo: 0.81

Role-physical: 49 (35,

54 mo: 45.09 (1.27)

(0.02)

56)

54 mo: 0.82

Bodily pain: 54 (44,

MCS:

(0.02)

63),

12 mo: 46.81 (1.33)

General health: 45 (36,

24 mo: 47.49 (1.34)

53)

36 mo 48.43 (1.23)

Vitality: 49 (40, 58)

48 mo: 49.44 (1.26)

Social functioning: 52

54 mo: 49.84 (1.33)

(41, 57)
Role-emotional: 55
(34, 55)
Mental health: 50 (44,
57)
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Pan uveitis:
Physical functioning:
52 (40, 57)
Role-physical: 49 (28,
56)
Bodily pain: 54 (45,
63)
General health: 48 (36,
52)
Vitality: 49 (40, 59)
Social functioning: 49
(35, 57)
Role-emotional: 55
(45, 55)
Mental health: 50 (39,
57)

Treatment group: SF36 Baseline Mean
(SE)

Implant group:
PCS: 46.16 (1.18)
MCS: 47.75 (1.31)

Systemic group:
PCS: 48.09 (1.13)
MCS: 48.58 (1.20)

**: EQ-5D, SF-36, SF-12, SF-6D, HUI-2 and HUI-3 are generic preference-based measures,
TTO and SG are direct elicitation methods; ARMD: age-related macular degeneration; IQR:
interquartile range; MCS: mental component score; PCS: physical component score; SD:
standard deviation; SE: standard error; b: Frick et al. and Sugar et al. were merged with this study
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Appendix L. Results of the Associations Between Predictor Variables
Pearson correlation coefficients for the associations between continuous
predictor variables.

Number of Nonocular
Comorbidities

Age

Age

Number of Ocular
Comorbidities

1.00

Number of Nonocular Comorbidities
Number of Ocular
Comorbidities

1.00

-0.05

0.27

0.09

1.00

Chi-square tests (p-value) for the associations between categorical
predictor variables.

Education

Education
Living

Living
arrangements

0.448

Socioeconomic
status during
COVID-19

Use of a

Retinal

mobility aid

disease

0.382

0.203

0.800

Glaucoma

Cataracts

0.817

0.850

0.567

0.360

0.941

0.718

0.088

0.583

0.870

0.801

0.116

0.087

0.720

0.647

<0.001

0.386

arrangements
Socioeconomic
status during
COVID-19
Use of a
mobility aid
Retinal
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disease

Glaucoma

0.010

Cataracts

Results of associations between continuous and categorical predictor variables.
Number of
Non-ocular
Comorbidities

Number of
Ocular
Comorbidities

mean (SD)

p-value
mean (SD)

p-value
mean (SD)

0.550

0.254

0.835

Completed high school or less

78.41 (8.29)

1.84 (1.83)

1.16 (0.45)

Completed more than high school

77.38 (7.79)

1.42 (1.63)

1.18 (0.44)

0.372

0.237

0.330

Home alone/ Nursing/Retirement home

79.09 (8.77)

1.96 (1.92)

1.09 (0.29)

Home with others

77.36 (7.70)

1.46 (1.65)

1.20 (0.49)

0.319

0.125

0.671

less than $10,000

72.33 (3.79)

0.33 (0.58)

1.00 (0)

$10,001 - $25,000

77.55 (7.03)

2.30 (1.75)

1.29 (0.69)

$25,001 - $50,000

79.08 (9.36)

1.29 (1.46)

1.13 (0.34)

$50,001 - $75,000

74.42 (6.25)

1.58 (1.50)

1.00 (0)

$75,001 - $100,000

78.00 (4.24)

1.29 (1.98)

1.17 (0.41)

$100,001 - $125,000

81.33 (10.42)

1.67 (1.21)

1.25 (0.50)

79.50 (7.94)

0.25 (0.50)

1.25 (0.50)

Age

p-value

Education

Living arrangements

Socioeconomic status during COVID19

$125,001 - $150,000
Greater than $150,000
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Use of a mobility aid

0.027

0.005

0.006

No

77.13 (7.73)

1.32 (1.47)

1.10 (0.35)

Yes

82.13 (8.20)

2.60 (2.03)

1.46 (0.66)

0.001

0.585

0.973

No

75.61 (6.20)

1.69 (1.82)

1.17 (0.48)

Yes

81.87 (9.66)

1.47 (1.61)

1.17 (0.38)

0.038

0.348

0.078

No

79.84 (9.10)

1.50 (1.59)

1.08 (0.27)

Yes

76.00 (6.81)

1.88 (1.90)

1.26 (0.55)

0.532

0.025

0.051

No

78.18 (8.84)

1.46 (1.65)

1.12 (0.37)

Yes

76.76 (5.27)

2.53 (1.91)

1.35 (0.61)

Retinal disease

Glaucoma

Cataracts

Appendix M. Results of the Validation of Backwards Stepwise Linear Regression Models
1. 25-item National Eye Institute Visual Function Questionnaire model
Linearity:
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Constant variance of residuals:

Normality of residuals:

Multicollinearity:

2. Center for Epidemiological Studies-Depression
Constant variance of residuals:
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Normality of residuals:

Multicollinearity:
Variable

VIF

1/VIF

MobAid
ret3

1.04
1.04

0.963778
0.963778

Mean VIF

1.04

3. Hospital Anxiety and Depression Scale – Anxiety subscale
Constant variance of residuals:
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Normality of residuals:

4. Pittsburgh Sleep Quality Index
Constant variance of residuals:
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Normality of residuals:

5. Community Integration Questionnaire
Linearity:

Constant variance of residuals:
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Normality of residuals:

Multicollinearity:

Variable

VIF

1/VIF

ncomm2
educ2
ret3

1.03
1.02
1.00

0.974982
0.975670
0.997267

Mean VIF

1.02

183
Appendix N. Backwards linear regression model assessments from leave-one-out cross
validation.

Root Mean Square

Mean Absolute

Error

Error

NEI VFQ-25

10.98

8.98

CES-D

6.43

5.30

PSQI

3.02

2.56

HADS-A

2.62

2.18

CIQ

3.71

2.86

Model outcome
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